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Abstract 
 
Regulatory T cells (Tregs), expressing the transcription factor Foxp3, form a key component of 
peripheral immune tolerance, guarding against auto-ggressive immune responses. Multiple 
Sclerosis is an inflammatory and demyelinating disease of the central nervous system (CNS) 
which is largely believed to be mediated by immune components reacting to the self myelin 
antigens that insulate the nerve fibres. Recent investigations have reported that regulatory T cells 
are dysfunctional in MS patients; therefore enhancing the regulatory T cell responses in MS is an 
attractive therapeutic target. 
 
Using the mouse model of MS, experimental autoimmune e cephalomyelitis (EAE) we have 
attempted to develop disease-relevant Treg-based therapies to prevent disease induction. This 
required an understanding of the antigenic-reactivity of Tregs during disease. Results described 
in this thesis show that a proportion of Tregs in the draining lymph nodes and CNS were reactive 
to the disease initiating antigen(s) and could suppress in vitro responses of naïve T cells bearing 
transgenic T cell receptors, recognising the same antigen. Adoptive transfer of antigen-reactive 
Tregs suppressed disease induced with the same antigen, but also reduced disease induced with a 
distinct myelin antigen. Peptide-based tolerance using a high affinity MHC binding peptide 
analogue expanded and maintained antigen-reactive T cells which were tolerant to antigenic re-
stimulation, although these cells did not express Foxp3. Peptide-treated mice showed reduced 
incidence of disease relapses during EAE induced against a distinct myelin antigen. Thus, while 
EAE and MS will involve a polyclonal effector T cell response to many antigens, therapeutic 
targeting of Tregs reactive against one CNS component may be sufficient to reduce disease. 
 
Endogenous expression of myelin autoantigen did not gr ssly alter the response of antigen-
reactive Tregs in the periphery. However, expression of endogenously derived viral superantigen 
enhanced the proportion of superantigen-reactive Foxp3+ Tregs in the periphery. This 
observation was extended using exogenous superantigen, suggesting that prolonged exposure to 
low dose (super)antigen tips the balance of the immune system in favour of regulation. This has 
implications for the ability to successfully fight infection, as well as for the limitation of auto-
aggressive responses and may contribute to the understanding of the hygiene hypothesis. 
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Immune regulation is essential to prevent excessive and unwanted immune responses, 
including immune responses direct against self. Naturally arising Foxp3+ regulatory T 
cells (Tregs) play a major role in peripheral immune tolerance, demonstrated by the fatal 
lymphoproliferative and autoimmune manifestation of b th humans and mice that lack 
these cells. Multiple Sclerosis is a demyelinating disease of the central nervous system 
(CNS) (Hafler et al., 2005), thought to involve immune responses directed against 
antigens of the myelin sheath that functions to insulate nerves and allow efficient signal 
transduction. Tregs have been shown to have defective in vitro regulatory functions in 
patients with MS (Haas et al., 2005; Venken et al., 2008b; Viglietta et al., 2004) and 
studies from mouse models of the disease have emphasised the importance of Foxp3+ 
cells in both protection from disease and recovery from episodes of paralysis 
(McGeachy et al., 2005; Stephens et al., 2005). The aim of this study was to further 
characterise the regulatory T cells that arise during disease by using mouse models of 
MS, experimental autoimmune encephalomyelitis (EAE) and to attempt to harness 
Foxp3+ Tregs therapeutically for the prevention of paralysis. The data from these studies 
led us to investigate the effect of superantigenic st mulation on peripheral Foxp3+ 
populations and how encounter with superantigen may affect the balance of the immune 
system, including its implications for autoimmunity. 
 
CD4+ T cell Biology 
2 
1.1 CD4 T cell Biology 
 
To mount a protective immune response the immune system must be able to detect and 
respond to a vast number of pathogens. Cells of the innate immune system detect general 
pathogen associated patterns via receptors on their surface to initiate the inflamatory 
response. The adaptive immune system also use receptors, however these are designed 
to recognise specific epitopes of the invading organism. T cells represent one arm of the 
adaptive immune response and express a cell-surface receptor termed the T cell receptor 
(TCR).  The T cell receptor repertoire is estimated to be in the region of 108 (Mason, 
1998) while the potential antigenic peptides which the immune system may encounter is 
proposed to be in the region of 1012-1015 (Mason, 1998; Sospedra and Martin, 2006). 
Thus, the adaptive immune system relies on the receptors of T lymphocytes to become 
diverse during development and to show a high level of cross-reactivity in order to 
recognise all the peptides we may encounter in our lifetime (Mason, 1998).  T cells will 
express either CD4 or CD8, co-receptrs required for pr ductive TCR signalling. The 
expression of the co-receptor determines the fate and function of the T cell (Germain, 
2002) and determines the type of major histocompatibility (MHC) molecule the cell may 
interact with; CD4+ cells are MHC class II restricted, while CD8+ cells are MHC class I 
restricted (Mazza and Malissen, 2007). CD4+ T cells r present a population of cells that 
have unique properties in terms of activation, effector function and the ability to ‘help’ 
other cells of the immune system, making these cells key players in our immune 
responses. The TCR expressed by each individual T ce l affects the fate of that cell and 
ultimately affects the immune response each cell can mount (Aliahmad and Kaye, 2006). 
Selection of T cells bearing a suitable TCR therefore requires a tightly regulated process 
to remove those cells that recognise self-antigens with high enough affinities to 
potentially cause auto-aggressive responses, while sel cting for a broad diversity of 
functional T cells which can recognise foreign antigens. 
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1.1.1 Thymic generation of T cells and the TCR 
 
Progenitor T cells migrate to the thymus from the bone marrow as double-negative (DN) 
cells i.e. lacking expression of either CD4 or CD8, the molecules which will determine 
the cell status and function (Germain, 2002). Generation of a functional T cell receptor 
(TCR) is essential for T cell survival and progression through the thymic selection 
process (Falk et al., 2001). Expression of the TCRβ chain is the first process to occur, 
driven by the activation of recombinase activating genes 1 and 2 (RAG1 and RAG2). 
These initiate the opening and re-joining of DNA to combine the gene segments of the 
Vβ chain; variable (V), diversity (D) and joining (J) segments (Mombaerts, 1995; 
Swanson, 2004). The J segment is associated with one of two constant (C) regions, 
completing the full TCRβ chain (Spicuglia et al., 2006). If the Vβ chain is successfully 
formed the arrangement of the second Vβ allele is stopped, in a process termed allelic 
exclusion (Aifantis et al., 1997; von Boehmer and Fehling, 1997). This process is 
entirely random, such that each T cell generates a Vβ independently to the next T cell, 
thus forming one step in generating sufficient receptor diversity (Wagner, 2007).  
 
The Vβ chain then associates with the pre-TCRα chain, forming the pre-TCR which is 
expressed at the cell surface. Expression of the pre-TCR is required for progression 
through the stages of T cell selection, suggesting a signalling event occurs from 
successful pre-TCR arrangements (Huang et al., 2005). Indeed, RAG1 and RAG2 
become silenced at this point, while the T cell progresses from the double negative (DN) 
stage to double positive (DP) i.e. CD4+CD8+. The RAG genes are then re-activated to 
induce TCRα gene rearrangements. TCRα expression differs to TCRβ in that one cell 
can express more than one TCRα chain (Lacorazza and Nikolich-Zugich, 2004), the 
implications of which will be discussed later. The pairing of TCRα and β chains 
completes the TCR and provides antigen specificity to the T cells, required for the 
selection processes based on antigen recognition. 
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1.1.2 Repertoire Generation and Central Tolerance 
 
Because TCR rearrangements are random, there existsthe possibility that T cells which 
cannot recognise self MHC molecules or which may recognise self antigens or 
innocuous antigens (e.g. commensal bacteria) will be generated. The immune system 
therefore attempts to delete these cells before they exit the thymus in a process termed 
central tolerance. Central tolerance occurs via two main processes; Positive and 
Negative Selection (Hogquist et al., 2005). Positive selection ensures that only T cells 
which recognise self peptide-MHC complexes, expressed on cortical thymic epithelial 
cells (cTECs), receive survival signals and progress through the selection process. In this 
way T cell are classed as ‘MHC-restricted’ in that they will only respond to their 
corresponding self-MHC; CD4+ T cells recognising peptides presented by MHC class II 
and CD8+ recognise peptides in the context of MHC class I (Konig, 2002).  
 
Negative selection purges the repertoire of T cells xpressing TCRs which recognise 
self-peptide-MHC (p:MHC) complexes with too high an ffinity (Palmer, 2003; Siggs et 
al., 2006; Wagner, 2007). These cells are induced to undergo apoptosis, up-regulating 
pro-apoptotic factors such as Nur77 and Bim (Bouillet et al., 2002; Sohn et al., 2007). T 
cells which fail to detect p:MHC, or respond at tool w an affinity to be of use die by 
neglect. The window of affinity in which T cells are allowed to survive is therefore 
relatively narrow and only cells expressing TCRs with intermediate affinities are 
allowed to progress through the thymus. Cells which ave responded too strongly to self 
p:MHC can undergo receptor editing; re-activation of RAG-genes allows the T cell to 
change the TCRα chain to a less self-reactive TCR (Santori et al., 2002). This process 
has been suggested to also enhance positive selection, thus increasing the number of T 
cells in the repertoire. The avidity and affinity with which cells are positively selected 
has been suggested to determine cell fate decisions, such as wither to become a 
regulatory vs. effector cell as will be discussed later. 
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While attempting to rid our bodies of self-reactive c lls, the overall process of central 
tolerance presents a few problems. All T cells have be n selected on the basis of 
recognising self-antigens presented in the context of self-MHC, therefore a degree of 
self-reactivity must exist in every cell of the immune repertoire. Similarly, the 
expression of dual TCRs on one cell, by expression of two TCRα chains, also suggests 
that highly self-reactive T cells may escape deletion if selected on the TCR expressing 
an α-chain which is not self-reactive or confers a lower affinity for the selecting peptide 
(Sarukhan et al., 1998). The best available explanatio  as to why the immune system 
would risk this problem is that the cost:benefit raio of these process must be high 
enough. Firstly, if we were to delete all self-reactive cells in the thymus we would 
greatly restrict our peripheral immune repertoire (Anderton and Wraith, 2002). 
Secondly, while expression of dual TCRα chains has been demonstrated to allow the 
escape of self-reactive T cells from deletion (Zal et al., 1996) it has also been suggested 
to further extend the TCR repertoire to foreign antigens and contribute significantly to 
the peripheral TCR diversity (He et al., 2002).  
 
Central tolerance relies on the availability of self-antigens in the thymus that can be 
presented to developing thymocytes. This is easy to envisage with ubiquitous self-
antigens, however the immune system also requires to delete T cells reactive against 
tissue specific antigens (TSAs) (Kyewski and Derbinsk , 2004). These antigens were 
originally believed only to be expressed at peripheral sites and tolerance to these 
antigens would be controlled by deletion of the self-reactive T cells in the periphery 
upon encountering the tissue-specific antigen. However, expression of TSA’s has now 
been identified in the thymus (Heath et al., 1998). Ectopic expression of tissue specific 
genes was found to largely be confined to medullary thymic epithelial cells (mTECs) 
(Derbinski et al., 2001; Smith et al., 1997). The expr ssion of these self antigens was 
latershown to be under the control of a gene termed autoimmune regulator (AIRE). By 
analysing the mTECs of AIRE-/- vs WT mice it was shown that expression of TSAs is 
downregulated in mice lacking the gene (Anderson et al., 2002).  
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Mutations in AIRE are associated with a rare human autoimmune syndrome called 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) 
(Pitkanen and Peterson, 2003) while mice lacking AIRE also develop multi-organ 
autoimmunity and have a failure in thymic negative selection (Anderson et al., 2002; 
Liston et al., 2003). Discoveries in AIRE and its functions over the last decade have 
confirmed that this gene plays an important role in the central tolerance to antigens 
normally confined to peripheral tissues (Mathis and Benoist, 2007). Although mTECS 
exclusively express these TSAs, other antigen-presenting cells (APC) in the thymus, 
namely dendritic cells (DC) have been shown to acquire TSAs from mTECs and can 
help mediate positive selection (Gallegos and Bevan, 2004). Collectively these processes 
can delete highly self-reactive T cells while generating a broad repertoire of T cells 
capable of responding to invading pathogens and mounting a protective immune 
response upon activation. Central tolerance is not perfect, as evidence of self-reactive 
cells in healthy individuals has demonstrated. How T cell might escape these processes 
is discussed later. 
 
1.1.3 T cell activation 
 
Once selected, T cells emigrate to the periphery where they circulate and scan for their 
cognate antigen. To become fully activated, T cells require a two-step signal process; 
signal 1 is recognition of the cognate p:MHC complex via the TCR and TCR co-
receptors (CD4/CD8 and CD3) while signal 2 is received from co-stimulatory 
molecules. The cytokine profile released by the APC can also influence T cell activation 
and is often referred to as signal 3 (Mosmann and Coffman, 1989) These signals are 
provided by APC, that include macrophages, B cells and DC which take up antigens and 
present them in the context of MHC. 
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1.1.4 Antigen Presentation  
 
Antigen can be acquired in a passive process (pinocytosis) or actively via cell surface 
receptors which bind the antigen and are then endocytosed. Dendritic cells (DC) show 
the greatest capacity to stimulate T cells in this way, therefore they are classed as 
professional APC, and they can show many different phenotypes which depend on their 
location and function (Banchereau et al., 2000). Some DC are located at peripheral sites, 
e.g. Langerhans cells in the dermis, where they are poised to encounter antigen and 
become activated in response to danger signals, while other DC are resident in the lymph 
nodes (Banchereau et al., 2000). Many roles have been d scribed for DC, thus a number 
of different subsets exist that can carry out unique functions (Shortman and Liu, 2002). 
These subsets include myeloid DC (mDC), plasmacytoid DC (pDC) and CD8α+ DC, 
each defined by unique surface marker expression and functions.  
 
Antigens can be directly transported to the lymph nodes via the lymphatics where it will 
be ingested by lymph node resident APC, or be taken up by APC in the periphery. 
Uptake of antigen in the steady state (i.e. in the absence of inflammation) does not fully 
activate APC (Mahnke et al., 2002). T cells that encounter antigen presented by 
immature DC also do not become activated and in this way DC can promote tolerance to 
self or innocuous antigens. Under inflammatory conditions recognition of pathogens by 
innate pattern recognition receptors such as toll-like receptors (TLRs) (Kumagai et al., 
2008) drives maturation of DC, involving up-regulation of co-stimulatory and MHC 
molecules and acquisition of homing receptors for lymphoid organs (Turley et al., 2000). 
T cells migrating through the body scan the APC and upon encounter with their cognate 
antigen a crosstalk between the DC and T cell occurs, with the outcome of T cell 
function determined by the signals it receives from the APC. In this way DC are 
proposed to be able to tune the T cell response (Pul ndran et al., 2001)  
 
Presentation of peptide:MHC complexes to the cognate T cell results in T cell 
proliferation in the lymph nodes. (Garside et al., 1998). TCR stimulation induces the up-
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regulation of CD40L and CD28 that can interact with CD40 and B7.1/B7.2 respectively, 
which are expressed on the APC. Co-stimulation via CD28-B7.1/B7.2 induces up-
regulation of other co-stimulatory molecules, such as inducible co-stimulator (ICOS) on 
the T cell that can interact with its ligand, ICOSL, on the APC (Lenschow et al., 1996; 
Sharpe and Freeman, 2002). ICOS stimulation induces further upregulation of CD40L 
on the T cell and potentiates the activation of both the T cell and APC in a constant 
feedback loop to amplify the signals (Kroczek et al., 2004). Co-stimulation provides the 
signals for full T cell activation and IL-2 production which allows autocrine 
proliferation and activation of other T cells in the vicinity that express the IL-2R 
(Minami et al., 1993). The absence of co-stimulation, r ‘signal 2’, results in abortive T 
cell activation, resulting in un-responsiveness and inability to produce IL-2, a state 
known as anergy (DeSilva et al., 1991; Jenkins et al., 1991).  
 
1.1.5 MHC Structure and Function 
 
For T cells to recognise antigenic components they must be processed into peptides and 
presented in the context of MHC, specifically class II MHC for CD4+ T cells. Class II 
MHC is composed of two chains, the α and β chains, and can bind peptides of up to 20 
amino acids due to the open ends of the peptide binding groove (Fairchild, 1998). The 
genes which encode the MHC molecules are highly polm rphic in that multiple alleles 
exist for each MHC isoform. One copy of each allele is inherited from each parent, 
therefore evolutionary diversity increases the chane that at least a few individuals will 
possess alleles which are capable of binding and presenting peptides from any pathogen 
encountered. Further diversity involves mutations i the nucleotide sequences which 
code for the peptide binding domain and therefore aff ct the ability and orientation of 
peptide binding. Many diseases and disorders have been linked to MHC alleles, such as 
HLA-DR molecules in multiple sclerosis (Holmes et al., 2005) and Type-1 Diabetes 
(Wong and Wen, 2003).  
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1.1.6 TCR Structure and Function 
 
TCRs are composed of two chains as mentioned previously, the alpha and beta chains. 
Each chain possesses a constant (C) and variable (V) region. The Vα and Vβ TCR 
domains are structurally related to the immunoglobulin V domains on B cells and 
possess peptide loops termed complementarity-determining regions (CDRs) which 
contain the peptide/MHC binding sites (Bentley and Mariuzza, 1996). There are three 
CDRs on the V region of each chain. CDR1 and CDR2 are encoded in the V gene 
segment and largely bind to sequences on the MHC molecules. CDR3 is formed during 
site-specific Vα-Jα, or Vβ-Dβ-Jβ recombination during thymic selection. All of the CDR 
regions show diversity in their sequences; however CDR3 shows the highest diversity 
due to the random mutations which occur at this site. CDR3 regions recognise peptide 
residues and the greater diversity in this region therefore enhances the potential for 
TCRs to recognise a wider range of peptides (Mazza and Malissen, 2007). The 
orientation of the TCR on p:MHC has been proposed as a two step model; CDR1 and 2 
bind the α-helices on the MHC molecule initially, which then allows alterations in the 
CDR3 region to maximally recognise the peptide (Wu et al., 2002). 
 
1.1.7 Superantigen-mediated T cell stimulation 
 
It has been known for a number of years that certain endogenous and exogenous 
molecules can act as potent inducers of T cell prolife ation and these have been termed 
superantigens. Some exotoxins that are secreted by gram positive bacteria, for example 
Staphylococcal enterotoxins (SE’s), have been described to have superantigen activity 
and have been extensively studied over the past few decades (For a review see (Herman 
et al., 1991). 
 
T cell stimulation with superantigens requires MHC expression on APC, but does not 
show the requirement for antigen processing or MHC restriction as ‘classical’ antigen 
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presentation (Figure I). Superantigens function by simultaneously binding with class II 
MHC and TCR molecules, but the interaction with MHC molecules occurs outside of 
their peptide binding grooves (Sundberg et al., 2007). Although the MHC allele is not 
important, superantigen interactions show differential binding to the class II MHC 
isotypes. Most murine superantigens bind with a higher affinity to I-E than to I-A and 
there is a similar hierarchy with human class II and superantigen binding (Herman et al., 
1991). The interaction of superantigen with the T cells is mediated by the TCR Vβ 
chain, shown by the clonal elimination of thymocytes bearing superantigen-reactive 
TCR Vβ chians in mice expressing certain self-superantige/MHC combinations 
(Kappler et al., 1987). 
 
Staphylococcus aureus enterotoxin B (SEB) is one such bacterially derived superantigen, 
and has been shown to stimulate T cells bearing Vβ8+ TCRs (White et al., 1989). SEB 
administration to neonatal mice leads to the expansion of of Vβ8+ T cells, followed by 
the deletion of the majority of those cells after 4 days (Kawabe and Ochi, 1991).  The 
remaining cells have been shown to be anergic and potentially regulatory (Germain, 
2008). Similarly, SE stimulation in humans has been shown to be Vβ-dependent 
(Kappler et al., 1989). 
 
Endogenous superantigens also exist. Kappler and colleagues (Kappler et al., 1987) 
demonstrated that T cells bearing Vβ17a responded to splenocytes from I-E+ mouse 
strains by a B cell-derived superantigen, presented by I-E molecules. Subsequent 
analysis of I-E+ mouse strains showed that the periph y was devoid of Vβ17a+ T cells 
due to their thymic deletion induced by superantige encounter. Murine endogenous 
superantigens arise from the mouse mammary tumour vir ses (mmtv’s); these are 
encoded within the mouse genome and maternally inherited (Marrack et al., 1991). The 
expression of certain mmtv’s causes the deletion of mmtv-reactive T cells expressing 
particular TCR Vβ chains, similar to exogenous superantigens. Vβ5+ T cells are deleted 
in mice expressing mmtv-9 and are I-E+ (Fink et al., 1992). However, the deletion of 























Antigen Processing Not required By APC, internally in 
vesicles
Binding to MHC class II Binds outside of antigen 
groove
Binds in the peptide 
groove
Interaction with TCR Site specific interaction 
with TCR Vβ chain
Site specific interaction
with CDR loops of TCR
Vα and βchains
Table I: Comparison of the characteristics of Superantigen vs. peptide antigen presentation
Figure I: Schematic comparison of classical antigen presentation vs. 
Superantigen presentation to T cells.
m tv
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Vβ5+ T cells does not occur intrathymically in mice that lack I-E, but they slowly 
disappear from the periphery (Fink et al., 1994). 
 
Encounter with superantigens, endogenously or exogenously derived, will therefore have 
a major impact on the peripheral T cell repertoire. The deletion of an entire segment of 
the CD4+ T cell repertoire has important consequences on the ability to mount an 
effective immune response. While deletion of superantigen-reactive cells will protect the 
host from the systemic shock associated with toxic ba terial superantigens it may also 
determine susceptibility to diseases where a bias in TCR usage has been documented 
(Acha-Orbea, 1991).   
 
1.1.8 Effector Lineages of CD4+ T cells 
 
CD4+ T cells are named T helper (Th) cells due to their ability to ‘help’ B cells and 
CD8+ T cells to become fully activated. In this way, CD4+ cells can be seen as a highly 
important cell type, central to the adaptive immune response. Th cells were originally 
classified as either a Th1 or Th2 phenotype (Mosmann and Coffman, 1989). Dendritic 
cells have the ability to produce many of the cytokines responsible for driving the Th 
cell lineages. Different signals received by the DCcondition the cytokines each cell will 
make. This is also affected by the phenotype of the DC and therefore these cells can 
provide the third signal required for T cell activaon and polarisation (Kaiko et al., 
2008). 
  
CD4+ T cell differentiation towards a Th1, Th2 or Th17 fate occurs under the influence 
of distinct cytokines and transcription factors (Figure II). Th1 polarisation is driven 
mainly by IL-12 and the activation of the transcription factor T-bet (Rao and Avni, 
2000). Th1 cells produce IL-2, IFNγ and TNF, cytokines that are associated with 
bacterial infections and macrophage activation, but also in chronic immune responses 
that can be detrimental to the host (Peluso et al., 2006). Naïve CD4+ cell are driven 
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towards a Th2 fate by IL-4 and IL-13 and the up-regulation of the transcription factor 
GATA-3 (Rao and Avni, 2000). Th2 cells produce IL-4, 5 and -13 and are classically 
associated with parasite infections and B cell activ tion but are also responsible for the 
overt immune responses in asthma and allergy (Doherty and Broide, 2007). However, it 
is becoming clear that there are many overlapping fu ctions of these cell types.  
 
Recently, a new population of helper T cells was discovered that produced IL-17 upon 
differentiation with IL-6 and TGFβ (Bettelli et al., 2006a). These were termed Th17 
cells and are maintained by the cytokine IL-23 which shares a common subunit with IL-
12, IL-12p40 (Oppmann et al., 2000). The phenotype is driven by the transcription 
factors RORγT and STAT3 (Figure II), while it is inhibited by IL-2 (Laurence et al., 
2007). Th17 cells produce IL-17A, IL-17F, IL-21, IL-6 and TNFα (Langrish et al., 
2005) and have been discovered to be involved in may of the pathologies classically 
associated with Th1, including autoimmune disease (Cua et al., 2003; Murphy et al., 
2003; Ouyang et al., 2008). 
 































Figure II: Signals required to induce T helper cell  differentiation. IL-12 drives the 
differentiation of Th1 cells, amplified by IFNγ and Tbet transcription. TGFβ and IL-6 drive 
Th17 cell differentiation via the transcription factor RORγt. IL-4 polarises naïve T cells 
towards a Th2 cell fate via the induction of GATA3. Differentiation towards one subset 
represses the induction of opposing transcription factors. Furthermore, cytokine production 
by one subset blocks signalling via the cytokines released from other subsets, thus 
enhancing the polarisation towards a distinct Th population. 
(Adapted from Stockinger and Veldhoen, Current Opinnion in Immunology 2007).
Naïve T
cell
CD4+ T cell Biology 
15 
1.1.9 Peripheral T cell Tolerance 
 
Clearly, while maintaining a diverse immune repertoire allows us to respond to many 
foreign pathogens, the immune system will generate self reactive T cells. While many of 
these are purged from the system during thymic negative selection it is now clear that 
self-reactive T cells exist in the periphery. Every T cell in our bodies has been selected 
on the basis of self-reactivity. However for most cells this must have been of low 
enough affinity to escape deletion. Peripheral mechanisms of tolerance must therefore 
exist to ensure that these cells do not overtly respond to self (Walker and Abbas, 2002).  
 
1.1.9.1 Clonal Ignorance 
 
In some cases, self reactive T cells may exist in the periphery, but never encounter their 
cognate antigen, and do not become activated. This is termed clonal ignorance (Miller 
and Heath, 1993). Sequestration of antigen has been shown to occur in organs that have 
been termed ‘immune privileged’, such as the eye, testis and CNS (Simpson, 2006). 
Inflammation in these organs would be detrimental to the function of that organ and thus 
immune responses are prevented by ignorance, although active deletion at these sites has 
also been documented (Brabb et al., 2000).  
 
Self-reactive T cells may escape from the thymus if the antigen is not presented during 
the processes of positive and negative selection. Processing of antigen for presentation 
involves the specific cleavage of proteins at enzymatic sites. This results in the 
preferential presentation of immuno-dominant epitopes to the T cells (Sercarz, 2002). T 
cells reactive to epitopes of self antigen that are not presented in the thymus (often 
referred to as cryptic epitopes) will escape into the periphery. However, as the cryptic 
antigen is not presented in the periphery, the self-reactive T cells never become 
activated. 




As in the thymus, if T cells encounter antigen presented by activated DC with too strong 
an affinity then they are induced to undergo apoptosis, also known as activation-induced 
cell death (AICD) (Krammer, 2000). Mutations in the g ne encoding Fas (CD95) was 
shown to be responsible for the lympho-proliferative disorder in lpr mice (Watanabe-
Fukunaga et al., 1992). Later it was found that the mature T cells in mice with defects in 
Fas showed a defect in activation induced death and resistance to TCR mediated 
tolerance (Russell et al., 1993). Furthermore, gld mice that presented with a similar 
lympho-proliferative phenotype to lpr mice, were shown to have mutations in  the ligand 
for Fas, FasL (Bossu et al., 1993; Takahashi et al., 1994). Mature T cells in the periphery 
have been shown to up-regulate Fas (CD95) upon strog ligation of their TCR (Ju et al., 
1995) and cell death is then be mediated by the binding of Fas to FasL expressed on the 
same cell or on a neighbouring cell. In other cases, T cell which do not receive the 
appropriate survival signals will undergo activated cell autonomous death (ACAD) or 




Another outcome of peripheral-self recognition is anergy. Mature T cells will encounter 
many self antigens in the absence of inflammation, thus will recognise peptide:MHC 
complexes on DC in the absence of CD28/B7 co-stimulation. This results in abortive T 
cell activation. Dendritic cells that present antigen in the absence of inflammation are 
tolerogenic (Shortman and Heath, 2001). Upon secondary exposure to the same antigen 
proliferation and IL-2 production is blocked and the cells are termed anergic; however 
anergy can be overcome by the addition of IL-2 (Schwartz, 2003). The induction of 
anergy in the absence of co-stimulation results in distinct signalling pathways compared 
to TCR stimulation on the presence of co-stimulation  mediate specific unresponsivess 
of the T cells (Appleman and Boussiotis, 2003).  
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1.1.9.4 Active regulation  
 
Over the past few decades evidence has been gathered t at distinct, naturally arising cell 
populations exist to regulate immune responses. These include naturally arising CD4+ 
Tregs and CD8+ Tregs. However, the induction of regulatory cells in response to 
antigenic stimulation has also been documented.  
 
The focus of immune regulation has largely been on a population of naturally arising 
CD4+ regulatory T cells (nTregs) since their discovery by Sakaguchi et al. in 1995 
(Sakaguchi et al., 1995) and identification of the ranscription factor Foxp3, which is 
essential for the function of these cells (Fontenot et al., 2003). This population of Tregs 
and other regulatory cell populations are discussed in the following section, with 
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1.2 Regulatory T cell Biology 
 
Certain cells have regulatory properties which can actively suppress immune responses. 
These include a lineage of T cells which are selectd in the thymus to become regulatory 
cells, or Tregs. 
 
1.2.1 Discovery of natural Tregs 
 
In the early 1970’s Gershon and Kondo introduced the idea of ‘infectious tolerance’, 
after discovering that thymically-derived T cells may also negatively regulate immune 
responses in an antigen-specific manner (Gershon and Kondo, 1970; Gershon and 
Kondo, 1971). This was followed by numerous publications demonstrating suppression 
of immune responses in vitro by CD4+ and CD8+ T cells, termed suppressor T cells 
(Tsup) (reviewed in (Germain, 2008)). Identification and function of these cells 
remained elusive and as techniques developed over the next decade the evidence for 
Tsup cells was questioned and they rapidly fell out of favour. However, in the early 90’s 
studies into autoimmunity demonstrated that transfer of cells lacking activation markers 
into immunodeficient (athymic) hosts could cause autoimmunity, while cells expressing 
low levels of CD45RB (OX-22), or memory-like cells, could prevent disease (Powrie 
and Mason, 1990). These studies began to suggest that particular subsets of T cells did 
indeed have the capacity to suppress self-reactive T cells.  
 
It has been known for many years that mice which undergo thymectomy at, or before 
day 3 after birth succumb to organ-specific autoimmune pathologies (Nishizuka and 
Sakakura, 1969; Taguchi and Nishizuka, 1987).  Similarly, thymectomy at a later stage 
in development accelerated the onset of diabetes in the on-obese diabetic (NOD) mouse 
strain (Dardenne et al., 1989). Sakaguchi and colleagu s (Sakaguchi et al., 1995) 
identified that T cells expressing the high affinity IL-2 receptor (IL-2Rα), CD25, and 
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constituting 5-10% of peripheral CD4+ T cells played a major role in self-tolerance. 
Thymectomised mice show reduced CD25+ cells in the periphery and transfer of CD25+ 
cells immediately after thymectomy prevented the autoimmune disease, while CD25- 
cells did not (Asano et al., 1996). Furthermore, autoreactive T cells could be expanded 
from CD4+ T cells isolated from healthy, human periheral blood when the population 
was depleted of CD25+ cells (Venken et al., 2007). These studies concluded that CD25+ 
cells which arise in the thymus at day 3 after birth were responsible for peripheral 
tolerance by maintaining auto-reactive CD25- cells in a dormant state. CD4+CD25+ 
Tregs were later demonstrated to suppress both CD4+ and CD8+ responses in vitro by 
inhibiting IL-2 production (Itoh et al., 1999; Thornton and Shevach, 1998), although 
even now, a decade later, the full mechanism of Treg-m diated suppression is not fully 
comprehended.  
 
1.2.2 Identifying Treg-specific markers 
 
Initially, CD25 was the best defined marker of Tregs, but as CD25 is expressed by most 
T cells upon activation attempts to identify other markers of regulatory T cells were 




CD25+ cells isolated from naïve mice were shown to express high levels of 
glucocorticoid-induced TNF receptor-related gene (GITR) through gene expression 
analysis (McHugh et al., 2002). It was also demonstrated that stimulation of GITR, via 
GITR-specific monoclonal antibodies (mAb), along with TCR stimulation could block 
Treg mediated suppression and induce multi-organ autoimmune disease (Shimizu et al., 
2002). GITR knock-out (GITR-/-) mice have no defects in Tregs suggesting that while 
this molecule may have a role for Treg suppression it is not essential. However, GITR+ 
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cells were shown to prevent colitis induced by CD4+CD45RBhi when co-transferred 
into SCID mice (Uraushihara et al., 2003). Notably, both CD25+GITR+ and CD25-
GITR+ cells demonstrated the same suppressive activity, further emphasising that CD25 
is not a definitive Treg marker. More recently multi-organ autoimmune disease could be 
induced in athymic, nude mice by transfer of T cells depleted of GITRhi cells via anti-
GITR mAb (Ono et al., 2006). Overall these data suggest that GITR is expressed by 
cells which have regulatory potential but perhaps again is not a definitive marker of 
natural Tregs.  
 
The function of GITR had been suggested to be via modulation of Treg suppression. 
GITR is largely expressed on activated Tregs (McHugh et al., 2002) perhaps functioning 
as an ‘off switch’ for Tregs in situations where inflammation has been resolved or where 
a robust immune response is required. Indeed anti-GITR mAbs are now being used to 
promote Treg down-modulation where immune response would be beneficial, for 
example in tumours and enhancing vaccine responses (Cohen et al., 2006; Ko et al., 
2005). Also by blocking GITR-triggering it is possible to prevent Tregs from being 
turned off in order to maintain immuno-suppression and prevent excess inflammation 




Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152), has been demonstrated to 
function as a negative regulator of CD28 signalling and IL-2 production by binding to 
the B7 molecules on APC (Walunas et al., 1996). Like CD25, it is constitutively 
expressed on Tregs, but is also up-regulated by naive T cells after activation (Read et al., 
2000). The role of CTLA-4 in Treg-mediated suppression was demonstrated using anti-
CTLA-4 mAb Fab fragments, preventing its interaction with its ligand (Tang et al., 
2004a). CTLA-4 was shown to be important in the control of inflammatory bowel 
disease (IBD) (Read et al., 2000) and type-1 diabetes (Luhder et al., 1998). Tregs from 
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CTLA-4-/- mice develop normally and show normal homeostasis and maintain their 
suppressive ability in vitro. However CTLA4-/- mice still develop fatal autoimmune 
disease, suggesting this suppression is not effective in vivo (Sakaguchi et al., 2006).  
 
CTLA-4-B7 interactions have been shown to occur betwe n Tregs and APC, but also 
suggested to occur directly between Treg-Teff. The eff ct on dendritic cells was shown 
to be via tryptophan metabolism, specifically the induction of indoleamine 2,3-
dioxygenase (IDO) (Fallarino et al., 2003). This enzyme catalyses tryptophan 
degradation, an essential amino acid for T cells, and ultimately regulates the T cell 
response by inducing apoptosis (Mellor and Munn, 2004). CTLA-4 interaction with Teff 
cells has been shown to play a major role in Teff suppression in vitro and in vivo using 
B7-/- T cells (Paust et al., 2004). Transduction of full length B7, but not a truncated 
form which lacked the cytoplasmic tail, restored regulation. These results suggested that 
the CTLA-4-B7 interaction transduced a negative signal to the Teff cells. Blockade of 
CTLA-4 is therefore a promising target to downregulate Treg function. Indeed, this has 
already been investigated in clinical trials of patien s with metastatic melanoma (Phan et 
al., 2003). While some of the patients treated with CTLA-4-blocking agents showed 
regression of the cancer, others showed autoimmune manifestations, demonstrating the 
delicate balance of regulation in the immune system, something we must consider when 
attempting to target Tregs in therapy. 
  
1.2.2.3 Other Treg surface markers 
 
CD62L, or L-selectin, is expressed on naïve T lymphocytes and binds to vascular 
addressins on endothelium such as on the high endothelial venules (HEV) in the lymph 
nodes. This allows homing of T cells to lymphoid organs. It was recognised early on that 
T cells expressing CD62L also had suppressive potential (Herbelin et al., 1998) and the 
CD25+ Tregs which were found in the periphery also expressed CD62L (You et al., 
2004). It was demonstrated that specifically CD62Lhi Tregs played a role in tolerance to 
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autoimmune diabetes (You et al., 2004) and graft acceptance (Taylor et al., 2004). The 
expression of CD62L by Tregs enhances their homing to secondary lymphoid organs 
and this may increase the ability of these cells to in erfere with T cell activation at this 
stage. Accordingly, CD62L expression may not enhance Treg function, but rather allow 
these cells to preferentially locate with effector T cells in the lymph nodes. However, 
one investigation demonstrated that while CD4+CD25+CD62Llo were also anergic and 
expressed other Tregs markers, CD62Lhi Tregs were more potent suppressors in vitro 
and maintained their suppressive function better that CD62Llo or un-fractionated 
CD4+CD25+ cells (Fu et al., 2004). Accordingly, while CD4+CD25+ cells are readily 
used in many groups as ‘purified Tregs’ upon sorting from lymphocyte populations, 
further sorting into a CD62Lhi population routinely gives a purer population of Tregs in 
our hands (Leigh Stephens, manuscript submitted). 
 
CD103 is an αE integrin and is expressed by subsets of CD4+ and CD8+ T cells, but 
also some DCs, particularly in the intestine (Andrew t al., 1996). CD103 binds to E-
cadherin expressed by epithelial cells, particularly in the gut, therefore CD103 is 
suggested to be a gut-specific homing molecule (Cepek et al., 1994). CD103+ Tregs 
have been identified in the gut and this subset of Tregs can control wasting disease, 
particularly by production of the cytokine IL-10 (Banz et al., 2003). Another model 
demonstrated that only a CD103+ population of Tregs could control a cutaneous model 
of Leishmania major infection, with the function ofCD103 attributed to retaining of 
Tregs at the infection site (Suffia et al., 2005). However, CD103+ Treg populations have 
been isolated from both CD25+ and CD25- CD4+ T cells (Lehmann et al., 2002), 
suggesting these may not always represent a naturally arising Treg cell lineage but an 
induced Treg cell as will be discussed in section 2.8.  
 
Huehn and colleagues (Huehn et al., 2004) proposed that expression of CD103 and 
CD62L on Tregs may allow distinction of Tregs at different stages of development. 
CD25+CD62Lhi cells represent naïve Tregs which preferentially home to lymphoid 
organs, enhanced by expression of the chemokine receptor 7 (CCR7), while CD25+ (and 
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CD25-) CD103+ Tregs represent effector/memory-like Tr gs which preferentially home 
to peripheral and inflamed tissues by expression of receptors such as CCR2, CCR4 and 
CXCR3 that attract these Tregs to the site of inflammation. Accordingly, this group 
demonstrated that the CD103+ Treg subsets preferentially migrated to the inflamed joint 
in antigen-induced arthritis (Huehn et al., 2004). CD103+ Tregs have also been 
identified in the inflamed CNS during experimental autoimmune encephalomyelitis 
(EAE), a model of multiple sclerosis (McGeachy et al., 2005) suggesting that CD103-
expression on Tregs may identify a population which is particularly associated with 
inflammation and may be more potent in this setting.  
 
1.2.3 The Discovery of Foxp3 as a Treg-specific tra nscription 
factor 
 
Scurfy mice are a mutant strain where males are grossly affected as the gene harbouring 
the mutation is X-linked. These mice exhibit increas d T cell activation and responses 
(Clark et al., 1999), lymphadenopathy, splenomegaly and show massive lymphocytic 
infiltrates in many organs (Godfrey et al., 1991). The characteristics of these mice 
demonstrate that the scurfy mutation manifests as an autoimmune disease. The disease in 
scurfy mice is remarkably similar to the human disease X-linked neonatal diabetes 
mellitus, enteropathy and endocrinopathy syndrome (IPEX)  (Wildin et al., 2001). In 
2001 Brunknow and colleagues (Brunkow et al., 2001) identified the gene which is 
mutated in the scurfy mouse strain as Foxp3, a new m mber of the forkhead family of 
transcriptional regulators. It quickly followed tha this same gene was responsible for the 
human disease (Bennett et al., 2001). These discoveries sparked massive interest in 
Foxp3 and its function.  
 
In initial experiments, mice that over-expressed Foxp3 showed massively reduced 
peripheral T cell numbers, and were un-responsive to in vitro stimulation as 
demonstrated by lack of proliferation or IL-2 production (Khattri et al., 2001; Schubert 
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et al., 2001).  Later it became apparent that the Foxp3-transgenic mice showed reduced 
T cell-dependent immune responses by somehow regulating the function of effector T 
cells (Kasprowicz et al., 2003). A major breakthrough came when several labs 
simultaneously identified that Foxp3 was specifically involved in the control and 
development of CD4+CD25+ regulatory T cells (Fonteno  et al., 2003; Hori et al., 2003; 
Khattri et al., 2003). Using mixed bone marrow chimeras of wild-type and Foxp3-/- 
mice, Fontenot et al. (Fontenot et al., 2005a) found that only cells from the WT mice 
expressing the Foxp3 gene generated CD4+CD25+ Tregs d monstrating that Foxp3 is 
indispensable for Treg development.  
 
Furthermore, retroviral transduction of Foxp3 into aïve CD4+CD25- T cells resulted in 
up-regulation of Treg markers and acquisition of suppressive function (Fontenot et al., 
2003; Hori et al., 2003). The in vivo function of Foxp3-transduced cells was shown 
when these cells were co-transferred with CD4+CD25- cells to severe combined 
immuno-deficient (SCID) mice. The co-transferred mice were protected from 
inflammatory bowel disease (IBD) compared to when CD25- cells were transferred 
alone (Hori et al., 2003). Using antigen-specific, transgenic CD4+ T cells transduced 
with the Foxp3 gene, Jaekel et al (Jaeckel et al., 2005) demonstrated that these Tregs 
could induce protection from diabetes in the non-obese diabetic (NOD) model, however 
this was not achieved using Foxp3-transduced polyclonal CD4+ cells from the NOD 
mouse, suggesting that the frequency of antigen-specific Tregs may ultimately affect the 
control of autoimmunty.  
 
The discovery of Foxp3 was a substantial leap in Treg biology as these cells could now 
be identified as ‘true’ Tregs. However the intracellular expression of Foxp3 presented a 
problem for identification purposes. The generation f Foxp3-GFP mice by the 
Rudensky lab overcame this problem (Fontenot et al., 2005b). Using a knock-in allele 
which possessed an in-frame green fluorescent protein reporter (GFP) fused to the 
Foxp3 gene, Foxp3+ cells could be detected by confoal microscopy and by flow 
cytometry without the need for cell lysis. From studies using these mice it was realised 
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that Foxp3 is expressed exclusively in αβ T cells, 97% of which also express CD4. 
However, Foxp3 is not exclusively confined to the CD4+CD25+ subset, as 
approximately 60% of CD4+CD25- T cells in the spleen of naive mice expressing the 
gene. Both the CD25+ and CD25- Foxp3+ populations demonstrated in vitro 
suppressive capacity and expressed genes encoding previously identified Treg markers, 
such as CD103 and CTLA-4 (Fontenot et al., 2005b).  
 
The essential role of Foxp3+ Tregs in preventing autoimmunity was demonstrated in 
mice which were specifically ablated of Foxp3+ Tregs (Williams and Rudensky, 2007). 
Thus far, the data on Foxp3 identified this gene as a lineage specification factor for 
Tregs, similar to the role of T-bet, GATA-3 and RORγ-t in Th1, Th2 and Th17 cells 
respectively. Further characterisation of Foxp3 expr ssion and how it functions will be 
discussed in later sections.  
 
1.2.4 Thymic generation of Tregs 
 
The evidence that Tregs represent a functionally and developmentally distinct T cell 
lineage which arises in the thymus and could regulate immune responses existed even 
before the identification of Foxp3 (Itoh et al., 1999). Thymic selection was largely 
viewed in terms of two processes, positive and negative selection (as discussed in 
section 1.2.),  however evidence began to show that t e thymus was involved in 
selection of Tregs. A review by Seddon and Mason in 2000 suggested the generation of 
Treg cells as the ‘third function’ of the thymus (Seddon and Mason, 2000). 
 
1.2.4.1 Antigenic-reactivity of Tregs 
 
The processes in the thymus are based on self-reactivity. Negative selection deletes T 
cells with a high avidity for self-antigen, while positive selection allows survival of 
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weakly self-reactive T cells. However understanding of the antigenic-reactivity of Tregs 
and the selection events these cell undergo in the thymus was lacking. The activity of 
Tregs has been shown to require stimulation via the TCR to exert suppression in vitro 
and to control organ-specific autoimmune disease in vivo (Thornton and Shevach, 2000; 
Walker et al., 2003). Also, as antigen-specific Tregs were responsible for the prevention 
of diabetes in the NOD mouse model (Jaeckel et al., 2005) it was hypothesised that 
Tregs would express TCRs reactive to self antigens.  
 
Transgenic mice expressing a single TCR and which are crossed onto the RAG-/- 
background, i.e. cannot undergo TCR revision, rapidly evelop spontaneous 
autoimmunity (Lafaille et al., 1994; Van de Keere and Tonegawa, 1998). RAG-/- TCR 
transgenic mice were shown to lack CD4+CD25+ cells in the periphery as a result of the 
deficiency, suggesting that Treg development requird receptor editing (Hori et al., 
2002) and together these data further suggested a role for TCR specificity in thymic 
generation of Tregs. Using a TCR transgenic model where all T cells were reactive to an 
epitope of influenza heamagluttinin (S1 HA) crossed with an HA-expressing mouse 
strain, Caton’s group investigated the role of self-antigen in development of Tregs 
(Jordan et al., 2001). This study demonstrated that interaction with self-peptide on radio-
resistant thymic epithelial cells could select cells to become CD4+CD25+ Tregs. Only T 
cells which showed a high affinity for the antigen were selected to become regulatory 
cells as low affinity T cells did not become Tregs. Using a similar model with OVA-
expressing D011.10 TCR transgenic mice (all of the TCRs on CD4+ cells are reactive to 
an OVA peptide), Walker et al. demonstrated increased transgenic Treg numbers in the 
periphery of OVA-expressing mice compared to non-OVA expressing mice (Walker et 
al., 2003).  
 
In both of these studies the investigators demonstrated induced Treg generation in the 
periphery of RAG-/- TCR transgenic mice by introducing the cognate ligand of the TCR 
into the mouse. These findings explained the deficiency of Tregs in RAG-/- mice which 
did not express the cognate peptide – these mice lack d a peptide which the Tregs could 
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be selected upon and therefore were required to undergo TCR re-arrangements to 
generate a TCR capable of recognising a thymic peptid . RAG-/- mice could not 
undergo TCR rearrangements, therefore lacked Tregs. Using Foxp3-GFP mice it was 
confirmed that Foxp3+ thymocytes were restricted to the CD4 single-positive (SP) 
population and absolutely dependent on TCR-pMHC interactions, as demonstrated by 
the lack of Foxp3+CD4SP thymocytes in Aβb-/- mice which lack MHC class II 
(Fontenot et al., 2005b).  
 
As mentioned, thymic epithelia express the transcription factor AIRE which allows 
promiscuous expression of tissue-specific antigens in the thymus (Anderson et al., 2002) 
and has been suggested to play a role in selection of Foxp3+ Tregs (Aschenbrenner et 
al., 2007). However, the role of AIRE has been mostly at ributed to the deletion of auto-
reactive T cells rather than selection of Tregs. Some groups have produced data that 
supports the model that increased affinity for self-p ptide;MHC complexes favours Treg 
development (Jordan et al., 2001; Picca et al., 2006; Yu et al., 2008), proposing that 
Tregs show a higher affinity towards self-antigen than T effector cells. Investigations of 
the TCR repertoires of CD25+ and CD25- T cells showed that their TCRs were 
comparable in diversity, but distinct and only showing partial overlap (Hsieh et al., 
2006; Pacholczyk et al., 2007; Wong et al., 2007). Although one of these studies 
concluded that Tregs were reactive to non-self rather t an self (Pacholczyk et al., 2007) 
it is believed that most Tregs show an inherent self-reactivity and this has been proposed 
to be a positive factor in peripheral maintenance of Tregs.  
 
Compared to CD25- cells, CD25+ Tregs show increased proliferation in the steady state 
in vivo, proposed to be through constant low level TCR stimulation by self antigens in 
the periphery (Fisson et al., 2003). Furthermore, retroviral transduction of TCRs cloned 
from CD4+CD25+ Tregs, but not CD4+CD25- cells, resulted in T cells which 
underwent massive expansion upon transfer to a lymphopaenic host (Hsieh et al., 2004). 
Although a lymphopaenic environment is not the most physiologically relevant situation, 
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this enhanced proliferation of cells transduced with Treg TCRs was proposed to be due 
to the reactivity of these TCRs against self-peptides. 
 
1.2.5 Signals which drive Treg selection 
1.2.5.1 TCR signals 
 
Some of the studies mentioned in section 1.2.4 proposed a model of instructive Treg 
generation, whereby self-antigen specifically drives a cell towards a Treg fate (Jordan et 
al., 2001; Yu et al., 2008). However, other studies proposed a more selective model 
where commitment to the Treg fate is random, but Treg populations show enhanced 
resistance to deletion compared to non-Tregs. Self-reactive Tregs are not, therefore, 
deleted in the thymus and thus skews their TCR repertoir  towards self-reactivity (van 
Santen et al., 2004). A recent study by Lio et al (Lio and Hsieh, 2008) has suggested the 
thymic development of Tregs is an instructive mechanism divided into two processes; 1) 
TCR-mediated self-peptide recognition, driving up-regulation of CD25 and 2) TCR-
independent cytokine signals that drive Foxp3 expression and commitment to the Treg 
lineage. The requirement for TCR-mediated signaling events in Treg thymic generation 
was emphasised in mice which have a defect in a major TCR signaling component linker 
for activated T cells (LAT) (Koonpaew et al., 2006). The mutation prevents binding to 
the downstream signaling molecule PLCγ1 and these mice have a severe deficit in both 
thymic and peripheral Foxp3+ cells. Importantly, LAT-defective mice showed no 
defects in positive selection emphasising that this process is distinct from the signals that 




Deficiency of IL-2 or the components of its receptor, CD25 (IL-2Rα) and CD122 (IL-
2Rβ), result in fatal lympho-proliferative disease in mice (Horak et al., 1995) and similar 
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deficiencies have been reported in humans (Sharfe et al., 1997). These disorders were 
proposed to be due to deficiencies in either the thymic development or peripheral 
maintenance CD25+ Tregs (Bayer et al., 2005; Furtado et al., 2002; Malek et al., 2002). 
Using CD4+ cells from IL-2-/- mice, Furtado et al could transfer protection from 
autoimmunity to WT hosts, but this could not be seen with CD25-/- donor cells (Furtado 
et al., 2002). They reasoned that in the absence of IL-2 the thymic development of Tregs 
could occur, but that IL-2 was essential for their suppressive function in the periphery. 
With the use of  Foxp3-GFP mice it was confirmed that mice deficient in either IL-2 or 
CD25 had normal induction of Foxp3 in thymocytes (Fontenot et al., 2005a). However, 
this group also identified that the deficiency in Tregs was exacerbated in mice lacking 
the common γ-chain receptor, suggesting that in the absence of IL-2, IL-15 may 
compensate, thus some degree of signalling via the γ-chain is required for thymic 
generation of Tregs.  
 
While many have suggested that IL-2 is essential for Treg function, some studies 
suggest that it is dispensable for Treg-mediated suppression (D'Cruz and Klein, 2005). 
This study argued that IL-2 was only necessary for the maintenance of Tregs in the 
periphery, although they could not rule out the possibility that IL-2 may be a maturation 
signal that allows Treg emigration from the thymus.  
 
1.2.5.3 Downstream signals of IL-2 
 
Signalling via the common γ-chain activates signalling molecules, janus kinases (Jaks). 
Like the γ-chain deficient mice, Jak-/- mice also lack thymic and peripheral Foxp3 
expression (Mayack and Berg, 2006). IL-2-mediated Jak activation leads to the 
phosphorylation of members of the Stat family (Signal transducers and activators of 
transcription), Stat5a and Stat5b (Johnston et al., 1995). Investigating the role of Stat5a 
and b, Yao et al. (Yao et al., 2007) demonstrated that these signals occurring 
downstream of IL-2 signalling were essential and non-redundant for Treg cell function 
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and for optimal Foxp3 induction. Foxp3 was shown to be a direct target of Stat5 as 
STAT-5 binds to the Foxp3-promoter (Burchill et al., 2007). More recently a study 
demonstrated that constitutive STAT-5 signalling could overcome the deficiency of 
Tregs in CD28-/- mice and drive T cells that would normally become effector T cells 




CD28 co-stimulation forms part of signal 2 in the T cell activation cascade and is 
essential for full T cell function. NOD mice deficient in CD28 signalling were shown to 
develop accelerated diabetes and to lack peripheral Tregs. This was proposed to be due 
to the lack of IL-2 from activated Teff cells and therefore Tregs could not be maintained 
(Salomon et al., 2000). However, thymocytes in CD28-/- mice also did not express 
Foxp3 (Tai et al., 2005). CD28 signalling in thymocytes was shown to directly drive 
Foxp3 expression, independently of IL-2 signalling (Tai et al., 2005); however, while 
these cells expressed GITR and CTLA-4, they did not up-regulate CD25 or show 
suppressive capacity, therefore were described as immature thymic Tregs.  
 
A recent article by Burchill et al combines the pathways mentioned above and suggests 
that the TCR/CD28 and cytokine signals together drive the development of regulatory T 
cells (Burchill et al., 2008). Their data present a model where TCR/CD28 signalling 
initiates the pathway towards the Treg lineage, including up-regulation of Treg markers 
and cytokine receptors, followed by the production of cytokines that drive the activation 
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1.2.6 Activity of Foxp3. 
 
Foxp3 is a member of the forkhead/winged-helix family of transcriptional regulators 
which possess three functional domains (Figure IIIA) (Campbell and Ziegler, 2007). 
Mutations in these domains have begun to reveal the functions of each (Lopes et al., 
2006; Marson et al., 2007; Wu et al., 2006). The forkhead domain (FKH) acts as a 
nuclear localisation factor and DNA-binding domain (Schubert et al., 2001). NFAT 
(Nuclear factor of activated T cells) proteins play a major role in the transcription of key 
genes in T cell activation, including many cytokine genes. NFAT binds co-operatively to 
transcriptional co-factors, notably AP-1, which allows binding to composite sites in the 
regulatory regions of their target genes to initiate transcription (for a review on NFAT 
and its function, see (Rao et al., 1997)). FKH binding sequences have been identified 
next to NFAT regulatory sites in the promoters of cytokine genes (Schubert et al., 2001). 
Foxp3 was shown to repress NFAT-mediated transcription, suggested to be via 
competition with NFAT (Schubert et al., 2001). Later work showed that suppression of 
transcription was associated with direct Foxp3-NFAT interactions (Bettelli et al., 2005).  
 
More recently, Wu et al. (Wu et al., 2006) determined that Foxp3 directly interacts with 
NFAT. Using guided mutations determined by the crystal structure of the protein 
interactions the investigators could interfere with the Foxp3-NFAT binding in a graded 
fashion. Progressive disruption of the interaction affected the ability of Foxp3 to repress 
il-2 transcription in a graded manner. This study suggested that NFAT can drive both 
immunity and tolerance in T cells via differential recruitment of the transcription factors 
AP-1 and Foxp3 respectively (Figure IIIB) (Wu et al., 2006). Following on from this 
observation, it was shown that the N-terminus of Foxp3 inhibits the promoter activity of 
AP-1 by binding to phosphorylated sites and altering ts sub-nuclear localisation, 
suggesting a mechanism of how Foxp3 may compete against NFAT-AP1 binding (Lee 
et al., 2008a).  













Figure III: Structure and function of FOXP3 . A: Schematic diagram of the 
FOXP3 showing individual domains and a description of their function as 
discovered by site directed mutagenesis (Adapted from Campbell and Zeigler 
Nat. Rev. Imm. 2007). B: Left: Schematic representation of the T cell activation 
program mediated by TCR/CD28 signals involving the NFAT:Fos:Jun complex. 
Right: In regulatory T cells TCR signalling may be affected by an as yet unknown 
signal that drives the co-operation of FOXP3 with NFAT and its interaction with 
composite DNA elements. The NFAT:FOXP3:DNA complex regulates the
expression of genes required for the development and function of Tregs. 
(Adapted from Wu. et al. Cell 2006). 
DOMAIN
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To determine the target genes of Foxp3 two groups have used chromatin-
immunoprecipitation (ChIP) and DNA microarray techniques to identify the promoter 
regions bound by Foxp3. One group, using FLAG-tagged Foxp3-transduced CD4+ T 
cell hybridomas, identified ~1,100 genes regulated by Foxp3 (Marson et al., 2007). The 
other group used primary CD4+ T cell cultures and identified ~700 genes targeted by 
Foxp3 (Zheng et al., 2007b). Discrepancies in the target gene number may be 
attributable to the different cell types analysed, however, one similar observation from 
both groups is that while Foxp3 acts as a negative regulator of many factors, such as IL-
2, it also induced upregulation of other genes, encoding CD25, CTLA-4 and GITR 
(Marson et al., 2007; Zheng et al., 2007b) suggesting Foxp3 can also act as a positive 
regulator of some genes.  
 
1.2.7 Foxp3 – essential to the Treg lineage? 
 
The experiments involving ectopic expression, or over-expression, of Foxp3 in T cells 
showed conversion of naïve T cells towards a Treg phenotype (see section 2.3). These 
observations led to the hypothesis that Foxp3 acts as a Treg lineage specification factor. 
However, it was not clear if Foxp3 expression occurs as a consequence of developing 
thymocytes becoming committed towards the Treg lineage, or if Foxp3 initiates the 
commitment towards the Treg lineage. Lin et al. (Lin et al., 2007) addressed this 
question by using a Foxp3 allele which directs the expression of a non-functional fusion 
protein of Foxp3 and enhanced GFP (Foxp3∆GFP). This fusion protein generates a 
Foxp3 lacking the C-terminus therefore cannot translocate to the nucleus to bind NFAT. 
Mutant Foxp3∆GFP mice showed normal thymocyte development, similar to wild-type 
mice, and mutant thymic GFP+ cells expressed the Treg markers CD25, CD62L, CTLA-
4 and GITR. This study suggested that Treg thymic generation could occur in the 
absence of Foxp3 and that Foxp3 was not responsible for driving the Treg lineage.  
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In confirmation with this study, the majority of signature Treg-associated genes were 
shown not to be due to Foxp3 expression, but were gn s that could be co-regulated with 
Foxp3 (Hill et al., 2007). These studies highlighted that signals up-stream of Foxp3 
expression must drive T cells towards a Treg lineage. However, the Foxp3- mutant cells 
could not suppress the anti-CD3 induced proliferation of naïve splenocytes, suggesting 
that nuclear localisation is required for suppressive function of the Tregs (Lin et al., 
2007). Foxp3∆GFP thymocytes showed a four-fold increase in the number of late 
apoptotic cells, consistent with the notion that Foxp3+ Tregs have an intrinsic resistance 
to apoptosis and enhanced survival compared to Foxp3- cells (Papiernik et al., 1998; 
Taylor et al., 2007).  
 
The requirement for Foxp3 expression to maintain Treg function in the periphery was 
demonstrated by Williams et al. (Williams and Rudensky, 2007) using a loxp-flanked 
Foxp3 allele. When Foxp3 was removed from these cells they lost suppressor cell 
function and, interestingly, gained the ability to produce IL-2 and effector cytokines 
(Williams and Rudensky, 2007).  
 
1.2.8 Other regulatory cell types 
1.2.8.1 Tr1 cells 
 
T regulatory type 1 cells (Tr1) were described the Roncarolo group in the late 90’s as a 
population of  CD4+ T cells activated in the presence of high dose of IL-10 which 
produced significant amounts of IL-10, TGFβ and IL-5 (Groux et al., 1997). These cells 
were shown to suppress T cell proliferation in vivo and when co-transferred with 
CD45RBhigh T cells they could suppress IBD in SCID mice. Murine Tr1 cells do not 
produce IL-4 or IFNγ (Battaglia et al., 2006a) making these cells distinct from Th cells, 
however human Tr1 cells were shown to make IFNγ albeit at a lower level than Th1 
cells (Bacchetta et al., 2002). Like nTregs, Tr1 show a very low proliferative capacity to 
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TCR stimulation, but can be expanded in vivo in the pr sence of IL-2 (Bacchetta et al., 
2002). Tr1 cells also express normal levels of activ tion markers after activation, 
although these cells do not express Foxp3 and a definitive marker for Tr1 remains 
elusive (Battaglia et al., 2006a; Vieira et al., 2004). IL-10 is largely considered to drive 
Tr1 generation (Groux et al., 1997) although stimulation of T cells with vitamin D3, 
dexamethaosone and anti-IL-12, -IL-4 and -IFNγ antibodies have all been reported to 
induce Tr1 differentiation (Barrat et al., 2002). Stimulation of T cells with immature DC 
(iDC) also generate an IL-10-producing population which resembles the Tr1 phenotype 
(Wakkach et al., 2003) and these IL-10-producicng cell have been proposed to play a 
tolerogenic role in the steady state.  
 
The investigation into IL-10+ Tregs began after discovery of this cell phenotype in a 
SCID patient displaying long-term graft tolerance (Bacchetta et al., 1994). Since their 
identification, Tr1 cells have been associated in modulating responses to self-antigens 
(Groux et al., 1997) and their function is altered in certain autoimmune pathologies, for 
example in rheumatoid arthritis (Yudoh et al., 2000) and diabetes (Battaglia et al., 
2006b). Low dose peptide therapy has also been associ ted with an increase in antigen-
specific IL-10+ cells for cat dander allergy (Smith and Larche, 2004). Tr1 cells 
constitute a regulatory population that arises in the periphery in response to antigenic 
stimulation in the presence of high levels of IL-10 and may play a functional role in 
allergic/autoimmune settings. 
 
1.2.8.2 Th3 cells 
 
T helper type 3 (Th3) cells are generally associated with oral tolerance, secrete large 
amounts of TGFβ and suppress Th1/Th2 responses (Weiner, 2001). Th3 cells have also 
been reported to suppress autoimmunity (Carrier et al., 2007b) but this may be through 
their de novo induction of Foxp3+ Tregs (Carrier et al., 2007a) as TGFβ signals have 
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been shown to convert CD25- T cells to Foxp3+ T cells in the periphery (Zheng et al., 
2007a). 
 
1.2.8.3 CD8+ Tregs 
 
The initial discovery of suppressor T cells by Gershon and Kondo in the 1970’s was 
largely focussed on CD8+ cells (Gershon and Kondo, 1970; Gershon and Kondo, 1971). 
Since the revival of regulatory T cells in the early 1990’s, CD4+ cells have taken centre 
stage, however, CD8+ Tregs are now coming back into fav ur (Smith and Kumar, 2008) 
. CD8+ cells have been demonstrated to be induced to become regulatory and are 
dependent on the production of IFNγ, which stimulates the production of TGFβ (Myers 
et al., 2005) and CD8+ Tregs have been demonstrated to play a role in allograft survival 
(Guillonneau et al., 2007). This study identified that IFNγ production by CD8+ cells 
induced IDO expression by the vascular endothelial cells of the graft, thus generating an 
immune privileged site. A recent study has identified CD8+ regulatory T cells in MS 
patients (Correale and Villa, 2008). These cells show cytolytic activity against myelin-
reactive CD4+ T cells and interestingly, reduced levels of CD8+ Tregs correlated with 
relapses in the patients. CD8+ Tregs have also beenimplicated in recovery from EAE, 
the mouse model of MS (Lee et al., 2008b). 
 
1.2.8.4 B cell regulation 
 
While B cells have been implicated in the pathogenesis of many chronic immune 
responses, including autoimmunity, more recent studies have identified a role for B cells 
in regulating immune responses. Triggering of naïve B cells via TLRs induces IL-10 
production, while CD40 signalling has also been shown to be important (Fillatreau et al., 
2008). B cells producing IL-10 have been shown to play a role in models of chronic 
intestinal inflammation (Mizoguchi et al., 2002), rheumatoid arthritis (Mauri et al., 
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2003) and EAE (Fillatreau et al., 2002). Indeed, B cell IL-10 production was shown to 
be reduced in patients with MS attributed to the fact that there were fewer naïve B cells 
in these patients compared to healthy controls (Duddy et al., 2007). However, while B 
cell IL-10 has been shown to be essential in EAE (Fillatreau et al., 2002), Foxp3+ Tregs 
were found to be the essential source of IL-10 within e CNS (McGeachy et al., 2005). 
 
1.2.9 Mechanisms of Regulation 
 
In the periphery Tregs have been described to have four main functions of suppression; 
suppressive cytokines, cytolysis, metabolic disruption and modulation of APCs (Vignali 
et al., 2008). Originally, upon the discovery of Tregs it was suggested that they function 
in a cell-contact dependent fashion either between Tregs and APC (Takahashi et al., 
1998) or between Tregs and responder cells in vitro (Thornton and Shevach, 1998). 
However, in vivo models have revealed behaviour of Tregs which is not seen in vitro, 
and may represent more physiologically relevant mechanisms of Treg-mediated 




IL-10 and TGFβ are the cytokines most commonly associated with TReg-induced 
suppression. As mentioned above, IL-10 and TGFβ are produced by peptide-induced Tr1 
and Th3 cells respectively, but thymically derived Foxp3+ Tregs are also proposed to 
secrete these cytokines. IL-10 was shown to be responsible for Treg suppression of 
intestinal inflammation, as Tregs from IL-10-/- mice or blockade of IL-10 using mAbs 
prevented recovery from CD4+CD45RBhi transfer-induced colitis in SCID mice 
(Asseman et al., 1999). Also, IL-10 has been shown to play a role in allergic and 
asthmatic responses (Hawrylowicz, 2005) and in autoimmunity (McGeachy et al., 2005). 
As mentioned above peptide-induced Tr1 cells are proposed to be a major source of IL-
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10 however, both natural and induced Tregs have been shown to play a role in the 
resolution of some responses (Hawrylowicz, 2005). IL-10 is produced by a number of 
cell types, including B cells, mast cells, NK cells and DCs (Moore et al., 2001) but a 
recent study has targeted the specific deletion of IL-10 from Foxp3+ T cells (Rubtsov et 
al., 2008). By generating Foxp3YFP-cre mice crossed with il10flox/flox this group 
showed that Treg-derived IL-10 was not solely respon ible for prevention of 
autoimmune responses, seen with Foxp3-/- mice, but are essential to the control of self- 
and environmental antigen tolerance and limiting hyper-responsiveness to antigens at 
mucosal surfaces.  
 
The role of TGFβ in Treg-mediated suppression appears more contentious, with some 
reports suggesting it is not important in nTreg-mediated suppression (Piccirillo et al., 
2002) while others have reported that CD45RBhigh T cells expressing a dominant 
negative TGFβ receptor could not be suppressed by Tregs in the SCID transfer model of 
IBD (Fahlen et al., 2005). Some in vitro studies have suggested that while soluble TGFβ 
does not play a role in T cell suppression, membrane bound TGFβ is required for 
maximal Treg suppression (Nakamura et al., 2001). Membrane bound TGFβ has also 
been shown to play a role in suppression of CD8+ T cells (Green et al., 2003) and the 
decline of membrane-bound TGFβ is associated with the loss of Treg suppression and 
subsequent development of autoimmune diabetes (Gregg et al., 2004). 
 
More recently a new member of the IL-12 family, IL-35, has been proposed to play a 
role in Treg suppression (Collison et al., 2007). This study demonstrated that the two 
components of IL-35, Ebi3 (IL-27β) and Il12a (p35) are up-regulated in Foxp3+ Tregs 
and are boosted when Tregs are co-cultured with Teff cells. IL-35 suppressed T cell 
proliferation and conferred regulatory activity when ctopically expressed in naïve T 
cells (Collison et al., 2007).  IL-35 has also been shown to be effective at suppressing 
Th17 cells and can function therapeutically in collagen-induced arthritis model 
(Niedbala et al., 2007). Further investigation into this cytokine will determine if it is 
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indeed a Foxp3+ Treg specific cytokine and the role it may play in Treg 




Release of granzymes as mediators of virally-infected or tumour cell elimination has 
long been associated with the activity of CD8+ T cells and NK cells (Lieberman, 2003). 
However, investigation into the genes up-regulated by Foxp3+ Tregs revealed the 
expression of granzyme B in these cells (Zheng et al., 2007b). Gondek et al. have also 
demonstrated that Tregs do possess cytolytic activity in a granzyme B-dependent fashion 
in vitro (Gondek et al., 2005) and this was later confirmed to be required for Treg 
suppression of B cells in vivo (Zhao et al., 2006). Other granzyme-independent 
pathways of apoptosis have also been suggested, for example via galectin-1 (Garin et al., 
2007) and TRAIL (Ren et al., 2007). While Treg killing has been demonstrated, the 
importance of this mechanism in suppression is yet to be fully elucidated and it would be 
difficult to explain bystander suppression mechanism in this context, as direct cell 
contact would be required for this function of Tregs. 
 
1.2.9.3 Metabolic disruption 
 
As Tregs constitutively express the high affinity IL-2 receptor acting as an IL-2 ‘sink’ 
was one of the intital hypothesis of Treg function (Sakaguchi et al., 1995) and was 
shown to be an effective mechanism in vitro (de la Rosa et al., 2004; Scheffold et al., 
2007). Recently Treg-mediated cytokine deprivation and apoptosis of Teff cells was also 
shown to function in vivo in a mouse model of IBD (Pandiyan et al., 2007).  
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1.2.9.4 Effects on APC 
 
While suppression of T cell responses has been shown t  occur in vitro in the absence of 
APC (Shevach, 2002) it is clear that Treg-APC interactions also occur. This has 
predominantly been shown via CTLA-4-B7 interactions (Takahashi et al., 2000) that 
have been proposed to increase IDO expression by DCs (Fallarino et al., 2003). Two 
studies which utilised two-photon laser scanning cytometry have been able to visualise 
Treg function in vivo (Chappert et al., 2008; Tadokoro et al., 2006). These studies have 
shown that Tregs can form stable contacts with DC, after which the DC do not form 
stable interactions with Teff cells. Recently, Sarris et al described selective expression of 
Neuropilin-1 on Tregs that enhances their interaction with DC in vitro and may give 
them a selective binding advantage over Teff (Sarris et al., 2008). The exact mechanisms 
involved in the in vivo models has not been fully examined yet, but they suggest that 
Treg may induce DC release of soluble mediators which prevent Teffector cell 
interaction or that Treg can directly prevent the activ tion of DC. Consistent with the 
later hypothesis, some studies have demonstrated that CTLA-4-B7 interactions induced 
down-regulation of co-stimulatory molecules on the surface of  immature DC (Oderup et 
al., 2006). 
 
1.2.10 Overcoming Treg suppression 
 
Obviously in some settings a robust immune response is r quired and the suppression 
mechanisms of Tregs must be turned off. As previously mentioned, GITR ligation on 
both Tregs and Teff cells has been shown to abrogate suppression, although this has 
been attributed to GITR signalling in the responder T cells rather than in Tregs 
(Stephens et al., 2004). Other cell surface molecules such as OX40 (Valzasina et al., 
2005) and 4-1BB (Choi et al., 2004) have also been proposed to play a role in negative 
stimulation to Tregs and blocking their suppression.  
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Certain cytokines, such as IL-6 and IL-12 can act to release Teff cells from Treg 
mediated suppression (Dominitzki et al., 2007; Fehervari and Sakaguchi, 2004). 
Importantly, these cytokines are released from activ ted DC, usually via TLR 
stimulation. TLR expression has also been detected on Tregs (Caramalho et al., 2003). 
Two recent studies have investigated the effect of TLR2 ligation on Tregs. Combined 
with IL-2 and TCR stimulation, ligation of TLR2 induced Treg proliferation and 
abrogated their suppressive capacity (Kabelitz, 2007; Liu et al., 2006). Foxp3 expression 
was also shown to be reduced following TLR2 stimulation (Liu et al., 2006) suggesting 
a possible, undefined mechanism for controlling suppression. 
 
Tregs clearly function by a number of different mechanisms, proposed by Vignalli – 
how many mechanisms do Tregs need? (Vignali et al., 2008). It is likely that the varied 
mechanisms of Tregs represent the many functions they play in our immune system. 
Depletion of some mechanisms of suppression results in T cell hyper-activation and 
autoimmunity, while elimination of other does not result in autoimmunity, but in the 
activation of T cells at mucosal surfaces. These diff rences probably reflect the multiple 
roles that Tregs play, from maintaining peripheral homesostasis, to preventing excessive 
damage during inflammation and maintaining potentially uto-aggressive lymphocytes 
in the periphery in a dormant state. These functions may be controlled by different 
subsets of Tregs including both natural and induced Tr gs, but also sub-division between 
these groups based on their integrin and chemokine receptor expression. Ultimately, the 
balance between these cells and effector T cells determine the outcome of our immune 
response in both the steady state and during infecton, for better or worse. 
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1.3 Multiple Sclerosis and EAE 
 
Multiple Sclerosis (MS) is a chronic inflammatory neurological disease, characterised by 
infiltration of mononuclear cells in the central nervous system (Noseworthy et al., 2000). 
Clinically, the effects of the inflammation result in plaques in the CNS that is visible via 
magnetic reasonance imaging (MRI) (Napoli and Bakshi, 2005). The plaques represent 
areas of destroyed myelin, an important component which insulates axons and allow the 
effective transmission of nerve impulses to and from the brain. The damage to myelin 
prevents signals to the muscles, resulting in muscle weakening and progressive disability 
in many patients (Trapp et al., 1999). MS usually begins in young adulthood and can 
follow a primary-progressive course or relapsing-remitting course, where between 
episodes of disease there is a period of time where no disease is apparent (Noseworthy et 
al., 2000). Initiation of MS, genetic and environmental factors affecting disease course 
and the cellular components which propagate the disase have been investigated as 
extensively as possible in humans. However, much of our understanding has come from 
development of a mouse model of MS, EAE. Encephalomyelitis was first identified by 
Rivers et al. after injection of attenuated rabies vaccines grown in rabbit brain. Brain 
lesions that were observed after vaccination were suggested to be due to antigens in the 
rabbit brain tissue Active induction of encephalomyelitis was shown to be induced in 
animals using CNS-derived antigens emulsified in complete Freunds adjuvant (CFA) 
and formed the basis of the EAE model (Kabat et al., 1946). EAE is therefore an induced 
model of disease and while it has obvious differences from MS, it provides an effective 
immunological tool to study the basis of disease mechanisms and highlight potential 
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1.3.1 Susceptibility to MS 
 
There is strong evidence to suggest that environmental a d genetic factors play major 
roles in susceptibility to MS (Sotgiu et al., 2004). The geographical clustering of high 
incidence of MS strongly suggests environmental factors can enhance the risk of 
developing MS. These factors include exposure to certain infectious oragnsims 
(Ascherio and Munger, 2007a), but also non-infectious parameters such as exposure to 
sunlight (Ascherio and Munger, 2007b). 
 
Genetic linkage to MS susceptibility has long been suggested (Jersild et al., 1973) and 
confirmed with recent investigations into the genes that are associated with disease 
susceptibility. Of the genes associated with MS, the strongest genetic association is with 
the MHC complex. Certain human leukocyte antigens (HLA) have shown the strongest 
correlation with MS, particularly HLA-DR2 (Etzensperg r et al., 2008). Transgenic 
mice were generated that expressed the HLA-DR2 element DRB1*1501 and that 
expressed a TCR from patients with MS (Madsen et al., 1999). These mice developed 
clinical signs of paralysis and confirmed that exprssion of particular MHC genes will 
affect susceptibility to MS.  
 
More recently using DNA microarray technology, alleles of IL2RA and IL-7RA were 
confirmed along with alleles of the HLA locus as heritable risk factors for MS (Hafler et 
al., 2007). As the IL-2Rα chain (CD25) is expressed by the majority Tregs (Sakaguchi et 
al., 1995) and the recently described role for IL-7 in the generation of Foxp3+ Tregs 
(Bayer et al., 2008; Mazzucchelli et al., 2008) theeffect of these risk alleles on Treg 
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1.3.2 MS as an immune-mediated disease 
 
The damage of the myelin sheath in MS is largely believ d to be the result of a 
autoimmune response, mediated by self-reactive lymphocytes (McFarland and Martin, 
2007). The role of the immune response in MS is highlighted by the efficacy of 
therapeutic targets of MS and EAE which almost exclusively target at least one aspect of 
the immune response. Monoclonal antibody therapies that deplete immune cells 
(Brostoff and Mason, 1984) or that target immune cell activation and migration to the 
CNS (Linker et al., 2008)  have been shown to stop inflammation.  
 
B cell-specific depletion using the mAb Rituximab (anti-CD20) reduced inflammatory 
lesions in the brain (Hauser et al., 2008). Further contributing to the evidence for a role 
of B cells in MS, anti-myelin antibodies can be detected in the cerebro-spinal fluid of 
patients after a primary MS event (Berger et al., 2003).  
 
T cells have also been identified in the lesions of chronic MS lesions (Traugott et al., 
1983) and T cells isolated from peripheral blood of MS patients are reactive against a 
number of CNS components, including myelin basic protein (MBP), proteo-lipid protein 
(PLP), myelin ologodendrocyte glycoprotein (MOG) and stress proteins such as αB-
βcrystallin (Steinman, 2001). Although CD4+ and CD8+ neuroantigen-specific T cells 
can be found in both healthy people and MS patients, the T cells in MS patients have an 
altered phenotype, suggesting differential activation (Crawford et al., 2004). While 
CD8+ T cells have been suggested to proliferate more extensively than CD4+ cells in 
MS patients (Babbe et al., 2000), perhaps the largest indicator that CD4+ T cells are 
involved in MS is the association of HLA (MHC) class II molecules with heightened 
susceptibility to disease (Olsson et al., 2006). How MHC background can affect 
autoimmunity is discussed in the next section.  
 
Autoreactive CD4+ T cells which can proliferate in response to MBP and PLP have 
been identified in the peripheral blood and CSF of MS patients (Zhang et al., 1994). A 
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more recent study has identified a correlation betwe n the presence of T cells and 
antibodies in the blood which react to myelin epitoes and the formation of lesions in the 
brain (Greer et al., 2008). These studies strongly suggest that adaptive immune cells play 
an important role in the pathogenesis of MS and support the classification of MS as an 
immune mediated disease. 
 
Treatment with IFNβ is an approved therapy for MS, and is associated with a reduction 
in inflammatory lesions (de Andres et al., 2007; Li et al., 2001). Treatment is associated 
with closure of the blood-brain barrier (BBB) and down-regulation of VLA-4 on CD4+ 
T cells (Calabresi et al., 1997; Stone et al., 1995). Human trials of an anti-VLA-4 mAb 
have shown reductions in inflammatory lesions and reduced relapse rates (Miller et al., 
2003). TNFα and IFNγ induce up-regulation of VCAM on endothelial cells and 
increased VLA-4 on CD4+ T cells, thus facilitating their migration across the BBB. 
However, to migrate through the extracellular matrix, matrix metallo-proteinases (MMP) 
are required to degrade the collagen and allow lymphocyte access. MMPs are detected in 
the CSF of MS patients and are secreted from endothelial cells, macrophages and 
astrocytes of the lesions and myelin-specific T cells have been shown to produce MMPs 
upon activation (Conlon et al., 1999).  
 
Other cell types, including CNS-resident cells and cytokines have also been shown to be 
involved in the destruction of the myelin sheath. Steinman (Steinman, 2001) has 
proposed a two-stage model of MS whereby neuroantige -reactive T cells become 
activated (see later discussion) and induce inflammtory cytokine release, including 
IFNγ and TNFα which can allow their migration across the BBB by up-regulation of 
adhesion molecules. Secondarily, activation of macrophages, microglial cells 
(Benveniste, 1997) and astrocytes in the CNS by lymphotoxin-α (LTα) and TNFα 
induces the up-regulation of iNOS, which catalyses nitric oxide (NO) synthesis, and 
mediates killing of oligodendroglial cells. Many cells, both immune and non-immune, 
can therefore contribute to MS pathogenesis, however from these studies it is likely that 
an immune-mediated mechanism is ultimately responsible for development of disease. 
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1.3.3 EAE as an immune mediated disease 
 
Like MS, macrophages play a major role in the initiation of the EAE by release of 
cytokines, such as LTα and TNFα and IL-12 (Bauer et al., 1995; Benveniste, 1997). 
These upregulate co-stimulatory molecule expression and enhance antigen presentation 
on microglia and astrocytes and allow permeability of the CNS to other leukocytes. The 
pathogenesis of EAE is mediated by CD4+ T cells, demonstrated by the appearance of 
clinical disease upon transfer of CD4+ cells purified from mice with EAE (Zamvil et al., 
1985) and the requirement of CD4+ T cell activation f r disease (Grewal et al., 1996). 
Furthermore, EAE cannot be induced when CD4+ T cells are depleted (Brostoff and 
Mason, 1984).  
 
Originally EAE was described as a Th1 mediated disease, however it has been 
documented that IFNγ-/- mice still develop EAE, even suggesting IFNγ has a regulatory 
role in EAE as these mice have a more severe phenotype than IFNγ-sufficient mice 
(Ferber et al., 1996). With the discovery of the Th17 subset many models with Th1 
origins are now being re-assessed as Th17 mediated dis ases, including EAE. This 
discovery began with the finding that mice deficient in the IL-12 subunit, p35, were 
susceptible to EAE, while IL-12 p40-/- mice were resistant (Cua et al., 2003; Gran et al., 
2002). As mentioned, IL-23 was discovered to be comp sed of the p19 and the IL-12p40 
subunits (Oppmann et al., 2000), the role of IL-23 in driving the Th17 subset was 
identified and reported to be the mediator of the CNS inflammation (Langrish et al., 
2005). Investigations into the Th17/Th1 mechanisms of CNS inflammation represent an 
extensive field of current immunology and while some studies have discredited Th1 
cells from pathogenesis, others studies have found that IFNγ and Th1 populations are 
still involved in EAE  (Kroenke and Segal, 2007; O'Connor et al., 2008; Thakker et al., 
2007).   
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1.3.4 Antigenic targets for CNS-reactive lymphocyte s 
 
The target antigens known to be involved in MS and EAE are components of the myelin 
sheath. PLP compromises more than 50% of myelin protein and was identified as a 
target for autoimmune cells in EAE using synthetic PLP peptides (Tuohy et al., 1989; 
Williams et al., 1982). MBP also contributes to a large proportion of myelin protein 
(~30%) and has been shown to have encephalitogenic potential (Einstein et al., 1962). 
MOG constitutes less than 0.05% of total myelin protein, however it has been shown to 
be encaphalitogenic in mice, including in the C57BL/6 model (Mendel et al., 1995), as is 
used in this study. The pathogenic potential of MOG has been attributed to its 
accessibility to the immune system compared to MPB and PLP (Johns and Bernard, 
1999). 
 
The encephalitogenic region of MBP was first discovered in experiments that used 
synthetic peptides to induce EAE in guinea pigs (Eylar et al., 1970). Over a decade later 
the residues of MBP that can induce EAE in mice of the H-2u haplotype was shown to 
be the n-terminus Ac1-9 epitopes (Zamvil et al., 1986). Residues 80-100 of MBP also 
show encephalitogenic activity in different strains of mice and were also identified as 
targets in human disease (Kono et al., 1988; Pette  al., 1990). Later, the 
encephalitogenic region of PLP was found to be PLP139- 51 in mice of the H-2s 
haplotype, specifically in the SJL strain of mice (Tuohy et al., 1989). The 
encephalitogenic region of MOG, MOG35-55, was identified in C57BL/6 mice in 1995 
(Mendel et al., 1995). 
 
1.3.5 TCR transgenic models in EAE 
 
The use of TCR transgenic mice in EAE has allowed investigation of myelin reactive T 
cells in a system where antigen-specific cell numbers would normally be limited. TCR 
transgenic mice are generated by the expression of TCR Vα and Vβ genes that were 
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found to be used by encephalitogenic T cell lines that were isolated from mice that had 
been immunised with the antigen of interest.  
 
In the case of MBP-reactive TCR transgenic mice, four different strains were developed. 
All found that the n-terminal acetylated residues were responsible for disease in mice of 
the H-2u haplotype; Goverman and colleagues (Goverman et al., 1993) and Tonegawa 
and colleagues (Lafaille et al., 1994)  produced transgenic mice that recognised the 
Ac(1-11) epitope of MBP, while Janeway and colleagues (Hardardottir et al., 1995) 
generated a TCR transgenic that recognised Ac(1-16) of MBP. Tg3 and Tg4 mice were 
generated by Liu et al. after demonstrating that MBP-reactive T cell clones isolated from 
B10.PL mice (H-2u) express the Vβ8.2 chain and recognised the Ac(1-9) residues of 
MBP (Liu et al., 1995). Tg4 mice require immunisation with peptide to induce EAE and 
rarely develop EAE spontaneously. In this thesis, Tg4 mice are used extensively as the 
MBP(Ac1-9)-reactive TCR transgenic model to investigate Foxp3+ Tregs in EAE.  
 
The transgenic mouse relevant to the 35-55 epitope of MOG is the 2D2 mouse strain, 
developed by Betelli et al (Bettelli et al., 2003). The TCR in this model utilise the Vα3.2 
and Vβ11 gene segments and are expressed on the C57BL/6 (H-2b) background. 
 
PLP-reactive TCR transgenic mice were also generated from T cell clones derived from 
PLP-immunised SJL mice (Waldner et al., 2000). The  cells in these mice express 
Vα4+Vβ6+ TCRs and respond to PLP(139-151) presented by cells from mice on the H-
2s background. However, PLP(139-151)-reactive transgeic mice frequently developed 
spontaneous EAE and could not be maintained on the SJL background. 
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1.3.6 Breach of tolerance to CNS antigens 
1.3.6.1 CNS antigen expression in the thymus 
 
The CNS was largely believed to be devoid of immune infiltrates and proposed to be a 
site of immune privilege (Barker and Billingham, 1977). However, the CNS has now 
been shown to be immune competent (Ransohoff et al., 2003) therefore other 
mechanism of tolerance must exist to prevent CNS-reactive T cell activation. One such 
mechanism that has been proposed is in situ CNS-mediated tolerance of myelin-reactive 
T cells (Brabb et al., 2000). Some of the CNS self-antigens which are relevant for MS 
pathogenesis are expressed in the thymus. For example, MBP is expressed in the mouse 
thymus and increased thymic expression is associated with higher resistance to MBP-
induced EAE (Liu et al., 2001). MBP-reactive T cells however are still present in the 
periphery of mice and humans.  
 
In the thymus, MBP shows dominant expression of one epitope due to the activity of 
specific protesases, including Asparagine Endopeptidase (AEP) (Antoniou et al., 2000; 
Manoury et al., 1998). AEP has been suggested to cut MBP at the asparagine at position 
94 (Manoury et al., 2002). Alterations in the activity of AEP has therefore been 
suggested to alter the availability of normally cryptic eptiopes that the immune system 
may encounter and potentially cause autoimmunity (Anderton et al., 2002). Using the 
Tg4 MBP(Ac1-9) transgenic, Liu et al. demonstrated that T cells reactive to this peptide 
are not deleted in the thymus (Liu et al., 1995). These studies show that expression of 
self-peptide in the thymus is not sufficient for central tolerance and that the peptide must 
be recognised by the TCR with a high enough affinity to induce deletion.  
 
PLP is also expressed in the mouse thymus, however it is only in the form of a splice 
variant termed DM20, which lacks the amino acids 115- 51 (Pribyl et al., 1996). SJL 
mice, a strain which is highly susceptible to PLP-induced EAE, possess a high frequency 
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of PLP139-151-reactive CD4+ T cells (Anderson et al., 2000). The absence of this 
epitope in the thymus prevents deletion of these autoreactive T cell from the repertoire.  
 
MOG-expression has also been detected in the thymus using highly sensitive detection 
methods in both mice (Pitkanen and Peterson, 2003) and humans (Gotter et al., 2004). 
However, studies have suggested that expression of MOG in the thymus is insufficient at 
affecting the peripheral MOG-reactive repertoire (Delarasse et al., 2003; Fazilleau et al., 
2006). 
  
Thymic deletion can also be affected by MHC and the ability to present antigen. One 
study has demonstrated the effect of poor HLA binding in the thymus can lead to an 
increased frequency of myelin-specific T cells in MS patients (Bielekova et al., 2004). 
The T cells were biased towards recognition of epitopes with predicted low binding 
affinities for HLA-DR molecules. This suggests that MHC background will affect 
repertoire of self-antigen which can be presented in the thymus and differential binding 
affinity of peptides to the MHC may allow escape of auto-reactive T cells in the 
periphery and ultimately determine susceptibility to autoimmune diseases. 
 
1.3.6.2 Molecular mimicry 
 
As mentioned, T cells may recognise a molecule which expresses similar amino acid 
patterns to their cognate peptides in a process termed molecular mimicry. Viruses such 
as herpes-siplex virus 6, influenza, measles and Epstein-Barr virus all express genes 
encoding myelin-like sequences (Wucherpfennig and Strominger, 1995).  Human T cell 
clones reactive against MBP were shown to respond t viral peptides in vitro, suggesting 
this may be a functional process which can activate uto-aggressive T cells 
(Wucherpfennig and Strominger, 1995). A similar model of virus-induced disease has 
been shown in EAE (Gautam et al., 1998). While this mechanism of T cell activation has 
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been proposed in many inflammatory disorders (Wucherpfennig, 2001) a clear role for 
molecular mimicry in MS is lacking (Benoist and Mathis, 2001). 
 
1.3.6.3 Defective Regulation 
 
In EAE, CD25+Foxp3+ Tregs have been shown to accumulate and proliferate in the 
CNS concomitant with recovery from disease (McGeachy et al., 2005; O'Connor et al., 
2007). Depletion of Tregs prevents the recovery from disease and allows activation of 
low affinity self-reactive T lymphocytes, therefore these cells are strongly implicated in 
control of the inflammatory response (McGeachy et al., 2005; Reddy et al., 2004; 
Stephens et al., 2005). One study has suggested that Tregs are impaired in chronic EAE, 
with reduced total Foxp3+ cells and reduced expression of Foxp3 mRNA (Matsumoto et 
al., 2007). Depletion of Tregs also abrogated the resistance of mice to undergo a 
secondary disease episode in response to immunogenic challenge (McGeachy and 
Anderton, 2005) suggesting that these cells are key to both recovery and protection from 
relapses. Another study demonstrated the role of Tregs in raising the threshold at which 
auto-reactive T cells could respond to self antigens (Stephens et al., 2005). Variant 
analog peptides of the MBP Ac1-9 immuno-dominant epi ope that have sub-agonist 
activities do not normally induce disease when immunised in CFA. However if Tregs 
are depleted from the system using anti-CD25 antibodies (PC61), MBP-reactive T cells 
could respond to sub-agonist peptides and induce disease (Stephens et al., 2005).  
 
No quantitative defects in Treg have been detected in the blood of MS patients 
compared to healthy controls; however the function of the Tregs in MS is impaired. This 
was shown in one study of relapsing-remitting MS (RR-MS) to be correlated with a 
reduction in Foxp3-expression on a per-cell basis (Venken et al., 2008b). This same 
group also identified that in contrast to RR-MS, secondary-progressive MS (SP-MS) did 
not have Treg alterations and suggested that naïve Treg vs memory Treg homeostasis 
may different in these two types of the disease (Venken et al., 2008a; Venken et al., 
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2006). These studies suggest that differential defects in Treg function may be associated 
with differences in MS etiology. Interestingly, a study into the therapeutic effects of 
IFNβ-1α therapy demonstrated a positive effect on the suppressive activity of Tregs 
from MS patients (de Andres et al., 2007). However, wether Treg dysfunction has a 
causal role in autoimmunity is not yet clear (Baecher-Allan and Hafler, 2004). The 
results of these studies would imply that although the Tregs in MS patients are defective, 
there are therapeutic targets that can allow effectiv  Treg function and disease 
regression.  
 
1.3.7 Targeting regulation for therapy in MS and EA E 
 
Identification of Tregs as a key mediator of disease prevention and resolution in EAE 
resulted in the targeting of these cells for theraputic intervention strategies.  
 
1.3.7.1 Oral and Nasal tolerance 
 
T cells that encounter antigen in a soluble form and in the absence of any ‘danger 
signals’ undergo abortive T cell activation and results in un-responsiveness to future 
antigen encounters – termed anergy (Schwartz, 2003). Oral tolerance describes the 
phenomenon of induced T cell tolerance to antigens which are fed and enter the body via 
the gut mucosa and gut associated lymphoid tissue, GALT. Feeding of antigens mimics 
the tolerance we continuously develop to commensal bacteria and food and has routinely 
been used in experimental settings (MacDonald, 1998). The outcome of oral tolerance 
depends on the dose of antigen used (Weiner, 1997). High dose antigen results in clonal 
deletion of antigen-reactive T cells, while low dose results in active suppression, largely 
by the induction of TGFβ-secreting Th3 cells (Weiner, 2001). The dose effect in oral 
tolerance has been investigated in an MBP-reactive TCR transgenic mouse model (Chen 
et al., 1996). Mice which were fed high dose MBP showed deletion or anergy of the 
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MBP-reactive T cells. However, low dose antigen result d in T cells which produced IL-
4, IL-10 and TGFβ. These cells protected mice from MBP-induced EAE when 
transferred prior to disease induction. The feeding of low dose MBP also prevented EAE 
induced directly in transgenic mice.  
 
Another study investigated intranasal administration of MBP in the Tg4 model (Burkhart 
et al., 1999). Similarly, this model demonstrated high dose antigen-induced deletion of 
the MBP-reactive T cells, although deletion was incomplete and the remaining cells 
showed hyper-responsiveness to re-stimulation with MBP. However, repeated 
administration effectively tolerised the transgenic T ells and correlated with increased 
IL-10 production. Importantly, while the transgenic mice required repeated doses of 
MBP to prevent EAE, non-transgenic mice only required a single i.n. dose, 
demonstrating that the outcome of tolerogenic protoc ls depends on the precursor 
frequency of antigen-reactive T cells (Burkhart et al., 1999). This mechanism of 
tolerance was shown to be most effective when using a high affinity MHC peptide 
analogue of MBP, MBP(Ac1-9)4Tyr. This peptide binds with a higher affinity to the 
MHC compared to WT MBP(Ac1-9) and therefore suggests that antigen presentation is 
central to the tolerance induction event.  
 
Later investigations found that intranasally-induced tolerance to MBP was mediated by 
the generation of IL-10 producing CD4+ regulatory T cells, which were largely CD25-
CTLA-4+ and lacked Foxp3 expression (Sundstedt et al., 2003). IL-10 and TGFβ have 
been implicated in the orally administered peptide-induced protection from EAE (Faria 
et al., 2003), however a later study demonstrated oral tolerance in IL-10-/- mice, 
attributing the role of IL-10 to the reduction of Th1 mediated IFNγ production (Gonnella 
et al., 2004). In MS, clinical trials using oral antigen administration has been relatively 
unsuccessful (Kappos et al., 2000; Weiner et al., 1993). 
 
Multiple Sclerosis and EAE 
54 
1.3.7.2 Transfer of regulatory T cells 
 
Adoptive transfer of CD4+ T cells into transgenic mice reactive to MBP on a RAG-
deficient background effectively prevented the mice from developing spontaneous EAE 
(Van de Keere and Tonegawa, 1998). Since realising the importance of Tregs in 
prevention and recovery from EAE, the direct transfer of Tregs to prevent disease has 
continued. One obstacle which makes Treg therapy a difficult prospect is the low 
frequencies of Tregs in the total lymphocyte population. This is further complicated by 
the much reduced frequency of antigen-relevant Tregs. Work from the Bluestone group 
demonstrated that Tregs could be isolated from mice and expanded in vitro using a 
combination of anti-CD3, anti-CD28 plus high levels of exogenous IL-2 (Tang et al., 
2004b). Importantly they demonstrated that these antige -specific Tregs were 
suppressive both in vitro and in vivo, with low numbers of expanded Tregs required to 
prevent development of Type 1 diabetes in the NOD mouse model. Kohm et al. (Kohm 
et al., 2002) demonstrated that transfer of high numbers of polyclonal 
CD4+CD25+CD62Lhi Tregs isolated from the LNs of C57BL/6 mice resulted in 
significant suppression of both active and passive MOG-induced EAE. Protection was 
associated with an increase in Th2 cytokines, namely IL-4 and IL-5, suggesting immune 
deviation.  
 
Other mechanisms which target expansion of polyclonal Tregs via drug administration 
or vaccination have shown moderate effects on EAE (Fernandez-Martin et al., 2006; 
Ochoa-Reparaz et al., 2007). Investigations into the ability of transferred CD4+CD25+ 
Tregs which are isolated from the CNS vs naïve CD4+CD25+ Tregs to suppress EAE 
demonstrated that Tregs isolated from the CNS, and presumably reactive against CNS 
components, could suppress EAE even when very low numbers of cells were transferred 
(McGeachy et al., 2005). These data demonstrate tha antigen-relevant Tregs are more 
potent than naïve or polyclonal Tregs. Generation of Treg therapies therefore requires 
targeting of disease-relevant Tregs to induce a population of regulatory cells which are 
potent enough to reduce clinical disease.  
Multiple Sclerosis and EAE 
55 
1.3.7.3 Antigen-specific Treg therapy 
 
Expansion of antigen-specific regulatory T cells can be achieved through a number of 
mechanisms, one of which, oral tolerance, was mentioned previously. The von Boehmer 
group has shown generation of Foxp3+ Tregs in two models with the use of sub-
cutaneous osmotic mini pumps (Apostolou and von Boehmer, 2004; Verginis et al., 
2008). These allow the continuous infusion of low dose peptide over a period of 14 days 
and confer immunological tolerance to future challeng  with the self-antigen.  
 
Targeting of antigen to dendritic cells in the steady state and without activation is 
possible by conjugating peptide to anti-DEC-205 antibodies. This results in uptake of 
and presentation of the peptide without subsequent p-regulation of co-stimulatory 
molecules. Using this approach it has been possible to g nerate de novo, antigen-specific 
Foxp3+ regulatory T cells (Kretschmer et al., 2005). This approach, and those using the 
osmotic mini-pumps, confirmed that up-regulation of Foxp3 expression is associated 
with low levels of proliferation. Only administration of low dose antigen with the mini 
pumps resulted in minimal T cell proliferation and generated Foxp3+ Tregs (Apostolou 
and von Boehmer, 2004). Similarly, if the anti-DEC205/peptide conjugate was 
administered in combination with anti-CD40, the T cells proliferated extensively and no 
Foxp3-expression could be detected (Kretschmer et al., 2005). However, in all of the 
settings, induced Foxp3+ Tregs could be expanded upon immunisation with the cognate 
antigen.  
 
These studies suggest that optimal generation of Foxp3+ Tregs is associated with low 
dose antigen administration, resulting in low level proliferation. This finding may 
explain the benefits of the drug Rapamycin in promoting Tregs in vitro and in vivo. 
Rapamycin inhibits microtubule rearrangement and therefore prevents proliferation of T 
cells. One study has demonstrated antigen-specific Treg induction, independent of 
antigen dose, by co-administration of Rapamycin (Kang et al., 2008). While this study 
allows the generation of antigen specific Tregs, administration of an anti-proliferative 
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drug systemically will also affect other cell populations limiting the use of this drug in 
Treg based therapies.  
 
Understanding the mechanism behind their conversion and/or expansion is crucial to 
developing protocols to promote Foxp3+ Tregs. Peptid  therapy therefore shows 
potential in inducing Foxp3+ Tregs. However, by understanding the antigenic-reactivity 
of disease relevant Tregs it may be possible to administer peptide alone, without the 
requirement of APC targeting or continuous peptide infusion. This is the ultimate aim 




MS is a complex human disease with many potential risk factors and mechanisms of 
disease. It is clear that the immune system plays a key role in the inflammation 
associated with MS and destruction of the myelin sheat . The role of Tregs in 
maintaining autoreactive lymphocytes in a silent sta e is well documented; therefore the 
fact that perturbances in Treg function are associated with disease is of little surprise. By 
using EAE, the mouse model of MS, the function of Tregs in disease prevention, 
regression and remission is also clear. The disease course of some EAE models and 
indeed some MS cases suggests that regulation can be restored after episodes of disease; 
however this regulation is clearly lost, thus allowing relapses. It is likely the balance 
between effector, auto-aggressive T cells and Tregs will play a role. These findings 
suggest that restoration of Treg function and number may prevent disease development 
or induce disease regression. Therapeutic targeting of regulatory T cell is therefore a 
promising prospect for MS but requires greater understanding of the antigenic targets of 
Tregs and the optimum conditions which favour their conversion, expansion and potent 
regulatory function. 
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1.5 Aims of the Project 
 
This project aimed to: 
 
Identify the antigenic reactivity of Foxp3+ Tregs tha  expand during actively induced 
EAE (Chapter 3) 
 
Determine the antigenic requirements for the generation of Foxp3+ Tregs in response to 
immunisation (Chapter 3) 
 
Attempt to therapeutically expand disease-relevant Foxp3+ cells in situ for the 
prevention of EAE (Chapter 4) 
 
From the investigations into Foxp3+ cells in naïve mice, the role of superantigen 
encounter on the peripheral Treg repertoire was subsequently investigated and is 
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2 Materials and Methods 
2.1 Mice 
 
C57BL/6, 2D2 (Bettelli et al., 2003), MOGKO (Delarasse et al., 2003), Foxp3-GFP 
reporter mice (Fontenot et al., 2005b) and µMT (Kitamura and Rajewsky, 1992) mice 
(all on the C57BL/6 background, H-2b), B10.PL (H-2u), Tg4 mice (Liu et al., 1995), 
B10.PLxSJL (H-2uxs) mice were bred and maintained in specific pathogen-fr e 
conditions at the University of Edinburgh. All mice were sex-matched within 




MOG(35-55) peptide (MEVGWYRSPFSRVVHLYRNGK), MBP(Ac1-9) peptide 
(ASQKRPSQR), MBP(Ac1-9) 4Tyr peptide (ASQYRPSQR) and PLP(139-151) peptide 
(HSLGKWLGHPDKF) were synthesized at the Advanced Biotechnology Centre 
(Imperial College, London). 
2.2.2 Superantigens 
Staphylococcal enterotoxin B (SEB) was obtained from Sigma and stored at 1mg/ml in 
PBS according to health and safety regulations at -80oC. 
2.3 General Reagents 
2.3.1 Wash Buffer 
RPMI 1640 medium containing 25mM HEPES buffer (Gibco, Life Technologies, 
Paisley, UK), 2mM L-Glutamine (Gibco), 100U/ml Penicill n, 100µg/ml streptomycin 
and 5x10-5M 2-mercaptoethanol (all Gibco). 
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2.3.2 RPMI-5 tissue culture medium 
Wash Buffer as above, with the addition of 5% heat-in ctivated fetal calf serum (FCS) 
(Sigma, Poole, UK). 
2.3.3 MACS Buffer 
HANKS Balanced Salt Solution (Sigma), supplemented with 2% heat-inactivated FCS 
(Sigma) and 100U/ml Penicillin plus 100µg/ml streptomycin (both Gibco). 
2.3.4 FACS Buffer 
PBS supplemented with 2% heat-inactivated FCS (Sigma) and 0.05% sodium azide 
(Sigma) 
 
2.4 Antibodies and FACS analysis 
 
Cells were stained for FACS using the following antibodies (all from eBioscience, CA, 
except where stated). For clones see Antibody Table I. 
2.4.1 Surface stains: 
anti-CD4 FITC/APC/PercP (BD Pharmingen), anti-CD4 AlexaFluor700 (Caltag), anti-
CD25 FITC/PE (clone 7D4, Miltenyi Biotech), anti-CD45.1 FITC/PE/biotinylated, anti-
CD45.1, anti-CD90.1 FITC, anti-CD62L FITC, anti-CD44 FITC/PE, anti-CD103 FITC 
2.4.2 Intracellular stains: 
anti-IFNγ FITC, anti-IL-17 PE, anti-IL-10 FITC, anti-Foxp3 FITC/PE/APC staining kits 
and isotype control, IgG2a FITC/PE/APC, were purchased from eBioscience and used 
according to manufacturer’ instructions. Anti-BrdU FITC/APC (BD Biosciences). 
FACS data were collected on either FACSCalibur or LSR flow cytometers (BD 
Biosciences) and data were analysed using FlowJo software (Tree Star, CA). 
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2.5 Cell isolation and purifications 
 
Peripheral lymph nodes, spleens or thymi were removed and disaggregated to single cell 
suspensions. Red blood cells (RBC) were lysed by incubation with Red Blood Cell Lysis 
Buffer (Sigma) for two minutes at room temperature (RT), followed by washing twice 
with MACS Buffer.  
2.5.1 Preparation of mononuclear cell populations f rom CNS 
Mice, sacrificed by CO2 asphyxiation, were perfused with 10ml PBS through the left 
ventricle of the heart. Spinal cords were removed by intrathecal hydrostatic pressure 
using cold RPMI. Brains were removed by dissection. Spinal cord and brain were 
digested by mechanical disruption using a 1ml syringe then incubated for 40 minutes at 
37oC in 300µl of 2.5mg/ml collagenase (Worthington Biochemicals, NJ) and 1mg/ml 
deoxyribonuclease (DNAse) (Sigma). Cells were washed in Wash Buffer and the pellet 
resuspended in 30% Percoll (Gibco) (made in Wash Buffer) then underlaid with 70% 
Percoll. These discontinuous gradients were spun at 2000g for 20 minutes without brake. 
Approximately 2ml of the gradient interface was removed and washed thoroughly to 
obtain a single cell suspension. 
2.5.2 CD4+ T cell purifications 
CD4+ T cells were isolated by positive selection using CD4-conjugated MACS beads 
(L3T4) and MS or LS columns (all Miltenyi Biotech), according to manufacturer’s 
instructions. Cells were incubated with 90µl MACS Buffer and 10µl CD4 Beads per 107 
total cells for 15-20 mins at 4oC. Cells were then passed through a MACS column, pre-
washed with MACS Buffer attached to a MACS magnet (VarioMACS, Miltenyi 
Biotech). CD4+ cells were flushed from the magnet using MACS Buffer. A sample of 
cells was stained with a PercP-conjugated CD4+ antibody (BD Pharmingen) to assess 
cell purity by FACS analysis. Purity of the T cells was consistently >95%. 
CD4+ cells were then either used directly for cell transfer or in vitro manipulation, or 
stained for further sorting on the FACSAria. 
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2.5.3 Regulatory T cell sorting 
CD4+ cells purified by MACS as above were stained with CD4 PercP- and CD25 FITC-
conjugated antibody and, in some cases, CD62L-PE conjugated antibody (all BD 
Pharmingen). CD4+CD25+ or CD4+CD25+CD62Lhi cells were sorted on a FACSAria 
(BD biosciences) to >93% purity. Expression and purity of Foxp3 was assessed by 
Foxp3 staining using a Foxp3-APC staining kit (eBioscience) according to 
manufacturer’s instructions. 
 
2.6 In vivo manipulations and antigen administratio n 
2.6.1 Immunisations 
Each mouse received 100µg pMOG, or 100µg MBP(Ac1-9 4K) or 200µg PLP(139-151) 
emulsified in complete Freund’s adjuvant (CFA) contai ing 50µg of heat-killed 
Mycobacterium tuberculosis H37Ra (Sigma-Aldrich) at a final volume of 100µl injected 
sub-cutaneously into the hind legs.  
2.6.2 Induction of EAE 
Mice were immunised as above and also given 200ng of pertussis toxin (Health 
Protection Agency, Dorset, UK) in 0.5ml PBS was given intraperitoneally (i.p.) on the 
same day and two days after immunisation. Mice were then monitored daily for clinical 
signs of EAE and assessed using the following scoring system: 0, no paralysis; 1, flaccid 
tail; 2, impaired righting reflex; 3, partial hind limb paralyis; 4, total hind limb paralysis; 
5, partial front limb paralysis; 6, moribund or dea. Mice which had lost >20% of their 
initial body weight or those scored as grade 5 for two consecutive days were culled. 
Hydrated food was provided to cages showing any signs of paralysis. 
2.6.3 Peptide administration  
For experiments to induce peptide tolerance, mice re ived peptides resuspended in PBS 
intravenously into the tail vein of pre-heated mice in a final volume of 200µl per mouse 
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at concentrations stated. As controls, mice received either PBS only i.v. or antigen plus 
10µg LPS (Sigma, Poole) i.v.  
2.6.4 Superantigen administration 
SEB in PBS was given i.v. at a final dose of 1µg/mouse in 200µl over three consecutive 
days (unless stated otherwise). Syringes were disposed into incineration bins clearly 
marked for the disposal of SEB. Mice were maintained in individually vented cages 
(IVC) for the duration of experiments and all administrations carried out under 
ventilated hoods. At the end of experiments bedding was incinerated and cages 
autoclaved. Mice were sacrificed for analysis 24h after the final dose. 
2.6.5 BrdU administration 
Mice were treated with 2mg BrdU i.p. in a final volume of 200µl per mouse at the time-
points described. Mice treated with BrdU were house in individually vented cages (IVC) 
and all administrations carried out under ventilated hoods. At the end of experiments, 
bedding was incinerated and cages autoclaved. 
2.6.6 T cell transfers 
Purified whole splenocytes, sorted CD4+ or CD4+CD25+CD62Lhi cells resuspended in 
PBS were transferred at stated numbers in a final volume of 200µl i.v. into the tail vein 
of pre-heated mice. 
 
2.7 In vitro assays 
2.7.1 3H-Thymidine incorporation assays 
Single cell suspensions in RPMI-5 medium (number and source indicated in figure 
legends) were cultured in flat-bottomed 96-well microtiter plates (Becton Dickinson, 
CA) with the indicated antigen at indicated dose(s). After 48h culture 0.5µCi/well of 
tritiated thymidine (3H-dThd, Amersham) was added in a volume of 25µl. 18h after 
addition, dThd incorporation was measured using a liquid scintillation β-counter 
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(Wallac). Results are expressed as a mean counts per minute (cpm) of duplicate or 
triplicate cultures, as indicated in the figure legend. 
2.7.2 Supernatant cytokine quantification by ELISA  
Single cell suspensions were cultured in 96-well microt ter plates (Becton Dickinson, 
CA) with indicated antigen at indicated dose(s). After 48h of culture supernatants were 
removed (~150µl) and used directly for ELISA or frozen @ -20oC until required. 
 
96 well MaxiSorp microtiter plates (Nalge Nunc Inter ational, Roskilde, Denmark) were 
coated overnight at 4oC with 50µl/well of the relevant cytokine-capture antibody; anti-
IL-2 (JES6-1A12), anti-IL-10 (JESS-2A5), anti-IFNγ (R4-6A2), and anti-IL-17 (TC11-
18H10) (all BD Pharmingen) diluted to 2µg/ml in bicarbonate buffer (0.05M, pH 9.6). 
Plates were washed twice with PBS/0.1% Tween (Sigma) then blocked for 1h @ 37oC 
with 200µl PBS/1%BSA (Sigma) per well. After two washes in PBS/Tween, followed 
by two washes in PBS, cytokine standards were diluted in PBS/BSA were added at 
100µl/well and two fold dilutions performed to give a standard curve for each plate (top 
and bottom concentrations: IL-2 1000-4pg/ml, IL-10 and IFNγ  100-0.4ng/ml, IL-17 10-
0.04ng/ml). Samples were then added at 50µl/well in duplicate and incubated at room 
temperature for 2 hours. Plates were then washed with PBS/Tween before adding 
appropriate secondary biotinylated antibodies diluted in PBS/BSA, 100µl/well -  anti-IL-
2 (E56-5H4) at a final concentration of 5ng/ml, anti-IL-10 (SXC-1), anti-IFNγ 
(XMG1.2) and anti-IL-17 (TC11-8H4.1) at a final concentration of 100ng/ml. Plates 
were then incubated for 1 hour at room temperature. Once washed, ExtrAvidin 
peroxidase (Sigma) diluted to 2µg/ml final concentration in PBS/BSA was added 
(100µl/well) for 30 minutes at room temperature. After 6 washes with PBS/Tween, 
cytokines were detected using 100µl phosphate-citrate buffer, (prepared by adding 100µl 
of 10mg/ml Tetramethylbenzidine (TMB; Sigma) in DMSO to 9.9ml of phosphate-
citrate buffer pH5 and 3µl of hydrogen peroxide (Sigma)). Reactions were stopped using 
100µl of 2M sulphuric acid. Absorbance values were read at 450nm using a Multiskan 
plate reader (Labsystems, Basingstoke, UK). All cytokines were quantified with 
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standard curves obtained with known concentrations of recombinant mouse cytokines. 
Values of 0 represent undetectable levels of cytokine in culture. All antibodies and 
mouse standard cytokines were obtained from BD Pharmingen. 
2.7.3 Intracellular cytokine staining 
Cells were cultured in 96 well round bottomed plates (Costar) at stated concentrations 
with stated concentrations of antigen overnight. Brefeldin A (eBioscience) was added to 
wells at a final dilution of 1:1000 in a volume of 25µl/well. Cells were incubated for 4 
hours @ 37oC. Cells were then washed in FACS buffer and surface stained as described. 
Cells were then incubated overnight in eBioscience Foxp3 Fix/Perm buffer (200µl/well). 
After ~18h, cells were then stained for intracellular cytokines along with Foxp3. Cells 
were washed and re-suspended in 500µl FACS buffer for analysis. 
2.7.4 Foxp3/BrdU staining 
Cells were surface stained as described above then incubated in 
fixation/permeabilisation buffer (eBioscience Foxp3 kit, at a 3:1 diluent:concentrate 
ratio) for 18h overnight at 4oC. Cells were then washed in Permeabilisation buffer 
(eBiosience kit), diluted to 1X in PBS. DNAse@10mg/l (Sigma) was then diluted 1:20 
with 1X Permeabilisation buffer, 200µl/sample and then incubated at 37oC for 1hour. 
Cells were washed in Permeabilisation buffer x 2 then stained for antibody; anti-BrdU-
FITC (BD bioscience), anti-Foxp3-APC (eBioscience) both at 1:50 dilution in Perm. 
buffer for 20 minutes at room temperature. Cells were washed in FACS buffer then 
resuspended in 500µl FACS buffer for collection at a rate of ~500 events/second. 
2.7.5 In vitro BrdU assays 
2.7.5.1 C57BL/6 WT and MOGKO BrdU assays:  
Draining lymph nodes (inguinal and paraortic) were removed from mice that had been 
immunized 10 days earlier with 200µg pMOG/CFA. Single cell suspensions were 
prepared as described previously and resuspended at 5-6x106 cells/ml in RPMI-5. 500µl 
of cells were added per well of a 24 well plate. Antigens were added resuspended in 
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500µl of RPMI-5; pMOG (final concentration 10µg/ml), pOVA (10µg/ml) or anti-CD3 
(1ug/ml). Cells were incubated at 37oC for 24, 48 or 72h as indicated in the figure 
legends. For the final 18 hours of each culture (unless otherwise stated), 25µl BrdU was 
added to give a final concentration of 30µg/ml, diluted in RPMI-5. After the final 18h of 
culture with BrdU, cells were harvested from the plates into 15ml Falcon tubes and 
washed twice in RPMI-5 before staining for FACS analysis. 
 
2.7.5.2 CNS-derived Treg BrdU assays:  
Brain and spinal cord were removed from mice that 17 days earlier had been induced to 
develop EAE by immunization with 200µg pMOG emulsified in CFA. CD4+CD25+ 
cells were sorted as described and cultured at 3x105 cells/ml, 100µl per well of 96 well 
round bottom plates. Irradiated splenocytes from Thy1.1+ C57BL/6 mice were used as 
APC and added to wells (50µl/well) at a concentration of 5x106 APC/ml. Antigens were 
resuspended in RPMI-5 to give the final concentrations as indicated in the figure legends 
by adding 50µl per well. Cells were incubated at 37oC for 24, 48 or 72h as indicated in 
the figure legends. For the final 18 hours of each culture (unless otherwise stated), 25µl 
BrdU was added at a final concentration of 30µg/ml, diluted in RPMI-5. After the final 
18h of culture with BrdU, cells were harvested from the plates into 5ml FACS tubes 
(BD Falcon) and washed twice in RPMI-5 before staining for FACS analysis. 
2.7.6 In vitro suppression assays 
2.7.6.1 CNS-derived Treg suppression assay:  
CD4+CD25+ cells were sorted from the CNS of mice at day 17 of EAE induced with 
pMOG/CFA and pertussis toxin. CD4+CD25- cells were also sorted from CNS of mice 
at day 17 of EAE, from naïve 2D2 or naïve OT-II mice. CD4+CD25+ cells were 
resuspended in RPMI-5 at 2x105 cells/ml and 200µl was added to the top row of a 96 
well round bottom plate. 100µl of CD4+CD25+ cells were double diluted into 100µl of 
RPMI-5 down the plate to give two fold dilutions ofthe CD4+CD25+ T cells. 2x104 
CD25- cells in RPMI-5 were added to the wells containing Tregs, 50µl/well. Irradiated 
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splenocytes from naïve C57BL/6 were used as APC at 5x106/ml. Antigens (pOVA or 
pMOG at final concentration of 10µg/ml) were diluted in APC and 50µl added to the 
appropriate well. Cells were cultured at 37oC for 48 hours prior to the addition of 3H-
thymidine. After a further 15-18 hour culture at 37oC, well were assessed for 3H-
thymidine incorporation as described. 
 
2.7.6.2 Vβ5 suppression assays:  
CD4+Vβ5+, CD4+Vβ5-, CD4+CD25+ (supressor) and CD4+CD25- (responder) c lls 
were sorted by CD4+ MACS purification and FACSAria sorting to >95% purity as 
described. Suppressor cells were reuspended at 4x105cells/ml in RPMI-5, 200µl of cells 
added to the top wells of a 96 well round bottom plate and double diluted into 100µl 
RPMI-5 down the plate. 50µl of CD4+CD25- responder cells (at 8x105/ml in RPMI-5) 
were then added to the wells. Irradiated splenocytes from naïve C57BL/6 mice were 
used as APC, resuspended at 5x106/ml in RPMI-5. Anti-CD3 antibody (eBioscience) 
was added to APC at a concentration of 4µg/ml to give a final concentration of 1µg/ml 
in 50µl of APC +/- anti-CD3 that was added per well. Cells were cultured at 37oC for 48 
hours prior to the addition of 3H-thymidine. After a further 15-18 hour culture at 37oC, 
well were assessed for 3H-thymidine incorporation as described. 
2.7.7 SEB in vitro assays 
2.7.7.1 Naïve cell in vitro stimulations:  
Naïve splenocytes were cultured at 5x106 per well in 24-well tissue culture plates 
(Becton Dickinson, Oxford, UK) with either medium alone, 2.5µg/ml con A (SIGMA) 
or the indicated dose of SEB (SIGMA) for 96h. Cells were then analysed for expression 
of foxp3, using anti-foxp3 staining kits as described above. In some experiments, BrdU 
was added at a final concentration of 10µM for the final 12 hours and incorporation was 
detected by FACS as described previously.  
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2.7.7.2 Co-culture suppression assays:  
5x105 naïve Tg4 Thy1.1+ CD4+ splenocytes were cultured alone or together with 5x105 
CD4-purified splenocytes from mice treated with PBS or 1ug SEB in vivo for three days 
prior to sacrifice. 2x106 APC (B10.PL irradiated splenocytes) +/- 10µg SEB or 10µg 
MBP(Ac1-9) were used to stimulate cultures for 72h. BrdU was added at a final 
concentration of 10µM for the final 12-15 hours of culture and incorporation by Foxp3+ 
and Foxp3- cells was detected by FACS. 
 
2.8 T cell hybridomas 
2.8.1 Cell isolation and expansion 
CD4+CD25+, CD25+CD25- and CD4+CD25+CD62Lhi cells were sorted by MACS 
purification and FACSAria sorting as described above. Cells were expanded in vitro 
using anti-CD3/anti-CD28 coated Dynabeads (Miltenyi Biotech) at a 1:1 ratio of 
cells:beads with the addition of 1000U/ml IL-2. After 7 days cells were washed 
extensively in serum free RPMI (that had been warmed to 37oC) and counted. Cells were 
resuspended in serum free RPMI (SFM) at 1x106 cells/ml. 
2.8.2 BW5147 cell preparation 
BW5147α-β- T cells (White, J 1989 JI) were grown in RPMI-5 for 4-5 days until at 
sufficient cell numbers. Cells were washed and counted on the day of fusion in serum-
free RPMI. Cells were then resuspended in 50ml Falcon tubes (BD Biosciences) at 
1x106 cells/ml in warmed serum free RPMI. 
2.8.3 PEG Fusion 
PEG 1500 solution (Roche Diagnostics, Germany) was rmed by transferring the 
solution to a 15ml Falcon tube and resting in a 37oC water bath. Expanded T cells and 
BW5147 cells were mixed at a 1:1 ratio – T cells were centrifuged at 1500 RPM for 5 
minutes in a 50ml Falcon tube. Cells were then resuspended by the addition of an equal 
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number of BW5147 in SFM. Tubes were filled with SFM and re-centrifuged. The cell 
pellet was aspirated to dryness carefully, using a 10ml pipette (Sterilin) and gently 
resuspended. Using a 1ml pipette (Sterilin) 1ml of PEG 1500 was added to the cell pellet 
slowly (over 1 minute) while gently stirring the pellet with the pipette tip. This was 
repeated using 2mls of warmed SFM added slowly, over 2 minutes and again using 7mls 
of warmed SFM over 2 minutes. Cells were centrifuged at 1000 RPM with no brake for 
5 minutes. Supernantant was aspirated as described before. 
2.8.4 HAT preparation 
Hypoxanthine Aminopterin Thymidine (HAT) medium (Sigma) was stored at -20oC in 
powder form. 10ml RPMI-5% FCS was added to create a 50X solution. A 2X solution 
was prepared for addition to cell cultures. 
2.8.5 Clonal growth and maintenance of hybridomas 
Cells were counted and resuspended at 2x105/ml of the original T cell number. 100µl of 
cells were added per well of a 96 well flat bottom plate (Corning Incoporated). After 24h 
of culture at 37oC 100µl of 2x HAT solution was added per well and plates r turned to 
37oC incubators. After 6-10 days, wells were assessed for clonal growth of hybridomas, 
assessed as <20% of wells per plate having cells that expanded. Successful hybridomas 
were transferred to cell culture flasks in RPMI-5% FCS and maintained at 37oC until at 
sufficient cell numbers to be tested for TCR-reactivity. 
2.8.6 Assessing hybridoma TCR-reactivity 
50µl of hybridoma cell cultures were transferred to 96 well plates (Costar) containing 
100µl PL-8 B cell lines at 5x105/ml in RPMI-5% FCS +/- MBP(Ac1-9) at a final 
concentration of 4µg/ml. After 24h culture at 37oC, 100µl of the supernatant per well 
was removed for detection of IL-2 by ELISA (see previous section). Positive results 
were indicated by production of IL-2 only in response to both APC and antigen, not to 
either APC or antigen alone. 
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2.9 Statistics 
Statistical analysis performed on in vitro data used Student’s t test. P values of less than 
0.05 were regarded as significant. Statistical analysis on EAE mean clinical disease 
curves used Mann Whitney or statistical analysis based on the area under the curve.  
 
Table 2.1: Flow cytometry antibody clones and dilutions 
Antibody Conjugate Clone Dilution  
CD4 -FITC, -PE, -APC L3T4 1:500 
 -PercP RM4-5 1:500 
CD25 -FITC 7D4 1:200 
 -PE, -APC PC61 1:200 
CD62L -FITC, -PE MEL-14 1:200 
Foxp3 -FITC, -PE, -APC FJK-16s 1:50 
BrdU -FITC, -APC PRB-1 1:50 
CD103 -FITC M290 1:200 
Vβ5 -FITC MR9-4 1:200 
Vβ3 -FITC KJ25 1:200 
Vβ8 -FITC MR5-2 1:200 
Vβ11 -FITC RR3-15 1:200 
Vα3.2 -PE RR3-16 1:200 
CD45.1 -FITC, -PE, -bio A20 1:200 
CD44 -PE IM7 1:200 
TCRβ -APC H57-597 1:200 
CTLA-4 -PE UC10-4F10-11 1:100 
OX40-L -bio RM134L 1:200 
GITR -PE DTA-1 1:200 
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3 Investigating the antigenic-reactivity of Foxp3+ 
Tregs in EAE  
3.1 Introduction 
 
Defective regulatory T cell function has been demonstrated in patients with MS 
(Viglietta et al., 2004). The pivotal role of regulatory T cells in recovery from disease 
has been shown in EAE by the depletion of CD25+ cells in both pMOG (McGeachy et 
al., 2005) and PLP models (Reddy et al., 2004; Zhang et al., 2004). Assessment of Tregs 
directly in the CNS has shown that these cells accumulate as disease progresses and 
importantly that the Tregs proliferate extensively in situ (O'Connor et al., 2007). The 
accumulation of Tregs in the CNS is associated with recovery from EAE and their 
ability to suppress auto-aggressive T cells. Tregs have been shown to initially require 
stimulation through the TCR by cognate antigen to become activated and suppress in 
vitro, although they may later suppress T cell respon es in the absence of cognate 
antigen via bystander suppression (Thornton and Shevac , 2000). As Tregs are 
proliferating extensively in the CNS, it is likely that they are receiving stimulation via 
the TCR. While Tregs are largely believed to be self-reactive, the antigenic targets of the 
Tregs which accumulate in the CNS are unknown. Therapeutic targeting of Tregs is a 
major aim for many diseases associated with excess inflammation. Polyclonal 
CD4+CD25+ Tregs have been shown to suppress EAE (Kohm et al., 2002) and 
polyclonal expansion of human Tregs in vitro can geerate functional Tregs (Earle et al., 
2005). However, there is clear evidence that antige-specific Tregs are more effective 
than polyclonal Tregs in suppressing organ-specific autoimmunity (McGeachy et al., 
2005; Tang et al., 2004b). Determining the antigenic reactivity of Tregs that are relevant 
to EAE/MS is therefore essential to specifically target these cells by therapeutic 
strategies. This chapter describes experiments design d to determine the antigenic 
reactivity and suppressive capacity of the regulatory T cells which arise during EAE




3.2.1 Generating regulatory T cell hybridomas 
 
Hybridoma technology initiated with the finding tha fusion of B cells to immortal 
cancer cells allowed the continuous generation of mnoclonal antibodies (Kohler and 
Milstein, 1975), a discovery which has enhanced immune research dramatically. In the 
late 70’s, Goldsby et al. (Goldsby et al., 1977) expanded the potential of hybridoma 
technology into the realms of T cell biology, using T cell meyloma cells. The generation 
of T cell hybridomas have allowed extensive investigation into T cell biology and 
remains an important tool in the understanding of the TCR diversity, reactivity and 
function (De Silva et al., 2000; Donermeyer et al., 2006; Ezquerra et al., 1990). One of 
the major obstacles in determining the antigenic-reactivity of Tregs, particularly from 
the CNS, is the low recovery of cells to test against potential peptides. The isolation of 
sufficient Treg cell numbers on which to perform functional assays requires a large 
cohort of mice which have to undergo the process of EAE. In order to overcome this we 
hypothesised that generation of hybridomas from CNS-derived Tregs could provide us 
with a pool of immortal cells expressing Treg-derivd TCRs on which to assess their 
reactivity. 
 
The generation of Treg hybridomas was attempted at length using a number of different 
TCR transgenic mouse models (as a proof of concept that the Treg hybridomas will 
maintain the TCR of the fused T cell – for an outline see Appendix Ia) and later with 
sorted Foxp3+ populations sorted from Foxp3-GFP mice. While the transgenic Treg 
hybrids fused successfully, Foxp3-expression was not evident in any of the hybridomas 
tested (Appendix Ib and Ic). Our aim was to determine the antigenic-reactivity of CNS-
derived Tregs after pMOG-immunisation; therefore Trgs were sorted from Foxp3-GFP 
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mice (Fontenot et al., 2005b) that were in the recov ry stages of EAE. None of the CNS-
derived hybridomas were grown out successfully. 
 
Our attempts to generate hybridomas which express Foxp3 were unsuccessful, however 
a recent study has also reported that hybrids generated from Treg populations lack 
Foxp3-expression (Pacholczyk et al., 2007). This group used mice which expressed a 
fixed TCRβ chain and a selection of TCR α-chains from a mini locus to track Foxp3+ 
cells based on their TCR after they had lost Foxp3-expression. Thus, while we could not 
use Treg hybrids to determine antigenic reactivity of CNS-derived Tregs, advances in 
technology may make this possible in the future. 
 
3.2.2  Determining the antigen-reactivity of Tregs after 
pMOG-immunisation 
 
As the use of hybridoma technology to generate immortal Treg clones was unsuccessful, 
we attempted to determine antigenic-reactivity in other ways, by using Tregs isolated 
directly ex vivo. The development of Tregs is believed to be dependent on self-peptide 
interaction in the thymus (Fontenot et al., 2005b; Jordan et al., 2001) and that Treg 
expansion depends on high avidity TCR ligands (Yu et al., 2008). This dogma proposes 
that most Tregs are selected on their bias towards higher levels of self-reactivity and that 
Tregs in the periphery will respond to these self antigens and thereby contribute to self 
tolerance against these antigens. It is not clear if immunisation with self-peptide can 
expand naturally arising, self-reactive Tregs and/or induce antigen-reactive Tregs in the 
periphery. We therefore attempted to determine the antigenic reactivity of Tregs in 
C57BL/6 mice after immunisation with pMOG. By utilis ng mice which lack the 
expression of the CNS protein MOG (Delarasse et al., 2003) we have also addressed the 
role of endogenous antigen expression on the peripheral Treg repertoire. As Tregs are 
believed to require self-peptide interactions in the ymus it might be predicted that 
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MOG-KO mice would lack MOG-reactive Tregs in the peri hery and therefore MOG-
reactive Tregs would not be detectable upon immunisation with pMOG. 
 
3.2.2.1 BrdU incorporation as a measure of the antigenic reactivity of Tregs 
 
BrdU can be used to detect cells which are undergoing DNA synthesis by incorporating 
this thymidine analogue into the newly formed strands of DNA. We initially confirmed 
that BrdU is a measure of cell division in order to u ilise this method to measure antigen-
induced proliferation (Appendix II). Double staining of Foxp3 and BrdU had not yet 
been documented, therefore a protocol was developed which allowed the detection of 
BrdU and Foxp3 in the same cells by combining the buffers required for Foxp3 staining 
and the BrdU staining protocols (see materials and methods section for details). 
 
To determine if pMOG-immunisation could expand MOG-reactive Tregs, C57BL/6 
mice were immunised with pMOG/CFA. Draining lymph nodes (DLN) were removed 
after 10 days and cultured in vitro with pMOG or recombinant MOG protein (rMOG) 
for 72h, with BrdU added for the last 18h of culture. Cells were then stained for Foxp3 
and BrdU to assess the proliferative response of both F xp3+ and Foxp3- cells. The 
Foxp3+ cells from pMOG-immunised mice showed increased BrdU incorporation in 
response to pMOG and rMOG compared to un-stimulated cultures (Fig. 3.1A). Foxp3- 
cells also showed increased proliferation in pMOG and rMOG stimulated cultures 
compared to medium alone (Fig. 3.1B). While these results suggested that pMOG-
reactive Tregs are generated in response to pMOG immunisation, the levels of BrdU 
incorporation were very high, with >50% of Foxp3+ cells in culture responding to 
pMOG. The frequency of pMOG-reactive splenocytes after pMOG immunisation has 
been demonstrated to be in the region of 2-3% using pMOG-specific tetramers (Korn et 
al., 2007). It is therefore unlikely that the 50% BrdU incorporation observed in the 
Foxp3+ population is due to the sole proliferation of this small compartment of antigen-
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reactive cells in the culture and suggests that not all of the proliferation in these cultures 
was antigen-induced.  
 
3.2.2.2 Refining the BrdU staining protocol to measure antigenic-reactivity 
 
To determine if BrdU incorporation could more sensitively reflect antigen-induced 
proliferation we conducted time-course experiments to assess the levels of BrdU 
incorporation over time in response to antigen. BrdU incorporation was detected after 
the addition of BrdU for the last 12 hours of 24h, 8h and 72h antigen or anti-CD3 
stimulated cultures.  
 
At the first time-point, very little BrdU incorporation was visible in any cultures (Data 
not shown). Foxp3+ and Foxp3- cell division was evid nt at 48h in culture with pMOG 
and anti-CD3, with ~12% of Foxp3+ cells proliferating to pMOG and 63% to anti-CD3 
(Figure 3.2A, top panels). At 72h, proliferation also occurred in both Foxp3+ and 
Foxp3- populations in response to pMOG and anti-CD3, but to a much higher level than 
at 48h, with up to 55% of Foxp3+ cells proliferating in response to pMOG at this point 
(Fig. 3.2A, bottom panels).  
 
Upon immunisation, antigen-reactive T cells may expr ss immunodominant TCRs 
bearing particular Vβ-Dβ-Jβ rearrangments. If these rearrangements are found to be 
common in all mice of the same strain then they are te med public rearrangements. In 
C57BL/6 mice, actively induced EAE using pMOG shows preferential use of the Vβ8.2 
gene segment (Fazilleau et al., 2006). In this situation, the Vβ8.2 gene segment is 
expressed by the ‘public’ MOG-reactive repertoire as the CD4+ T cells in most mice 
will show preferential use of the Vβ8 gene segment upon immunisation with pMOG. 
Analysis of BrdU incorporation within the Vβ8+ and Vβ8- populations of the Foxp3+ 
compartment demonstrated that at the 48h time-point, nly the Foxp3+Vβ8+ cells had 
proliferated in response to pMOG (Fig. 3.2B). However, at 72h both Foxp3+Vβ8+ and 
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Foxp3+Vβ8- populations showed levels of BrdU incorporation comparable to whole 
CD4+ cells in response to anti-CD3 (Fig. 3.2B). The Foxp3-Vβ8+ and Foxp3-Vβ8- 
populations demonstrated similar differences in the kin tics of BrdU incorporation also 
(Fig. 3.2C). These results suggest that proliferation of Foxp3+ and Foxp3- cells at the 
48h timepoint is reflective of expansion of Vβ8+ cells only, arguing that Foxp3+ 
proliferation in these cultures is antigen-specific. If the proliferation of Foxp3+ cells was 
induced in response to the proliferation of Foxp3- cells in the same cultures then the 
proliferation would not be restricted to the Vβ8+ population. 
 
3.2.2.3 Assessing the cytokine levels in pMOG stimulated cultures 
 
IL-2 has been shown to be required for Treg proliferation in vitro (de la Rosa et al., 
2004; Thornton et al., 2004). It has more recently been reported that in vivo 
administration of IL-2 selectively expands Foxp3+ Tregs (Brandenburg et al., 2008). We 
therefore reasoned that high levels of IL-2 in culture may account for the enhanced 
proliferation observed by the Tregs (Fig. 3.1A). To assess the levels of IL-2 in culture 
we measured the IL-2 concentrations in the supernatants of LN cultures by cytokine 
ELISA (Fig. 3.3A). The level of IL-2 was highest after 24h stimulation with anti-CD3, 
although over time these levels rapidly declined presumably as IL-2 was consumed 
during proliferation. Stimulation with pMOG induced a small level of IL-2 after 24h and 
this was gradually reduced over time. The level of IL-2 in medium only cultures 
increased over time to levels higher than those seen in pMOG stimulated cultures. 
However, enhanced proliferation of Tregs was not seen in medium only cultures at any 
point (Fig 3.2A), arguing against IL-2-induced proliferation. The role of IL-2 in these 
cultures could be more readily addressed with the use of blocking anti-IL-2 antibody.  
 
We also measured the levels of IFNγ in supernatants at each time-point, over serial 
dilutions of the supernatant (Fig. 3.3B). pMOG stimulated cultures showed increased 
IFNγ production over time, suggesting that the cells have become activated in response 
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to pMOG stimulation, as is the case with anti-CD3. A small level of IFNγ was detectable 
in medium only cultures at 24h but this was reduced over time.  
 
From the data above it was decided that the detection of antigen-specific activation and 
proliferation via BrdU incorporation was optimal after antigenic stimulation for 48h in 
vitro. 
 
3.2.3 The effect of endogenous MOG expression on th e 
peripheral Treg repertoire 
3.2.3.1 The antigen-reactivity of Tregs in WT vs MOGKO mice  
 
To understand the role of self-antigen expression on the repertoire of self-antigen-
reactive Tregs we compared the pMOG-reactive Treg repertoire of WT mice with 
MOGKO mice. Both WT and MOGKO mice were immunised with pMOG/CFA. After 
10 days, cells were isolated from the DLN and stimulated with pMOG in vitro for 48h, 
with the addition of BrdU for the final 12h of cultre. The proportion of Foxp3+ cells 
from MOGKO mice was repeatedly higher than the propo tion of Foxp3+ cells from WT 
mice in both un-stimulated and pMOG stimulated cultures, although this was not 
significantly different (Fig. 3.4A). When stimulated with pMOG, both WT and KO 
Foxp3+ cells showed a significant increase in BrdU incorporation compared to their un-
stimulated counterparts (Fig. 3.4B). Interestingly, at this time-point MOGKO Tregs also 
showed significantly enhanced BrdU incorporation compared to WT Tregs (Fig 3.4B), 
suggesting that Tregs generated in MOGKO mice after pMOG immunisation are more 
responsive to pMOG stimulation in vitro.  
 
To determine if Tregs from MOGKO mice show differenc s compared to WT Tregs 
specifically in their response to pMOG, the above experiment was repeated with an extra 
group immunised with pOVA. In accordance with previous experiments, both WT and 
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KO Tregs from pMOG immunised mice incorporated BrdU in response to pMOG, but 
not in un-stimulated or pOVA stimulated cultures (Fig. 3.5A). Apart from the un-
responsiveness of one culture in the MOGKO group, the rend for higher BrdU 
incorporation in KO vs WT Tregs was maintained. When mice had been immunised 
with pOVA, BrdU incorporation was only evident in pOVA stimulated cultures and no 
significant difference was observed between WT and KO Treg proliferation (Fig. 3.5B). 
These trends in Foxp3+ populations were also confirmed by analysis of cell numbers 
(Fig. 3.5C and 3.5D).  These data again suggested that a proportion of WT and KO 
Tregs can respond to pMOG after pMOG immunisation and that MOGKO Tregs may 
show an enhanced proliferation compared to WT Tregs.  
 
In each experiment analysed, Foxp3+ proliferation was accompanied by an increase in 
Foxp3- proliferation (Fig. 3.6). In this setting it would be possible that the proliferation 
observed in the Foxp3+ compartment could be in respon e to Foxp3- cell proliferation 
and release of IL-2. To assess if this was the case, we sorted CD4+CD25+ cells from the 
DLN of WT and MOGKO mice which had been immunised with pMOG 10 days earlier. 
These ‘Tregs’ (~85% Foxp3+) were then stimulated in vitro with peptide or anti-CD3 
using congenically marked (Thy1.1+) irradiated splenocytes as APC. Using FACS 
analysis, Tregs could be identified from APC based on their lack of Thy1.1 expression. 
At 48h the level of BrdU incorporation in both WT and KO Tregs was significantly 
enhanced compared to un-stimulated controls (Fig. 3.7A). No difference in WT vs KO 
Treg proliferation to pMOG was observed. At 72h both WT and KO Tregs continued to 
proliferate in response to pMOG stimulation. However, at this later time-point WT 
Tregs showed a significant increase in the proportion of BrdU+ cells to a level which 
was significantly higher then that of KO Tregs in pMOG stimulated cultures (Fig. 3.7B).  
Although there was a small Foxp3- fraction within the CD25+ sorted cells, these cells 
did not show the same levels or trends in BrdU incorporation as the Foxp3+ cells (Fig 
3.7C and D). Thus the proliferation of Foxp3+ cells in culture was unlikely to be due to 
the proliferation of Foxp3- cells also in culture.  
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These data suggested that the enhanced BrdU incorporation observed in MOGKO Tregs 
from unsorted T cell populations (Fig 3.4B) was theeffect of a factor which has been 
excluded in the sorting of CD25+ cells away from other cells in the DLN. This may 
include the preferential production of IL-2 from another cell population in the MOGKO 
vs WT cultures in response to pMOG stimulation. 
 
3.2.3.2 Treg co-cultures: Does the presence of effector T cells affect the 
ability of Tregs to proliferate in vitro? 
 
To assess the contribution of effector T cell respon es to driving Treg proliferation we 
co-cultured the sorted CD25+ from the DLN with the CD25- Teff cells also from the 
DLN at a 1:3 ratio (CD25+:CD25-). At 48h, Foxp3+ cells from un-stimulated cultures 
proliferated to levels observed in the sorted un-stimulated cultures (Fig. 3.8A). 
Stimulation with pMOG showed a small, but detectable increase in Foxp3+ cell BrdU 
incorporation (Fig. 3.8A). At 72h, the Tregs in co-ulture with no stimulation had almost 
no detectable levels of BrdU incorporation in both WT and KO cells (Fig. 3.8B). 
However, both WT and KO Tregs showed high levels of BrdU incorporation to pMOG 
stimulation at this later time-point (Fig. 3.8B). KO Tregs now showed BrdU 
incorporation to the same levels as WT Tregs, suggesting that a factor which was 
lacking in the CD25+ sorted KO cell cultures is now available to drive the KO Tregs 
proliferation to a high level. Unfortunately supernatants were not available from this 
experiment to assess the levels of cytokines such as IL-2 in each culture; however it is 
difficult to see why CD25+ fraction from WT mice should contain a factor that is 
lacking in the KO Treg cultures.  
 
The level of proliferation in the Foxp3- cells in the co-culture were also assessed (Fig. 
3.8C and D). Similar to the Foxp3+ fraction, the Foxp3- cells in co-culture proliferated 
in response to pMOG in vitro. No significant difference in proliferation was observed 
between the WT and KO groups. It may be suggested that T cells from MOGKO mice 
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should show enhanced responses to pMOG compared to WT as theses cells will not 
have been tolerised to the antigen in vivo. However th se data would suggest that there 
is no significant increase, or decrease, in the respon e of MOGKO mice to pMOG 
immunisation and restimulation compared to WT mice. 
  
One study, using the retinal antigen IRBP, has suggested that that immunisation with 
peptide in CFA does not expand IRBP-reactive Tregs in IRBP KO mice (Grajewski et 
al., 2006). They suggest the suppression of experimental autoimmune uveitis (EAU) by 
the Tregs generated after immunisation of IRBPKO mice is due to the expansion of 
Tregs reactive against the mycobacterial components in the adjuvant. To determine 
wether the mycobacterial component of CFA was playing a role in the generation of 
MOG-reactive Tregs, we repeated the above experiment usi g WT and MOGKO mice 
immunised with pMOG in both CFA and IFA. We confirmed that MOG-reactive Tregs 
can be detected in WT and MOGKO mice immunised withpMOG in both CFA and IFA 
(Appendix III). 
 
3.2.3.3 Assessing the effect of MOG on the repertoire of transgenic mice 
expressing MOG-reactive TCRs 
 
2D2 transgenic mice possess CD4+ T cells expressing a TCR which is reactive against 
pMOG. Mice on a RAG-/- background lack nTregs and spontaneously develop 
autoimmunity (Hori et al., 2002; Lafaille et al., 1994; Olivares-Villagomez et al., 1998). 
RAG-sufficient transgenic mice are therefore used for most experiments. As discussed, 
RAG allows editing of TCR genes and the expression of on-transgenic TCRs in TCR 
transgenic mice. In the transgenic mouse models used in our lab the proportion of total 
CD4+ cells expressing the transgenic TCR+ cells is routinely greater than 90%, however 
the TCR usage specifically in transgenic Tregs has not been studied.  
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3.2.3.4  The effect of endogenous pMOG expression in pMOG-reactive 
transgenic mice 
 
To investigate the effect of endogenous antigen expression on the repertoire of 
peripheral antigen-reactive Tregs we compared the expression levels of the MOG-
reactive TCR in WT 2D2 and 2D2xMOGKO mice. The proportion of CD4+Foxp3+ 
cells in WT 2D2 mice is routinely in the region of 1-2%. This is reduced compared to 
non-transgenic mice where approximately 5-10% of CD4+ cells will express Foxp3. 
Foxp3+ cells represented ~4% of 2D2 MOGKO CD4+ cells, approximately twice the 
levels of WT mice (Figure 3.9A). We next assessed the proportions of Foxp3+ and 
Foxp3- cells that expressed the 2D2 transgenic TCR, were determined by Vβ11 and Vα3 
expression (Fig. 3.9B). In WT 2D2 mice only 57% of CD4+Foxp3+ cells and 85% of 
CD4+Foxp3- cells expressed both the Vβ and Vα chains of the transgenic TCR (Fig. 
3.9B, left hand panels). Some of the cells had lost expression of Vα3 only, possibly 
representing T cells which had undergone TCRα revision induced by recognition of self-
antigen. A larger proportion of cells no longer expressed either of the transgenic TCR 
chains, but still expressed a TCR of unknown specificity as determined by staining with 
a pan TCRβ antibody (data not shown). 
 
In comparison, the Foxp3+ and Foxp3- populations from 2D2 MOGKO mice maintain 
the expression of the transgenic TCR to much higher levels (Fig. 3.9B, right hand 
panels). WT 2D2 mice therefore have fewer Tregs and almost half of these cells did not 
express the MOG-reactive transgenic TCR. This can be attributed to the endogenous 
expression of MOG in the WT mice, as MOGKO 2D2 mice have a higher proportion of 
Tregs almost all of which express the pMOG-reactive TCR.  
 
To determine if the revision of the transgenic TCR in WT 2D2 mice compared to 
MOGKO 2D2 mice was due to peripheral antigen encounter, the thymi of WT and 
MOGKO 2D2 mice were removed to assess TCR expression on thymocytes from each 
mouse (Fig. 3.10). Double staining for CD4 and CD8 revealed that thymocytes from WT 
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mice had a reduced proportion of CD4 single positive cells (CD4 SP) compared to 
MOGKO 2D2 thymocytes (Fig. 3.10A). However, CD4 SP cells from WT mice showed 
a higher proportion of Foxp3+ cells, suggesting that while WT mice had fewer CD4+ 
cells, more of the CD4 SP cell that remained were Foxp3+, arguing for their selective 
survival from negative selection or for their enhanced selection due to the presence of 
self antigen expression. While the proportion of Foxp3+ cells was higher in the CD4 SP 
fraction of WT mice, the total number of CD4+Foxp3+ cells was higher in MOGKO 
mice compared to WT mice as there is a higher proportion (~6 fold increase) of CD4 SP 
cells in KO mice vs. WT mice (Fig. 3.10A). 
 
Expression of the transgenic TCR was determined by staining for the transgenic Vβ 
chain, Vβ11 and for the expression of alternative TCR Vβ chains using a pan-TCRVβ 
antibody (Fig. 3.10B). Foxp3+ thymocytes from both WT and MOGKO showed little 
evidence of TCR revision, however, Foxp3- thymocytes from WT mice showed a 
greater loss of transgenic TCR expression compared to MOGKO Foxp3- thymocytes 
(Fig. 3.10B). The levels of TCR Vβ11 expression were compared in WT vs. MOGKO 
mice and showed that the Foxp3+ and Foxp3- thymocytes from MOGKO mice 
expressed a higher level of the transgenic TCR compared to WT mice (Fig. 3.10C). 
Foxp3- thymocytes from WT mice showed a general shift in the intensity of Vβ11 
expression compared to WT Foxp3- thymocytes. However, the majority of MOGKO 
Foxp3+ thymocytes expressed similar levels of the transgenic TCR, a small population 
expressed enhanced levels of Vβ11 (Fig. 3.10C). 
 
These data suggest that thymic encounter with MOG reduces the proportion of CD4 SP 
cells that are positively selected in MOG-reactive transgenic mice. Furthermore, MOG 
expression initiates TCR revision in Foxp3- thymocytes, while in the periphery, both 
Foxp3+ and Foxp3- cells are seen to lose expression of the transgenic TCR. This was 
not evident in MOGKO mice and suggests that endogenus antigen expression may 
reduce the thymic and peripheral self-antigen reactive Foxp3+ repertoire. 
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3.2.3.5  Tregs that have lost the expression of the transgenic TCR do not 
proliferate to antigen in vitro 
 
The response of Tregs expressing the transgenic TCR vs non-Tg TCR was assessed by 
sorting CD4+CD25+ lymphocytes (85% Foxp3+) from naïve 2D2 mice and stimulating 
them in vitro with pMOG. Of the CD25+ cells which were un-stimulated, only ~50% 
expressed Vβ11 in confirmation with the previous experiments (Fig. 3.11A). CD25+ 
cells stimulated with pMOG and anti-CD3 maintained the proportions of Vβ11+ vs 
Vβ11- cells at a 50:50 ratio (Fig. 3.11A).  
 
To determine if Vβ11+ cells responded better to pMOG over Vβ11- cells BrdU was 
added to the cell cultures to assess proliferation. When compared to un-stimulated 
cultures, Vβ11+ cells showed a significant increase in BrdU incorporation in response to 
pMOG stimulation while Vβ11- cells did not (Fig 3.11B). Both Vβ11+ and Vβ11- 
populations proliferated in response to anti-CD3, demonstrating that the Vβ11- cells are 
expressing a functional TCR, although the levels of BrdU incorporated was reduced in 
Vβ11- vs Vβ11+ cells (Fig 3.11B). This demonstrates that Tregs from WT 2D2 mice 
which do not express Vβ11 are less responsive to pMOG. 
 
3.2.4 Antigenic reactivity of CNS derived Tregs in active EAE. 
3.2.4.1 CNS-derived Treg reactivity: 3H-Thymidine incorporation 
 
Tregs have been shown to accumulate and proliferate in the CNS during EAE 
(McGeachy et al., 2005; O'Connor et al., 2007). It was not clear if the Tregs that 
arise/expand in the CNS in response to pMOG/CFA immunisation were also pMOG-
reactive, reactive against other CNS components or indeed reactive against CFA 
components. As Tregs were largely believed to be anrgic to in vitro stimulation it 
would be difficult to determine their antigenic responsiveness by proliferation 
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(Takahashi et al., 1998). However, it is now clear that Tregs can be induced to 
proliferate in vitro in response to antigenic stimulation (Tang et al., 2004b).  
 
In order to study the reactivity of Tregs isolated from the CNS during EAE, mice were 
sacrificed at day 16 post EAE-induction. Lymphocyte populations were then sorted into 
CD4+CD25+ (Tregs) or CD4+CD25- (Teff) to high purities, routinely >90%. The 
CD4+CD25+ Treg populations consistently showed ~85-90% Foxp3+ cells. Due to the 
difficult nature of obtaining lymphocytes from the CNS, coupled with the loss of cell 
numbers during the sorting process, very few CNS-derived Tregs could be recovered 
from any one experiment. From approximately 16 mice in the recovery stage of disease 
the average number of CD4+CD25+ cells that could be recovered from the pooled CNS 
samples was 0.5-1x106 total cells. Therefore, only low cell numbers (1x104cells/well) 
could be used to test the in vitro antigenic-reactivity of the Tregs by thymidine 
incorporation.  
 
In initial experiments, exogenous IL-2 was added to the cultures at 1000U/ml, a dose 
pre-determined in the lab to maintain Foxp3+ expression well in vitro. However, when 
cultured in the presence of IL-2 alone proliferation was observed in both the CNS-
derived Treg and Teff cells and proliferation of eith r subset was not significantly 
enhanced by the addition of pMOG to the cultures (Fig. 3.12). Exogenous IL-2 induced 
proliferation in naïve CD4+CD25+ to a low level, but did not induce proliferation in 
CD4+CD25- populations. These data emphasise that in naïve T cells, Tregs are sensitive 
to the addition of exogenous IL-2, while both Treg and Teff isolated from a site of 
inflammation are highly responsive to IL-2 (Figure 3.12). In a repeat experiment the 
addition of exogenous IL-2 alone again induced proliferation of both CNS CD25+ and 
CD25- and naïve CD25+ populations (Fig. 3.13A). The proliferation of both CNS 
derived and naïve CD25+ populations was not significantly enhanced by addition of 
pMOG or rMOG, however the CNS CD25- populations did show an enhanced 
proliferation to pMOG (Fig. 3.13A). In cultures where no exogenous IL-2 was added to 
the cultures proliferation could be detected in the CNS-derived CD4+CD25+ population 
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in response to pMOG and to a lesser extent, rMOG (Fig. 3.13B). CNS CD4+CD25- 
populations proliferated in response to pMOG but also showed a good proliferative 
response to rMOG (Fig. 3.13B). Neither of the naïve populations proliferated in 
response to pMOG or rMOG.  
 
These results suggested that in the absence of exogenous IL-2 CNS-derived 
CD4+CD25+ and CD25- populations show a small, but detectable level of proliferation 
in response to pMOG in vitro when EAE was induced with pMOG/CFA. CNS-derived 
CD25- populations can also proliferate in response to whole MOG protein, while CD25+ 
cells do not. However, while sorting for Tregs based on CD25 expression generated a 
population of cells of which ~85% expressed Foxp3, it is difficult to rule out that the 
proliferation observed in response to pMOG was due to the contaminating 15% of 
Foxp3- cells. We therefore required a method to determine the proliferation of the 
Foxp3+ cells specifically. 
 
3.2.4.2 CNS-derived Treg reactivity: BrdU incorporation 
 
To detect Foxp3+ cell proliferation we again utilised BrdU staining. The benefit of BrdU 
is that it allows detection of proliferation at a cellular level, while thymidine 
incorporation only measures the proliferation at a population level. As in previous 
experiments, mice were actively immunised for EAE induction using pMOG/CFA and 
Treg/Teff populations sorted from the CNS at day 16 (Fig. 3.14). Cells were then 
cultured with various peptides to test antigen-induced BrdU incorporation to antigens 
from the CNS, components of CFA and self antigens, i cluding heat shock proteins 
(HSP’s) (Table I). Heat shock proteins are highly conserved, with mammalian and 
prokaryotic HSPs showing up to 50% homology. HSPs are consitutively expressed in 
the CNS and up-regulated in MS plaques (Selmaj et al., 1992). HSP65 is the 
immunodominant mycobacterial protein which is recognised by the immune system 
after immunisation with CFA, while HSP60 is an endogenous HSP expressed in mice 
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and up-regulated response to inflammation (Birnbaum, 1995). The regulatory role of 
HSPs have been described in adjuvant induced arthritis (Anderton et al., 1995; Quintana 
et al., 2003) and in NOD mice (Quintana et al., 2002). Furthermore, phase II clinical 
trials have shown a beneficial effect of treatment with a peptide from HSP60 in type 1 
diabetes (Raz et al., 2007). It was therefore important to determine if the Tregs from the 
CNS were reactive against components of myelin or against components of the adjuvant 
which could contribute to non-specific regulation. 
 
Tregs or Teff were cultured in vitro for 48h with BrdU added for the final 18h of culture. 
As mentioned, CD4+CD25+ cells routinely contain ~85-90% Foxp3+ cells. After in 
vitro culture this proportion is reduced to ~70%, with a population of Foxp3- cells 
evident upon intracellular Foxp3 staining (Fig. 3.15A). Whether the appearance of these 
cells represented an outgrowth of Foxp3- cells, death of a proportion of Foxp3+ cells or 
loss of Foxp3-expression by cells which initially were Foxp3+, is unknown. However, 
by gating on the Foxp3+ population in culture (CD25+Foxp3+ refers to the population 
indicated by the red box in Fig. 3.15A) we can asses  the proportion of Foxp3+ cells 
which have incorporated BrdU in each culture. As was the case in the thymidine 
incorporation assays, Foxp3+ cells showed the greatest BrdU incorporation to pMOG 
and rMOG (Fig. 3.15B), but also incorporated BrdU in response to the CFA component 
mycobacterium purified protein derivative PPD (Fig 3.15C). Interestingly, exposure to 
PPD has been previously suggested to suppress EAE via a mechanism involving CD4+ 
T cells (Ben-Nun et al., 1993). The data presented here also suggests that immunisation 
with mycobacterial components can drive Treg proliferation. 
 
In the sorted CD25+ cultures the contaminating Foxp3- compartment also showed a 
degree of proliferation to the same antigens as the Foxp3+ cells (Fig. 3.15C, black bars). 
Thus, while Foxp3+ cells show responsiveness to some antigens from the immunising 
components, Foxp3- cell proliferation could also contribute to the levels of Foxp3+ cell 
proliferation observed in previous experiments. This raises the issue of wheter the Teff 
proliferation in response to the antigens results in IL-2 production, which could 
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indirectly induce Treg proliferation. As the Foxp3- population is such a small 
component of the sorted CD25+ population it would be unlikely that stimulation of this 
small fraction of cells would generate the levels of IL-2 to induce proliferation of 30% 
of the Foxp3+ cells in culture. The role of IL-2 in culture could again be assessed using 
anti-IL-2 blocking antibody. The data presented here would suggest that Tregs in pMOG 
induced EAE show a degree of proliferation to pMOG and rMOG, but also to 
components of CFA, which may contribute to suppression in a bystander fashion.  
 
In vitro responses of CD4+CD25- populations derived from the CNS were also 
investigated (Fig. 3.16). The CD25- populations showed a high degree of spontaneous 
BrdU incorporation (in culture with medium alone) and this was not significantly 
enhanced by the addition of antigen to the cultures. This demonstrated that CD25- cells 
from the CNS are in a highly activated state upon isolation from the CNS (Fig. 3.16A). 
When supernatants from the cell cultures were assessed for cytokine production by 
ELISA it was evident that only CD25- cells cultured with pMOG and rMOG produced 
high levels of IFNγ, while low levels of IFNγ could be detected in PPD and HSP60 
stimulated cultures (Fig. 3.16B). Thus, while Teff cell responses could not be 
distinguished at the level of proliferation, effector cytokines are released only in 
response to certain antigens, suggesting a level of activation induced by these antigens 
not seen in the other cultures. Interestingly, when the CD25+ cell cultures were assessed 
for IFNγ production, low levels of IFNγ (10-fold less than in CD25- cultures) were 
detected in the pMOG and PPD stimulated cultures, but not in the rMOG stimulated 
cells (data not shown). Again, these data suggest tha both CD25+ and CD25- 
populations from the CNS of pMOG/CFA immunised mice respond to pMOG in vitro, 
but clearly demonstrate that proliferation is not the most sensitive measurement of 
antigen-induced responses, particularly in CD4+CD25- cells isolated from an inflamed 
site. 
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3.2.4.3 CNS-derived Treg suppression assays 
 
While the Tregs from the CNS were shown to be respon ive to pMOG, it was not clear 
if these cells could suppress MOG-reactive effector ells or if suppression could only 
occur after stimulation with pMOG. CNS-derived CD4+CD25+ cells were therefore 
assessed for suppressive effects on proliferation. Responder cells were either their 
CD4+CD25- counterparts or naïve CD4+CD25- cell either from pMOG-reactive 2D2 
mice or pOVA-reactive OT-II TCR transgenic mice.  
 
When cultured with 2D2 responders and pMOG, CNS-derived Tregs dramatically 
suppressed the proliferation of the pMOG-reactive TCR transgenic cells, even at very 
low Treg:responder cell ratios (Fig. 3.17A).  However, when CNS Tregs were cultured 
with naïve OT-II responders and pOVA there was no evidence of suppression (Fig. 
3.17A). To determine if Tregs derived from the CNS of pMOG/CFA immunised mice 
required stimulation with pMOG to exert their suppressive effect, OT-II responders were 
cultured with CNS-derived Tregs and both pOVA and pMOG were added to the 
cultures. CNS-derived Tregs did not show suppression of OT-II responders even when 
pMOG was added to cultures (Fig 3.17A). 
 
The proliferative response of CNS effectors could not be suppressed by either naïve or 
CNS-derived Tregs (Fig. 3.17B). Indeed, proliferation appeared enhanced at high 
Teff:Treg ratios, suggesting the Tregs may have prolife ated in these cultures. The data 
here demonstrate that Tregs from the inflamed CNS show a response to pMOG. This is 
emphasised by the fact that these Tregs can suppress MOG-induced proliferation of 
pMOG-reactive Teff in vitro. However, the CNS-derived Tregs do not suppress T cells 
of other antigenic-reactivities.  
 
 
Chapter 3 - Results 
 88 
3.2.4.4 TCR analysis of CNS-derived Tregs 
 
Upon immunisation, antigen-reactive T cells bearing particular TCR Vβ chains will 
expand preferentially. This has been documented for Vβ8+ T cells in actively induced 
EAE using pMOG. To assess if the TCRs used by Tregs in the CNS during active EAE 
reflect the public expression of Vβ8 we analysed the TCR usage of each population 
isolated from the CNS of mice in the recovery phase of active EAE. Between 15-20% of 
CD4+ T cells from the CNS expressed Vβ8+ TCRs, however, this was not enhanced 
compared to the periphery of either the same mice or naïve mice or mice which had 
developed EAE (Fig. 3.18A). The proportion of Vβ8+ cells which expressed Foxp3 was 
also not enhanced in the CNS (Fig 3.18B). Later investigations in the laboratory 
determined that Vβ8+ T cells preferentially expand in both the Treg and Teff 
compartments over the course of the disease, although this effect was not dramatic 
(published, JI paper).  
 
Interestingly the analysis of Foxp3+ cells within each of the Vβ+ compartments 
highlighted that Vβ5+ T cells showed a dramatic skewing towards Foxp3+ cells, with 
approximately 1:3 of CD4+Vβ5+ cells expressing Foxp3 (Fig 3.18B). The mechanism 
behind this Foxp3+ enrichment in Vβ5+ cells is explored in Chapter 5.
Chapter 3 - Figures 
89 
3.3  Discussion 
 
While it is has been demonstrated that Tregs are important in the prevention and/or 
suppression of EAE (Furtado et al., 2001; McGeachy et al., 2005; Reddy et al., 2004; 
Zhang et al., 2006) the origin, antigenic-reactivity and dynamics of CNS-relevant Tregs 
were unclear. This chapter describes a number of attemp s to define the antigenic-
reactivity of Tregs from the CNS and DLN of mice with EAE induced using the 35-55 
epitope of MOG. We have also investigated how the expression of endogenous MOG 
can affect the generation of self-reactive Tregs and how this might affect their capacity 
to respond to immunisation with MOG. 
 
To determine the antigenic-reactivity of EAE-relevant Tregs we needed access to a large 
number of Tregs derived from the CNS. To overcome this, we attempted to generate 
Treg hybridomas. We could not identify any other studies at that time which had 
attempted to produce hybridomas specifically from Treg populations and unfortunately, 
none of our attempts resulted in successful hybridoma generation. If we had been 
successful in generating hybridomas from our CNS-derived Treg populations it is 
unlikely that we could determine if they originally were ‘true’ Foxp3+ cells, as 
expression of Foxp3 appeared to be lost in the fusion process. 
 
A recent paper from Pacholczyk et al (Pacholczyk et al., 2007) has demonstrated that the 
lack of Foxp3-expression by hybridomas is one shared by other labs. They have begun 
to answer the question of whether the hybridomas generated from sorted Treg 
populations were of Treg origin by using a TCR-mini mouse. These mice express a fixed 
TCRβ chain and generate a number of TCRα chains selected from a cassette of TCRα 
genes. This allows identification of T cell origin by comparing the CDR3 sequence of 
the TCR used by a population with the CDR3 sequence xpressed by the cell of interest. 
Their conclusion was that the TCRs expressed by the Treg hybrids were derived from 
the pool of TCRs expressed by the Foxp3+ cells in the s arting population. Similar to our 
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expansion protocols, while the initial Treg population was highly pure for Foxp3-
expression, the expanded Foxp3+ population still contained contaminating Foxp3- cells. 
With this finding it would be of great advantage to use this technology in our setting of 
EAE to confirm that the CNS-derived Treg-hybrids are derived from ‘true’ Foxp3+ 
Tregs. 
 
The ultimate goal of these studies would be to testhese Treg-hybrids for reactivity 
against potential peptide candidates, including CNS-derived epitopes and other self 
molecules, such as heat shock proteins (HSPs) to determine their reactivity. This would 
then allow us to expand these Tregs directly in vitro, via mechanisms that will be 
discussed further in chapter 4.  
 
While the immunisation of mice with self-peptide in CFA has been shown to activate 
Teff which are reactive to the peptide it was unclear if peptide-reactive Tregs could also 
be triggered in the autoimmune inflammatory response. As we could not successfully 
generate Treg hybridomas, we developed a model where w  could measure antigen-
induced proliferation of Tregs directly ex vivo. By utilising thymidine and BrdU 
incorporation as a measure of detecting antigen-induce  Treg proliferation we identified 
that a proportion of Foxp3+ cells from the DLN of mice that had been immunised with 
pMOG incorporated BrdU in response to 48h in vitro stimulation with pMOG (Fig 
3.2A). This reflected the proportion of pMOG-specific cells detected using tetramer 
staining by the Kuchroo group (Korn et al., 2007).  
 
Using the protocol we had developed we showed that after pMOG immunisation, Tregs 
which are reactive to pMOG in vitro can be identified in mice which lack the 
endogenous expression of pMOG (Delarasse et al., 2003). In un-sorted DLN cultures 
Tregs from MOGKO mice, compared to WT Tregs, demonstrated a small but consistent 
increase in the proportion of cells which proliferat d in response to pMOG in vitro (Fig. 
3.4). However, this capacity for enhanced responsive ess of KO Tregs to pMOG 
stimulation was lost when Tregs were sorted and cultured alone (Fig. 3.7A). 
Chapter 3 - Figures 
91 
Furthermore, of the CD4+Foxp3+ T cells from MOG-reactive transgenic mice (2D2) 
only 50% expressed the transgenic TCR (Fig 3.9B). However 2D2 mice which lacked 
endogenous MOG expression not only had higher levels of Foxp3+ cells (Fig 3.9A), but 
also showed that up to 96% of the Foxp3+ cells expressed the MOG-reactive TCR (Fig. 
3.9B). These data suggest that endogenous MOG-expression affected the proportion of 
Tregs which expressed pMOG-reactive TCRs.  Importantly, it was shown that T cells 
which lack the transgenic TCR do not respond to pMOG stimulation in vitro (Fig. 3.10).   
 
Pacholczyk et al. have argued that commitment to the Treg vs. Teff lineage is not 
determined by TCR avidity based selection in the thymus. They suggest that the two 
populations express the same TCRs, but these are asymmetrically distributed between 
them (Pacholczyk et al., 2006). The implications of the experiments described in this 
chapter are that thymic expression of cognate self antigen is not necessary for the 
generation of Foxp3+ self-antigen reactive Tregs. This would argue against the dogma 
that Tregs are selected in the thymus based on the high avidity of their TCRs for self 
antigen (Apostolou et al., 2002; Jordan et al., 2001; Yu et al., 2008) and proliferate in 
response to self-antigen encounter in the periphery (Hsieh et al., 2004; Walker et al., 
2003).  
 
However, Tregs that are reactive to non-self antiges clearly exist, for example 
CD4+CD25+ Tregs which contribute in the regulation towards parasite and 
mycobacterial components (Belkaid and Rouse, 2005) and during viral responses (Suvas 
et al., 2003). It has been proposed that while these Tregs may be able to suppress the 
inflammatory responses, in some cases this may be due to the ability of Tregs to respond 
to weakly cross-reactive antigens (Larkin et al., 2007) or the non-specific activation of 
Tregs via TLR stimulation from components of the immunising adjuvant (Grajewski et 
al., 2006). The Ignatowicz group argues that self-antigen interactions are not exclusively 
required for the generation of Tregs and that Tregs are selected as part of the natural 
CD4+ T cell repertoire (Pacholczyk et al., 2002). Furthermore, they suggest that the 
ligand which selects a cell to become a Treg in the thymus may differ from the ligand 
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which activates the same Treg in the periphery and that self-reactive Tregs are rarely 
found in the periphery (Pacholczyk et al., 2007). 
 
Two studies using antigen-KO mice have concluded that endogenous antigen-expression 
is required for the generation of antigen-reactive Tr gs. One study used a model of 
autoimmune gastritis, in mice lacking the major gastric antigen H/K+ ATPase (Zwar et 
al., 2006) and the other using mice lacking interphotoreceptor retinoid-binding protein 
(IRBP) in experimental autoimmune uveitis (EAU) (Grajewski et al., 2006). Both 
demonstrated that while the KO mice lacked antigen-specific Treg after antigen-
immunisation, the mice possessed Tregs capable of suppressing disease. Interestingly, 
the Caspi group could not generate Tregs capable of suppressing EAU when IRBP was 
immunised in IFA (Grajewski et al., 2006). Their suggestion is that Tregs are activated 
by the mycobacterial components of CFA, either via activation of mycobacterium-
reactive Tregs or polyclonal Treg stimulation via TLR ligation. While we could detect 
PPD-induced proliferation of CNS-derived Tregs after pMOG/CFA immunisation, we 
detected a much higher level of proliferation in response to pMOG (Fig 3.14). 
Importantly, we also detected pMOG-induced proliferation in both WT and KO Tregs 
after pMOG/CFA immunisation (Fig. 3.4) suggesting that the polyclonal pMOG-
reactive Treg repertoire is not affected by the lack of endogenous MOG expression.  
 
One study has reported that the Treg TCR repertoire is more diverse than that of non-
Tregs (Pacholczyk et al., 2006). They argue that the higher diversity of Treg TCRs 
allows these cells to match the specificites of auto-reactive effector T cells. Importantly, 
this study determined that the Treg TCR repertoire was not adversely affected by the 
lack of tissue-specific antigen expression, which would corroborate with our finding that 
MOG-reactive Tregs can be identified in MOGKO mice.  
 
While our findings are intriguing, our studies are limited as the detection of antigen-
induced proliferation is assessed by BrdU incorporati n of all cells in culture, not solely  
in MOG-reactive Tregs. It is particularly difficult to assess Treg proliferation in cultures 
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which also contain contaminating, proliferating Foxp3- populations, as is the case in 
most of our Treg assays. It is important to mention that sorting of 100% pure Treg 
populations may not be beneficial in this setting as Tregs are classically anergic to in 
vitro stimulation in the absence of IL-2 (de la Rosa et al., 2004; Thornton et al., 2004). It 
is likely that the proliferation of a small Foxp3- fraction in vivo provides the extra 
signals (such as IL-2) required to drive Treg proliferation. The detection of pMOG-
specific cells in vitro, and in vivo, could be overcome by the use of MOG-reactive 
tetramers, a protocol which is currently being develop d in the lab. Another important 
next step would be to assess the suppressive capacity of the pMOG-reactive Tregs from 
both WT and MOGKO mice. This could be assessed in vitro, but also in vivo by sorting 
the Tregs from WT and KO mice after pMOG immunisation and assessing their ability 
to suppress pMOG induced disease by adoptive transfer of the Tregs. 
 
By isolating Tregs directly from the inflamed CNS we have demonstrated that active 
induction of EAE results in Teff (Foxp3-) and Treg (Foxp3+) populations in the CNS 
which have the capacity to respond to the immunising a tigen (Fig. 3.14B). The cells 
isolated from the CNS also demonstrate a low level of responsiveness to components of 
the adjuvant, in this case CFA (Fig. 3.15C). Tregs from the CNS demonstrated a 
proliferative capacity to pMOG and suppressed MOG-reactive TCR transgenic effector 
T cells responses in vitro (Fig. 3.17A). However, CNS-derived Tregs could not 
efficiently suppress the proliferative response of CNS-derived Teff cells in response to 
pMOG (Fig. 3.17B).  
 
Our studies are in agreement with those of Korn et al. (Korn et al., 2007), utilising 
Foxp3gfp knock-in mice and MOG(35-55)/I-Ab MHC class II tetramers to track MOG-
reactive Tregs during MOG-induced EAE. They found that MOG-reactive Tregs 
accumulated in the CNS just before the peak of disease and that this population was 
significantly expanded after in vitro culture with pMOG. Similar to our studies, CNS-
derived Tregs suppressed naïve 2D2 cells, but not CNS-derived effector cell 
proliferation to pMOG in vitro. This may be reflective of the effector cells from 
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inflamed sites being in a heightened activation state, therefore making suppression of 
their response more difficult than in naïve T cells.  
 
It is interesting to note that in our studies the proliferation of TCR transgenic cells is 
much more robust compared to the proliferation of CNS-derived T cells (compare Y axis 
of Fig. 3.17A vs B) yet the response of CNS Teff is not affected by the presence of 
Tregs. It may be suggested that Tregs require a stronge  proliferative response of Teff 
cells to become activated to suppress, however the culture of OT-II Teff with pOVA and 
pMOG would argue against this (Fig. 3.17A). It has been suggested that once Tregs 
become activated by TCR stimulation they may suppress via bystander mechanisms 
(Fisson et al., 2006; Grajewski et al., 2006; Thornt n and Shevach, 1998) while others 
suggest that Tregs may only suppress Teff with the same cognate specificities (Tanchot 
et al., 2004). While the data from pOVA plus pMOG stimulated cultures suggest that the 
latter may be the case (Fig. 3.17A), this may reflect imitations of the assay, such as 
availability of pMOG for the Tregs to encounter in vitro. It may be possible that if CNS-
derived Tregs were previously activated with pMOG before addition to the OT-II-pOVA 
suppression assay then they may have been able to suppre s the level OT-II cell 
proliferation.   
 
As Th17 cells are now suggested to be the main effector T cell population involved in 
the pathology of EAE it is interesting to note that some studies are reporting that effector 
Th17 cells cannot be as efficiently suppressed as other Th subsets (O'Connor et al., 
2007; Stummvoll et al., 2008). Studies from our labhave investigated the ability to 
suppress effector cell cytokine production in the CNS (O'Connor et al., 2007).  We 
found that while Tregs from the CNS effectively suppressed CNS-derived Teff IFNγ 
production, levels of IL-17 in the same cultures was not affected (Appendix Publication, 
Fig. 4). This may be due to the release of cytokines by the CNS-derived effectors, such 
as IL-6, which has been shown to block de novo Treg g neration (Dominitzki et al., 
2007).  
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In the study by Korn et. al. the addition of exogenous IL-6 to in vitro suppression assays 
using CNS-derived Tregs and 2D2 effector T cells abrogated suppression by 50% (Korn 
et al., 2007). However, a combination of IL-6 and TNFα completely blocked the 
suppressive capacity of CNS-derived Tregs. In their CNS-Treg:CNS Teff suppression 
assays, high levels of IL-6 and TNFα were also detected in culture. Levels of IFNγ in 
these cultures were not assessed; however, addition of exogenous IFNγ to the assays 
only demonstrated minor effects on suppression. These studies strongly suggest that the 
ability to be suppressed by Tregs in the CNS is different in IFNγ-producing populations 
compared to IL-17-producing populations, perhaps due to their sensitivity to IL-6 in the 
CNS-environment. 
 
While unable to suppress CNS-derived Th17 effector cells in vitro, Tregs must 
eventually acquire the potential to suppress the eff ctor T cell response in the CNS in 
vivo as they are ultimately responsible for the recovery phase of disease. The conditions 
in vivo may provide an environment where Tregs become activated and their 
proliferation will increase the proportion of regulatory cells relative to effector cells over 
time. Indeed, Korn et al. demonstrated that the ratio of pMOG-reactive Tregs:Teff is 
increased from 1:13 at disease peak to 1:4 during recovery (Korn et al., 2007). This was 
attributed to the reduced levels of IL-6 at this point. The balance of inflammation vs. 
regulation is obviously more complex than the Teff:Treg ratio and involves CNS-
resident cells and the CNS microenvironment (Dittel, 2008).  
 
While these studies have investigated the antigenic-rea tivity of Tregs in actively 
induced EAE there is obviously no immunising antigen in patients with MS as disease is 
triggered by an unknown stimulus. Similar investigations to those described have been 
conducted in the lab using passive induction of EAE (O'Connor et al., 2007). This 
involves transfer of CD4+ T cells isolated from pMOG-immunised mice and activated in 
the presence of polarising cytokines in vitro. In this setting, Tregs from the CNS showed 
a much reduced proliferative response to pMOG in vitro (Appendix Publication, Fig. 
3A), however the Tregs isolated from the CNS during passively-induced EAE could still 
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suppress pMOG-induced 2D2 cell proliferation (Appendix Publication, Fig. 3C). 
Irrespective of the mechanism of EAE induction, we have demonstrated that it is 
possible to detect antigen-induced responsiveness in regulatory T cells by in vitro 
mechanisms. This will be important in identifying the antigenic-reactivity of Tregs in 
patients with MS, perhaps by isolating regulatory cells from peripheral blood, as will be 
crucial if these cells are to be specifically targeted in therapies. It will also be crucial to 
understand if Tregs and Teff during the disease course are reactive against the same 
antigens and/or epitopes of these antigens. It would be difficult to specifically target 
regulatory cells via antigen-based therapies if Tefc lls can respond to the same antigen. 
If this is the case it would be necessary to develop strategies to specifically target Tregs, 
perhaps through the use of antibodies which will deiver antigen to the appropriate 
subset of APC which can stimulate Tregs preferentially, s has recently been suggested 
in one study, identifying CD11c+CD11b+ DC in peptide-induced tolerance to EAE via 
the intravenous route (Li et al., 2008).  
 
Ultimately, it may be that disease-relevant Tregs do not equal antigen-specific Tregs, 
although as will be discussed in later chapters, thi  may be sufficient for Treg-based 
therapeutic strategies. It is likely that combination therapy involving the targeting of 
Tregs along with cytokine blockade will be required to generate an environment in the 
CNS where regulation will be favoured. The central aim would be to tip the balance 
towards specific CNS-targeted regulation at an earlier time-point, before any overt 
inflammation occurs. Maintenance of this regulatory state will also be key to induce 
long-term tolerance to myelin antigens and to prevent r lapses of disease. Understanding 
the antigenic reactivity and requirements for selectiv  expansion of CNS-relevant Tregs 
is therefore crucial for this to be achieved. 
 
Taken together, these data demonstrate that immunisation with peptide results in the 
appearance of Foxp3+ Tregs in the CNS and show in vitro responsiveness to the 
immunising antigen. CNS-derived Tregs can suppress naïve T cell antigen-induced 
proliferation in vitro, but not proliferation of eff ctor T cells isolated from the inflamed 
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CNS. The presence of endogenous antigen is not required for the expansion of antigen-
reactive Tregs. However, the endogenous expression of a tigen may have a detrimental 
effect on the generation of self-antigen-reactive Tr gs, although the mechanisms and 
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Figure 3.1: Foxp3+ and Foxp3- cells from C57BL/6 mic e immunised with 
pMOG proliferate in response to pMOG re-stimulation i n vitro. DLN were 
removed from WT C57BL/6 mice which had been immunised with pMOG/CFA  
10 days earlier and stimulated in vitro with medium, pMOG (10µM) or rMOG for 
72h. BrdU was added for the last 18h of culture. Levels of BrdU incorporation 
and Foxp3 expression were assessed by FACS, gated on live CD4+ cells. Bars 
show individual wells of pooled samples. Data is representative of three 
individual experiments with similar results. 
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Figure 3.2: Time-course analysis of BrdU incorporati on in response to in vitro 
stimulation with pMOG to determine antigen-induced p roliferation. DLN of B6 mice 
which had been immunised with pMOG/CFA 10 days earlier  were removed. Whole 
lymphocytes were cultured @  5x106/ml, 1ml per well of 24 well plate. Cells were left un-
stimulated or stimulated with pMOG (10µM) or αCD3 (1µg/ml). BrdU was added at 12, 24 
and 48h to assess BrdU incorporation over the next 12 hours. A: 48H and 72H time-point 
FACS plots of BrdU incorporation in Foxp3+ and Foxp3- cells, gated on live CD4+ 
lymphocytes. B: %BrdU incorporation of CD4+Foxp3+Vβ8+ cells (red line) and 
CD4+Foxp3+Vβ8- cells (black line) in Foxp3+ and Foxp3- gated populations. Data 
representative of three independent experiments showing similar results.
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Figure 3.3: Production of cytokines by DLN of MOG-i mmunised C57BL/6 mice 
after in vitro re-stimulation. Supernatants from cultures in Fig. 3.2A were removed 
and assessed for cytokine levels by ELISA. A: IL-2 levels in supernatants of un-
stimulated (blue line), pMOG (red line) and anti-CD3 stimulated (lack line) cells over the 
72h culture. B: IFNγ levels in supernatants at 24h (black lines), 48 h (blue lines) and 72h 
(red lines) under each stimulation over two-fold dilutions. Data represents one of two 
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Figure 3.4: Foxp3+ cells from DLN of pMOG-immunised WT and MOGKO mice 
show low levels of proliferation to pMOG after 48h i n vitro stimulation. DLN were 
removed from WT C57BL/6 (black) and MOGKO mice (red) were removed 10 days after 
immunisation with pMOG/CFA. Single cell suspensions were cultured with medium only 
or 10µM pMOG for 48h. BrdU was added after 36h of culture to assess proliferation by 
FACS at 48h. A: percentage of Foxp3+ cells after in vitro stimulation (gated on live 
CD4+ cells). B: Percentage of Foxp3+BrdU+ cells in each culture. Data points show 
triplicate cultures of pooled samples between groups. * p<0.05. Data represents one of 
four repeat experiments with similar results. 


































Figure 3.5: Foxp3+ cells from MOG-immunised MOGKO mi ce show enhanced 
proliferation compared to WT Foxp3+ cells in respon se to pMOG. DLN were 
removed from DLN of MOG-immunised (left panel) or pOVA-immunised (right panel) 
WT C57BL/6 (black) and MOGKO mice (red). Single cell suspensions were cultured 
with medium onle, pMOG or pOVA for 48h, with BrdU added for the final 15h of 
culture to assess proliferation of Foxp3+ cells by FACS. Top panels: Percentage of 
BrdU+Foxp3+ in A: pMOG immunised mice and B: pOVA immunised mice in 
response to in vitro restimulation with peptide. C and D: As above, shown as cell 
numbers. Data points show triplicate cultures of pooled samples between groups. 
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Figure 3.6: Foxp3- cells from pMOG or pOVA immunised W T and KO mice 
proliferate to the immunising antigen in vitro. DLN were removed from DLN of 
MOG-immunised (left panel) or pOVA-immunised (right panel) WT C57BL/6 
(black) and MOGKO mice (red). Single cell suspensions were cultured with 
medium onle, pMOG or pOVA for 48h, with BrdU added for the final 15h of culture 
to assess proliferation of Foxp3- cells by FACS. Top panels: Percentage of 
BrdU+Foxp3- in A: pMOG immunised mice and B: pOVA immunised mice in 
response to in vitro restimulation with peptide. C and D: As above, shown as cell 
numbers. Data points show triplicate cultures of pooled samples between groups. 
Data represents one of three repeat experiments with similar results.
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Figure 3.7: Sorted CD4+CD25+ cells from WT and MOGK O mice immunised with 
pMOG show proliferation in response to pMOG re-stimul ation in vitro that is not 
accompanied by Foxp3- proliferation. DLN cells from MOGKO and WT mice were 
sorted into CD4+CD25+ populations by MACS and FACS sorting were stimulated with 
irradiated splenocytes from Thy1.1+C57Bl/6 mice alone or plus pMOG (10µM) for 48H 
and 72H. BrdU was added for the final 12h of culture and Foxp3+ and Foxp3- BrdU
incorporation assessed by FACS. BrdU incorporation shown as a percentage of: A and 
B: Thy1.1-CD4+Foxp3+ cells and C and D: Thy1.1-CD4+Foxp3- cells. * = p<0.05. 
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Fig 3.8: The proliferation of Foxp3+ cells from WT and MOGKO mice in response 
to pMOG is not affected when co-cultured with Foxp3- T cells. CD25+ cells were 
cultured at a 1:3 ratio with sorted CD25- cells and irradiated splenocytes from Thy1.1+ 
C57BL/6 mice as APC. Cells were stimulated with medium alone or 10µM pMOG for 
48H and 72H. A and B: BrdU shown as a percentage of live CD4+Foxp3+ cells from 
WT (black bars) and MOGKO (red bars). C and D: Gated on CD4-Foxp3- cells. * = 
p<0.05. Bars represent individual wells of pooled samples, showing one of three 
separate experiments with similar results.
48h 72hA B
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Figure 3.9: Naïve 2D2 WT vs 2D2 MOGKO transgenic TCR  expression in 
Foxp3+ and Foxp3- populations in the spleen. A: Naïve lymphocytes from 
2D2 WT or 2D2MOGKO mice assessed for Fop3-expression via FACS, gated on 
live CD4+ cells. Isotype control = IgG2a. B: Levels of transgenic TCR expression 
on WT and MOGKO 2D2 transgenic mice. Top panels: CD4+Foxp3+ cells, 
bottom panels: CD4+Foxp3- cells. Data show one representative plot of three 
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Figure 3.10: Naïve 2D2 WT vs 2D2 MOGKO transgenic TC R expression in 
Foxp3+ and Foxp3- populations in the thymus. A: Thymocytes from naïve WT 
and MOGKO 2D2 mice were removed and assessed for expression of  CD4 and CD8 
(top panels) and Foxp3 expression in CD4 single positive populations (bottom 
panels). B: Foxp3+ cells (top panels) and Foxp3- cells (bottom panels) were 
assessed for the expression of the transgenic TCR using Vβ11 antibody and for the 
expression of an alternative TCR by pan TCRVβ staining. C: Histograms showing the 
expression of Vβ11 expression on Foxp3+ (top panel) and Foxp3- cells(bottom












































Figure 3.11: Only 2D2 cells expressing the transgen ic (Vβ11+) TCR respond to 
pMOG in vitro. CD4+CD25+ cells were sorted from splenocytes of WT 2D2 mice 
and stimulated with pMOG (10µM) or anti-CD3 (1µg/ml) in vitro. BrdU incorporation 
in Vβ11+ and Vβ11- populations as assessed by FACS at 48h. A: Percentage of 
CD4+Vβ11+ (open bars) and CD4+Vβ11- cells (filled bars) after 48h in vitro 
stimulation. B: Percentage BrdU+ cells in Vβ11+ (red bars) and Vβ11- cells (open 




















Figure 3.12: Proliferation of naïve and CNS sorted CD4+CD25+and 
CD4+CD25- populations to pMOG and IL-2 as determined by 3H-thymidine 
incorporation. Splenocytes from naïve C57BL/6 mice or lymphocytes isolated 
from the CNS of mice which have undergone pMOG/CFA-induced EAE for 16 
days were sorted into CD4+CD25+ or CD4+CD25- populations to >90% purity. 
Cells were cultured @ 1x104 cells/well with 5x105 irradiated splenocytes from 
C57BL/6 mice +/- pMOG (10µg/ml) + IL-2 (100U/ml) for 72h. Tritiated thymidine
was added to the cultures and assessed for thymidine incorporation after 18h. 
Error bars show mean +/- S.D. of triplicate wells of pooled samples between 
groups, data representative of one of three individual experiments with similar 
results.

























Figure 3.13: IL-2 induced proliferation masks antig en-induced proliferation as 
measured by thymidine incorporation. Splenocytes from naïve C57BL/6 mice or 
Lymphocytes isolated from the CNS of mice which have undergone pMOG/CFA-
induced active EAE for 16 days were sorted into CD4+CD25+ or CD4+CD25-
populations to >90% purity. Cells were cultured @ 1x104 cells/well with 5x105
irradiated splenocytes +/- pMOG (10µg/ml). A: cells cultured with APC, antigen and IL-
2 (100U/ml). B: cells cultured with APC + antigen in the absence of exogenous IL-2. 
Cultures were incubated for 72h. Tritiated thymidine was added for the final 18H of 
culture before detection of thymidine incorporation. Error bars show mean +/- S.D. of 
triplicate wells of pooled samples between groups, data representative of one of three 
individual experiments with similar results.
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Figure 3.14: Schematic representation of BrdU incorp oration assay. Cells isolated 
from CNS and sorted CD4+ (MACS) CD25+/CD25- (Aria). CD25+ sorted to 94% 
purity. CD25- sorted to 97% purity. Cultured at 3x105/ml, 100µl in 96 well round bottom 
plate. Irradiated Thy1.1 APC 1x107/ml, 50 µl/well,  IL-2 (when added) at 0.1ng/ml final.
Table 3.1: Antigens and concentrations used 
for in vitro stimulation of sorted populations.
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Medium only pMOG rMOG
Figure 3.15: Foxp3+ cells isolated from the CNS sho w BrdU incorporation in 
response to the immunising antigen. A: FACS plot demonstrating the post-in 
vitro culture Foxp3 vs BrdU plot of CD25+ sorted cells stimulated with rMOG in 
vitro. B: BrdU incorporation of cells from CD25+ cells in un-stimulated, pMOG
stimulated and rMOG stimulated cultures, gated on CD4+ Foxp3+ cells. C:CNS 
derived CD4+CD25+ sorted Foxp3+ cell (red bars) and Foxp3- cell (black bar) % 
BrdU incorporation in response to indicated antigen. Bars show individual wells of 

























































































Figure 3.16: CNS-derived Teff cell BrdU incorporation  and IFNγ production 
after in vitro stimulation. A: CNS derived CD4+CD25- sorted BrdU incorporation in 
response to indicated antigen. B: Supernatant IFNγ levels as detected by ELISA in 
CD4+CD25- populations (from figure A) after 72h in vitro stimulation with indicated 
antigen. Bars show individual wells of pooled samples between groups. Data shows 
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Figure 3.17: CNS Tregs can suppress proliferation of  naïve, pMOG-reactive TCR 
transgenic effector T cells, but not CNS-derived ef fector cells. CNS-derived Tregs
were cultured at the indicated ratio with purified CD25- cells (2x104) from A: 2D2 TCR 
transgenic mice + pMOG (squares), OTII TCR transgenic CD25- + pOVA (triangles) or 
OT-II CD25- cells + pMOG + pOVA (circles) and B: CNS derived Tregs (red bars) and 
naïve Tregs (black bars) were cultured with CD25- cells sorted from CNS and stimulated 
with pMOG. Irradiated slenocytes from niave C57BL/6 mice were used as APC in all 
cultures. Dotted line represents average c.p.m. of responders alone in culture with 
antigen. Error bars show mean +/- S.D. of triplicate wells of pooled samples between 














2:1 4:1 8:1 16:1 32:11:1
A
B














  2D2 pMOG










Chapter 3 - Figures 
115 
Figure 3.18: TCR V β analysis does not show skewing of TCR usage of Treg s
from the inflamed CNS vs. naïve splenocytes. Lymphocytes were isolated from 
the CNS of mice which had undergone pMOG/CFA immunisation 16 days earlier or 
from the spleen of naïve C57BL/6 mice. Cells are gated on live CD4+ from CNS (red 
bars) or naïve splenocytes (black bars) and assessed for A: TCR Vβ expression and 
B: Foxp3-expression within each Vβ+ population via FACS. Data represents one of 
three repeat experiments showing similar results.
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4 Therapeutic use of myelin basic protein-
reactive Tregs in CNS autoimmune disease 
4.1 Introduction 
 
It has been shown using animal models that transfer of T egs can suppress inflammatory 
disease. A number of studies have highlighted that antigen-specific, disease relevant 
Tregs are much more efficient at suppressing a model f diabetes, even at low cell 
numbers (Tang et al., 2004b; Tarbell et al., 2004). If the antigen reactivity of Tregs is 
essential to activate Treg mediated suppression it will be crucial to target the expansion 
of CNS-relevant Tregs in EAE and MS to ameliorate dis ase.  
 
Some inflammatory disorders in mice, such as EAE and models of diabetes, are 
associated with a diverse T cell repertoire, recognising more than one antigen (Acha-
Orbea, 1991; Mallone and van Endert, 2008). Furthermore, the disease initiating antigen 
is not always known. In EAE, as destruction of the myelin sheath occurs this mediates 
the release of new proteins and peptides which werepreviously ignored by the immune 
system (Vanderlugt and Miller, 1996). The release of inflammatory mediators in the 
CNS enhances antigen presentation by CNS resident cells and infiltrating APCs by 
inducing the up-regulation of MHC and co-stimulatory molecules (Becher et al., 2006). 
This can allow the activation of T cells against newly emerging epitopes of the same and 
distinct antigens resulting in epitope spreading. This phenomenon was described in the 
B10.PLxSJL model using MBP(Ac1-9)-induced EAE (Lehmann et al., 1992), where the 
immune response was shown to spread to other epitops f MBP as the disease 
progressed (intramolecular spreading). It had also previously been reported that 
spreading could occur to epitopes of PLP after immunisation with MBP (intermolecular 
spreading) (Perry et al., 1991). Furthermore, the initiation of disease against PLP(139-
151) resulted in the emergence of T cells reactive against other PLP epitopes, including 
PLP(178-191) and MBP epitopes (Vanderlugt et al., 2000). The fact that over the course 
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of disease distinct repertoires of T cells arise that are reactive against different myelin 
epitopes, suggests that epitope spreading contributes to the relapses associated with 
demyelinating diseases (Tuohy et al., 1999; Vanderlugt et al., 2000).  
 
This phenomenon presents a problem in antigen-specific therapy, as tolerance to one 
antigen will not necessarily induce tolerance to other antigens. However, previous 
studies using oral and nasal peptide administration have suggested that tolerance induced 
to one myelin epitope can induce bystander suppression against distinct myelin antigens, 
suggesting that antigen-specific therapy may be beneficial in this setting (Anderton et 
al., 1998; Metzler and Wraith, 1993; Miller et al., 1991)  
 
The results in this chapter describe experiments that aimed to target the expansion of 
myelin-reactive Tregs both in vitro and in vivo. We have investigated the capacity of 
MBP-reactive Tregs to suppress both MBP(Ac1-9)- andPLP(139-151)-induced EAE to 
determine if specific targeting of antigen-reactive Tr gs will be sufficient to overcome a 
disease that involves a diverse autoimmune T cell repertoire. These studies have 
important implications in the development of Treg-targeted peptide based therapy for the 
treatment of MS. 
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4.2 Results 
4.2.1 Generation of sufficient Treg numbers by in v itro 
expansion 
 
As has been discussed, isolation of sufficient antige -specific Treg cell numbers is a 
difficult task. However, the potential to expand ex vivo isolated Tregs in vitro using 
TCR stimulation and IL-2 has now been shown in both mouse and human studies (Earle 
et al., 2005; Fisson et al., 2006; Tang et al., 2004b) and importantly these Tregs 
maintained their suppressive capacity in vitro and in vivo after the expansion protocol. 
Recent investigations have also suggested that expanded Tregs show an enhanced 
capacity to suppress (Chai et al., 2008). We therefore investigated the potential of 
myelin-reactive Tregs to be expanded in vitro, following their Foxp3-expression over 
the expansion period and assessed the suppressive capacity of the expanded Tregs in 
various models of EAE.  
 
Prior to the generation of Foxp3-GFP reporter mice (Fontenot et al., 2005b), sorting of 
Tregs based on their Foxp3-expression was not possible due to its intracellular 
expression. However, in naïve mice, sorting of CD4+ cells based on expression of CD25 
can isolate ~85% of all Foxp3+ cells (Sakaguchi et al., 1995). We therefore purified 
CD4+ cells via MACS sorting, followed by FACS-purification of CD25- (Teff) and 
CD25+ cells (Tregs) from spleen and lymph nodes of naïve Tg4 transgenic mice (MBP 
Ac1-9-reactive TCR). Cells were then cultured with anti-CD3/anti-CD28 coated beads 
plus high levels of IL-2 to overcome Treg cell anergy. In numerous attempts to generate 
highly pure Treg populations we consistently found that while the CD4+CD25+ 
population showed a high Foxp3+ fraction before expansion, this was dramatically 
reduced after 7 days of expansion (from ~85% pre-expansion to 20% post-expansion). 
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4.2.1.1 Sorting Tregs based on CD62L expression 
 
It has been demonstrated that CD25+CD62L+ Foxp3+ Tregs have an enhanced 
suppressive capacity compared to CD25+CD62L- Tregs in vivo and maintained the 
expression of Foxp3 when expanded in vitro (Fu et al., 2004). This is in agreement with 
studies from our lab showing that sorting of Tregs ba ed on high expression levels of 
CD62L generates a population of highly pure Foxp3+ cells (Leigh Stephens, personal 
communication). To test the ability to sort Tregs based on the expression of CD62L we 
purified CD4+ T cells from the spleen and LN of naïve Tg4 mice and sorted them into 
three groups based on their expression of CD25 and CD62L; CD25-, CD25+CD62Llo 
and CD25+CD62Lhi (Fig. 4.1A). Each population was sorted to >93% purity and 
assessed for Foxp3 expression by FACS. Both the CD25+ populations (CD62L+ and 
CD62L-) showed high proportions of Foxp3+ cells, while only low numbers of CD25- 
cells expressed Foxp3 (Fig. 4.1B, left panel). The levels of Foxp3 expression in each 
population was assessed after 7 days of in vitro expansion using anti-CD3/anti-CD28 
coated beads and IL-2 (Fig. 4.1B, right panel). The CD25- did not increase the 
proportion of cells expressing Foxp3 over the expansion period. While the 
CD25+CD62Llo population showed a high proportion of Foxp3 expression before 
expansion (>80%), this was dramatically reduced after the 7 day culture, suggesting 
either out-growth of the contaminating 20% Foxp3- population, death of Foxp3+ cells or 
the loss of Foxp3-expression by some of the cells. The CD25+CD62Lhi population 
showed a higher proportion of Foxp3+ cells after sorting (>90%) and while this was 
reduced after the 7 day culture to ~70%, it suggested that Foxp3 expression was more 
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4.2.1.2 In vitro expanded Tregs suppress EAE induced with their cognate 
antigen 
 
To assess the suppressive capacity of Tg4 Tregs in EAE, we sorted 
CD4+CD25+CD62Lhi cells from the spleen and LN of Tg4Ly5.1+ mice and expanded 
these cells in vitro. As a control, polyclonal CD4+CD25+CD62Lhi Tregs were also 
sorted and expanded from B10.PL mice. Tregs were routinely around 90% Foxp3+ in 
both Tg4 and B10.PL populations. 1x105 Tregs were transferred i.v. to B10.PL hosts 1 
day prior to immunisation with MBP(Ac1-9)/CFA and assessed for clinical signs of 
EAE over a 30 day period (Fig. 4.2). Mice that received polyclonal Tregs did not show 
any reduction in disease incidence or severity compared to mice that received PBS alone 
(Fig. 4.2). However, mice which received MBP-reactive Tregs had a reduced incidence 
of disease of 50% in Tg4 Treg transfer group vs. 100% in PBS only group (Fig. 4.2). 
Those mice developing clinical signs in the group that had received Tg4 Tregs had less 
severe disease compared to the PBS treated group with a mean maximal clinical score of 
1.5 and 3.75 respectively. These data demonstrated that a very small number of antigen-
specific Tregs could efficiently reduce EAE when given prior to disease induction, while 
polyclonal Tregs could not.  
 
4.2.2 Expanding Tregs in vivo using peptide-based th erapy 
 
The ultimate aim of antigen-specific therapy is to induce antigen-specific 
unresponsiveness in vivo. It has long been established that the administration of soluble 
peptides together with an adjuvant will induce immune activation and result in a 
sustained and productive immune response. However, administration of antigen in the 
absence of adjuvant leads to abortive immune activation, resulting in antigen-specific 
unresponsiveness, or tolerance (Dresser, 1962). Many tolerogenic protocols involve the 
administration of peptides from disease-relevant antige (s), also termed peptide therapy. 
This has been shown to be successful in models of aut immunity, inflammation and 
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allergy and represents a potential therapy that could be translated to human disease 
(Anderton, 2001; Larche and Wraith, 2005).  By using adoptive transfer models, some 
studies have demonstrated clonal elimination of most antigen-reactive T cells after 
peptide administration (Critchfield et al., 1994; Liblau et al., 1996). The few remaining 
antigen-reactive T cells could not be stimulated by their cognate antigen and were 
considered anergic (Pape et al., 1998). Other studies have documented the generation of 
T cells that produce high levels of IL-10 (Burkhart et al., 1999; Sundstedt et al., 2003), 
perhaps reflecting Tr1-like regulatory cells (see introduction). However, only a few 
studies have demonstrated the induction or expansion of Foxp3+ regulatory T cells. 
These studies used high levels of TGFβ and/or IL-2 to generate Foxp3+ T cells in vitro 
(Selvaraj and Geiger, 2007; Zheng et al., 2007a) or used low dose, antigen 
administration (Apostolou and von Boehmer, 2004; Kretschmer et al., 2005) to target 
Foxp3+ cell conversion/expansion in vivo in the absence of inflammation. We therefore 
attempted to target the expansion of antigen-reactive Foxp3+ T cells therapeutically in 
EAE using CNS-derived peptide administration. 
 
To track the expansion of Tregs in vivo, we used adoptive transfer of CD4-purified 
Tg4Ly5.1+ cells to Ly5.2+ B10.PL host mice. The Tg4 model is particularly useful for 
the study of peptide based tolerance as the TCR and MHC binding properties of the 
MBP (Ac1-9) peptide have been extensively studied. Residues 3 and 6 of the 
nonapeptide have been shown to be interaction TCR determinants for I-Au restricted T 
cells (Wraith et al., 1989). Wild-type MBP (Ac1-9) has been shown to bind poorly to I-
Au, such that the half life of peptide binding cannot be determined in vitro (Fairchild et 
al., 1993; Liu et al., 1995). This has been attribued to the lysine at positon 4 of the 
peptide which interacts unfavourably with the hydroph bic pocket in the MHC binding 
groove (Pearson et al., 1999). Substitutions for lysine at position 4 have been shown to 
affect the binding affinity of the peptide to the MHC, with the more hydrophobic 
4Tyrosine peptide showing binding affinities of 100, 0 fold higher than the WT 
peptide (Fairchild et al., 1993). Use of this altered peptide ligand (APL) showed it to 
have enhanced tolerogenic properties, suppressing EAE to a greater extent than the WT 
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4Lys peptide (Liu and Wraith, 1995). The persistence of Ac1-9(4Tyr) for long periods in 
vivo makes this a unique peptide that will provide continual stimulation of peptide-
reactive T cells; we therefore reasoned that this APL may induce the upregulation of 
Foxp3 or preferential expansion of Foxp3+ cells in vivo. 
 
4.2.2.1 Treatment with Ac1-9(4Tyr) maintains a population of MBP-reactive 
T cells which are tolerant to in vitro re-stimulation 
 
In order to assess the capacity of Ac1-9(4Tyr) to expand Foxp3+ T cells in vivo,  CD4+ 
cells were sorted from Tg4Ly5.1+ cells to ~98% purity, with approximately 3% of cells 
expressing Foxp3+ (Fig 4.3A). 2x106 cells were then tra sferred to B10.PL (Ly5.2+) 
mice one day before peptide treatment. The dose of Ac1-9(4Tyr) which would be 
optimal for expansion of Foxp3+ cells was unknown, therefore mice were given either 
10µg (low dose) or 100µg (high dose) of Ac1-9(4Tyr). As controls, mice were given 
PBS or 10µg Ac1-9(4Tyr) plus 10µg LPS i.v.. After 6 days spleen and lymph nodes 
were harvested to determine the proportion of Tg4 cells and the levels of Foxp3-
expression (Fig 4.3B and C). Mice that had received 100µg Ac1-9(4Tyr) maintained a 
greater proportion of Tg4 cells than 10µg Ac1-9(4Tyr) or PBS treated mice, 
demonstrating that high dose peptide treatment had expanded the Tg4 populations (Fig. 
4.3B). Mice which had been treated with Ac1-9(4Tyr) and LPS showed a greater 
expansion of Tg4 cells, as these cells should have been fully activated by the adjuvant 
and expanded in response to the antigenic stimulation (Fig. 4.3B). 
 
The levels of Foxp3 expression within each of the Tg4 populations was then assessed 
(Fig 4.3C, top panels). Mice which had been treated with 10µg Ac1-9(4Tyr) or Ac1-
9(4Tyr) plus LPS did not show enhanced proportions f Foxp3+ cells in the Tg4 transfer 
population (Fig. 4.3C). Mice that had received 100µg Ac1-9(4Tyr) showed an increased 
proportion of Foxp3+ cells compared to 10µg Ac1-9(4Tyr)- or Ac1-9(4Tyr) plus LPS-
treated groups, and compared to the proportion of Foxp3+ cells in the initial transfer 
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population. However, the difference in Foxp3 expression was not vast, only increasing 
by 1-2%. It is also notable that the level of Foxp3 staining within the PBS treated group 
was similar to the 100µg Ac1-9(4Tyr) treated group, and therefore represents a 
population of Foxp3+ within the normal range for naïve mice and is not enhanced by 
peptide treatment. The proportion of Foxp3+ cells in host populations was also only 
enhanced by ~2% in any of the treatment groups compared to PBS-treated controls (Fig. 
4.3C, bottom panels). 
 
To assess the in vitro response of each group, splenocytes were stimulated in vitro with 
MBP(Ac1-9) and proliferation measured after 72h (Fig 4.3D). Mice that had been 
treated with 100µg Ac1-9(4Tyr) were unresponsive to in vitro re-stimulation with the 
WT peptide. Mice treated with 10µg Ac1-9(4Tyr) did not show reduced responsiveness 
to Ac1-9 compared to PBS treated mice, while mice that had received Ac1-9(4Tyr)+LPS 
demonstrated enhanced proliferation in vitro. These data demonstrated that treatment 
with 100µg Ac1-9(4Y) maintained a population of Tg4 cells in v vo that were tolerant to 
in vitro re-stimulation with MBP(Ac1-9) but only showed a minimal increase in the 
proportion of cells expressing Foxp3.  
 
Previous data showed that tolerance induced with Ac1-9(4Tyr) was observed only if 
assessed 4 days after peptide administration (Liu and Wraith, 1995). However, studies 
that investigated the induction or expansion of Tregs which resemble naturally arising 
Tregs have described emergence of these only after 10 days (Apostolou and von 
Boehmer, 2004) and routinely assess Treg phenotype and function up to two weeks after 
treatment (Apostolou and von Boehmer, 2004; Kretschmer et al., 2005). We therefore 
assessed the capacity of 100µg Ac(1-9)4Tyr treatment to expand Foxp3+ T cells 14 days 
after antigen administration (Fig. 4.4). The proportion of Tg4 T cells in Ac1-9(4Tyr) 
treated mice was not significantly higher than in PBS treated mice at this time (compare 
Fig. 4.4A and B). The proportion of Foxp3+ cells within the Tg4 populations was also 
similar in both PBS and Ac1-9(4Tyr) treated mice (Fig. 4.4A and B). However, cells 
from 4Tyr treated mice were completely unresponsive to in vitro restimulation with 
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MBP(Ac1-9), as assessed by 3H-thymidine incorporatin (Fig. 4.4B). This suggested 
that 6 days after i.v. administration of Ac1-9(4Tyr) the transferred population of Tg4 
cells were tolerant to re-stimulation in vitro. After 14 days, the proportion of Tg4 cells in 
mice treated with Ac1-9(4Tyr) had contracted to similar levels in PBS-treated mice The 
cells from Ac1-9(4Tyr) treated mice maintained the levels of unresponsiveness seen at 
the earlier timepoints. Ac1-9(4Tyr) treatment did not significantly increase the 
proportions of Tg4 Foxp3+ cells at any timepoint studied. 
 
4.2.2.2 Ac1-9(4Tyr) treatment suppressed disease induced with WT MBP   
(Ac1-9) 
 
To assess the capacity of Ac1-9(4Tyr) to induce tolrance in response to MBP in vivo, 
CD4+ Tg4 cells were adoptively transferred to B10.PLxC57BL/6 hosts (H-2u x H-2s). 
Recipients were treated with 200µg Ac1-9(4Tyr) then immunised with MBP(Ac1-9) 7 
days later to assess EAE (Fig. 4.5A). Previous investigations from our group have 
shown that B10.PLxC57BL/6 mice require transfer of Tg4 T cells to develop EAE after 
immunisation with MBP (McCue et al., 2004), therefo any effect of Ac1-9(4Tyr) 
administration on EAE should be due to the effect of the peptide on the transferred Tg4 
population. As shown in Fig. 4.5B, mice that had been treated with a single dose of 4Tyr 
one day after the transfer of Tg4 cells were protected from EAE induced with 
MBP(Ac1-9). Mice that received Tg4 cells, and received either WT MBP(Ac1-9) or 
PBS were not protected from disease. These data demonstrated that treatment with Ac1-
9(4Tyr) had effectively tolerised the Tg4 cells that d previously been transferred. This 
was sufficient to prevent the induction of EAE. Tg4 cells could be detected in the CNS 
of both 4Tyr and PBS treated mice and showed an approximate two fold increase in the 
proportions of Tg4 cells expressing Foxp3, from ~20% Tg4 Foxp3+ cells in PBS treated 
to ~40% Tg4 Foxp3+ cells in Ac1-9(4Tyr) treated mice (Joanne Konkel, unpublished 
observations). This enhanced proportion of Foxp3-expr ssing Tg4 cells was only 
observed in the CNS Ac1-9(4Tyr) treated mice during EAE, suggesting that the CNS 
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inflammatory environment may be required to drive th expression or upregulation of 
Foxp3. Mice that were treated with Ac1-9(4Tyr) but were not induced to develop EAE 
did not show changes in the proportions of Foxp3+ cells in the transferred Tg4 
population. It is not clear if the Tg4 Foxp3+ cells seen in the CNS are expanded from the 
2-3% Foxp3+ cells from the initiating population or Foxp3- cells that have up-regulated 
the expression of Foxp3+. This could be assessed by sorting Foxp3-GFP negative 
populations prior to cell transfer. 
 
4.2.3 Can antigen-specific Tregs suppress disease i nduced 
with another peptide? 
 
To address the capacity of the in vitro expanded MBP-reactive Tregs to suppress disease 
induced against distinct myelin antigens, a different EAE model and strain of mouse was 
used. B10.PLxSJL mice express both H-2u and H-2s and can be induced to develop EAE 
by immunisation with spinal cord homogenate (SCH), MBP and PLP (Miller et al., 
1995). Immunisation with one peptide (e.g. Ac1-9) can initiate an I-Au restricted 
response, but the response can then spread to I-Eu and I-As restricted epitopes. By using 
this model we can assess the ability of Tregs reactive to one epitope to suppress disease 
induced with an epitope from another distinct CNS protein. To do this, we sorted 
CD4+CD25+CD62Lhi Tregs from Tg4 mice and expanded them in vitro. After 7-10 
days 3x105 Tregs were transferred i.v. to B10.PLxSJL mice. Mice were immunised with 
either MBP(Ac1-9) or PLP(139-151) one day after Treg transfer and assessed for 
clinical signs of EAE over the next 60 days (Fig. 4.6A). Mice that were immunised with 
MBP and received no Tregs developed a severe relapsing course of disease, where one 
out of four mice died as a result of disease severity (Fig. 4.6B). Mice that had received 
expanded Tg4 Tregs prior to MBP-immunisation were completely protected from the 
first episode of disease (Fig. 4.6B). At day 37 post-immunisation, 1 out of 4 mice 
developed clinical signs of EAE and rapidly progressed to death (Fig 4.6B). All other 
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mice that received Tg4 Tregs remained free of disease until the end of the 60 day 
observation period. 
 
Mice that were immunised with PLP(139-151) and had not received Tregs also 
underwent a relapsing course of disease and the onst f disease was not affected in 
mice which had received Tg4 Tregs one day prior to PLP-immunisation (Fig 4.6B). 
However, the mice treated with Tg4 Tregs began their recovery at a much earlier time-
point than the PBS treated group and also showed reduced incidence of relapses over the 
60 day period. The disease observed from day 25 to day 60 in the group that received 
Tg4 Tregs is due to chronic disease of one mouse in this group that remained at grade 2-
3 throughout the 60 days, while 75% of mice in the PBS treated group underwent 
relapses at some stage over this period.  
 
These data suggest that MBP-reactive Tregs can suppress disease induced with another 
antigen. This has important implications for Treg based therapies as it may be possible 
to target one antigen, but also suppress effector T cells reactive to other antigens in the 
vicinity.  
 
4.2.3.1 In vivo peptide therapy to suppress disease induced against multiple 
epitopes 
 
We next attempted to utilise the Ac1-9(4Tyr) APL to prevent disease in the B10.PLxSJL 
model and to assess if peptide-induced tolerance against MBP(Ac1-9) could prevent 
EAE initiated against PLP(139-151). To confirm that Ac1-9(4Tyr)-treatment suppressed 
MBP-induced EAE in the B10.PLxSJL model, we transferred 2x106 CD4-purified Tg4 
cells i.v. followed by Ac1-9(4Tyr) i.v. one day later. Mice were then immunised seven 
days later with MBP(Ac1-9) (Fig. 4.7A) or PLP(139-151) (Fig. 4.8A). Mice that had 
been immunised with MBP(Ac1-9) and pre-treated with Ac1-9(4Tyr) showed a dramatic 
reduction in disease incidence and severity compared to mice which received PBS (Fig. 
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4.7A). Two mice per group were harvested at day 7 of EAE and assessed for the 
presence of Tg4 cells in the CNS, lymph node and spleen via FACS by the absence of 
Ly5.1 on the surface of the transferred Tg4 cells (Fig. 4.7B). PBS treated mice had a 
greatly enhanced proportion of Tg4 cells in the CNS compared to Ac1-9(4Tyr) treated 
mice. When the cells from the CNS and LN were re-stimulated with MBP in vitro, Tg4 
cells from PBS treated mice showed a higher level of IFNγ and IL-17 production 
compared to the Tg4 cells from Ac1-9(4Tyr) treated mice (Fig. 4.7C and D), suggesting 
that the peptide treatment had tolerised the transferred Tg4 cells in vivo. Peptide 
treatment also reduced the levels of IFNγ and IL-17 produced by host CD4+ T cells in 
the CNS and LN in response to MBP (data not shown). The Tg4 cells from Ac1-
9(4Tyr)-treated mice in this system did not express Foxp3 (data not shown) but did show 
reduced levels of effector cytokine production. The severity of disease in PBS treated 
mice could be attributed to the high levels of Tg4 cells in the CNS with the capacity to 
produce IFNγ and IL-17. 
 
In mice immunised with PLP, Ac1-9(4Tyr) treatment did not affect disease development 
or the severity of primary disease, however, mice which had received Ac1-9(4Tyr) were 
completely protected from relapses (Fig. 4.8B). 3 mice per group were harvested at day 
14 and the proportion of Tg4 cells and Foxp3-expression assessed. Similar to the MBP-
immunised mice, PBS-treated mice showed a much higher proportion of Tg4 cells in the 
CNS (Fig. 4.8C). No Foxp3 could be detected in the Tg4 cells of either PBS or 4Tyr 
treated mice (data not shown) while the proportion of Foxp3+ cells in the CNS of host 
CD4+ cells was not significantly different (Fig. 4.8D).  
 
Lymphocytes from the CNS were assessed for cytokine production upon re-stimulation 
with WT MBP(Ac1-9) or PLP(139-151) in vitro. No cytokine production or Foxp3 
expression could be detected in the Tg4 cells in this experiment (data not shown). Host 
CD4+ cells from the CNS of PBS-treated mice consistently produced higher levels of 
IFNγ and IL-17 when stimulated with MBP(Ac1-9) and PLP(139-151) than Ac1-
9(4Tyr)-treated mice (Fig. 4.9A). However, the levels of IL-10 produced by total CD4+ 
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cells from the CNS of Ac1-9(4Tyr)-treated mice was higher than in cells from PBS-
treated mice (Fig. 4.9B). These data suggest that in the recovery stage of primary disease 
induced with PLP(139-151), CD4+ T cells in the CNS of mice which had been 
transferred with Tg4 cells and treated with Ac1-9(4Tyr) produced high levels of IL-10 
and lower levels of effector cytokines in response to myelin antigens compared to PBS 
treated mice. This may contribute to a regulatory environment which prevented relapses 
in Ac1-9(4Tyr) treated mice, however the levels of F xp3 were not enhanced in 4Tyr 
treated vs. PBS treated mice suggesting that the mechanism of regulation is not via 
expansion or induction of Foxp3+ Tregs. 
 
4.2.4 Does the inflamed CNS influence the balance b etween 
Foxp3+ and Foxp3- Tg4 cells? 
 
It had previously been shown that the transfer of CD4+Tg4 cells prior to immunisation 
with MBP(Ac1-9) or with PLP(139-151) resulted in the appearance of Tg4 cells in the 
CNS and of which up to 20% expressed Foxp3 (Steve Anderton, personal 
communication). This was not seen when mice were immunised with either peptide, but 
not induced to develop EAE (i.e. no pertussis toxin administered). This led us to 
question wether the inflamed CNS could drive the expansion of Foxp3+ cells resulting 
in their enhanced frequency. Furthermore, data from this laboratory had indicated that 
administration of Ac1-9(4Tyr) to hosts that had received Tg4 cells could further enhance 
the proportion of Tg4 Foxp3+ cells in the CNS to 40%. This suggested that prior 
exposure to Ac1-9(4Tyr) could influence the capacity of the CNS to drive the expansion 
of Foxp3+ cells in situ.  
 
To test this hypothesis, CD4+ cells were sorted from Tg4 mice that had been treated 
with 200µg Ac1-9(4Tyr) or PBS 6 days earlier. 2x106 cells were then transferred i.v. to 
B10.PLxSJL hosts that had been immunised with MBP(Ac1-9) 10 days earlier and had 
developed clinical signs of EAE (Fig. 4.10A). Mice were left for 7 days after the Tg4 
Chapter 4 - Results 
129 
cell transfer, then CNS, LN and spleen were harvested at day 17 post EAE induction 
(Fig. 4.10B). The proportion of Tg4 cells in each organ and the frequency of Foxp3+ 
cells within the Tg4 populations were assessed by FACS (Fig. 4.10B and C). Mice that 
had received Ac1-9(4Tyr)-treated Tg4 cells did not show any significant difference in 
disease course initially compared to mice which had received PBS treated Tg4 cells or to 
un-transferred mice, however at later stages the mice receiving 4Tyr-treated cells 
appeared to have a prolonged disease compared to the ther groups (Fig. 4.10B). The 
proportion of Tg4 cells in mice that had been given Ac1-9(4Tyr)-treated Tg4 cells was 
not significantly greater than PBS treated Tg4 cells in the CNS, spleen or LN (Fig. 
4.10C). Also, the proportion of Tg4 Foxp3+ cells in the CNS and LN was not 
significantly different in Ac1-9(4Tyr) vs. PBS pre-treated groups. Although the Ac1-
9(4Tyr) treated Tg4 cells showed a reduction in the proportion of Foxp3+ cells in the 
spleen, this could only be assessed in one animal as the others had died as a result of 
EAE severity (Fig. 4.10D).  
 
To assess the persistence of Tg4 cells in PLP(139-151) immunised mice, the experiment 
was repeated using PLP(139-151) immunisation instead of MBP(Ac1-9) (Fig. 4.11A). In 
this setting, the mice that received Ac1-9(4Tyr)-trea ed Tg4 cells did not show enhanced 
disease compared to non-transferred mice (Fig. 4.11B)  However, mice that received 
PBS-treated Tg4 cells showed a prolonged and more sev re disease course (Fig. 4.11B). 
No significant difference in the proportions of Tg4 cells in any organ could be detected 
(Fig. 4.11C). Similarly, there was no significant difference in the proportions of Foxp3+ 
Tg4 cells in the spleen, LN or CNS; however the Ac1-9(4Tyr)-treated Tg4 cells in both 
CNS and LN showed a trend towards reduced proportions of Foxp3+ cells compared to 
PBS-treated Tg4 cells (Fig. 4.11D). 
 
When splenocytes from each group were assessed for proliferation to PLP(139-151) in 
vitro, no significant difference was observed between the three groups (Fig. 4.12A). 
When stimulated with MBP(Ac1-9), both of the Tg4 transferred groups showed higher 
levels of proliferation compared to un-transferred mice, showing that both the PBS and 
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Ac1-9(4Tyr) treated Tg4 cells were capable of responding to MBP(Ac1-9) to a similar 
level in vitro (Fig. 4.12B). Cells from the CNS of each mouse were assessed for 
cytokine production in vitro. In response to MBP(Ac1-9) stimulation a higher proportion 
of the Ac1-9(4Tyr)-treated Tg4 cells from the CNS of PLP(139-151) immunised mice 
produced IFNγ and IL-17 compared to PBS treated mice (Fig. 4.12C). While a 
proportion of 4Tyr treated Tg4 cells from the CNS of PLP(139-151) immunised mice 
also produced IFNγ in response to PLP(139-151) stimulation in vitro (Fig. 4.12D), this 
was not significantly higher than the background leve s of proliferation. 




It has been documented that while the number of Tregs in MS patients are in the normal 
range, Tregs isolated from the patients are defectiv  in their capacity to suppress effector 
T cells (Haas et al., 2005; Venken et al., 2008b; Viglietta et al., 2004). Developing 
protocols to expand Tregs and enhance their functio through Treg based therapies is 
therefore of great interest. Here we have shown that purification and expansion of 
CD4+CD25+CD62Lhi Tg4 Tregs results in a population of MBP(Ac1-9)-reactive Tregs 
that maintains expression of Foxp3 and can suppress disease induced with the same or 
distinct antigen. We further attempted to expand Foxp3+ Tregs in vivo using peptide 
based therapy. We found that protection from EAE could be achieved using Ac1-
9(4Tyr), an APL with high affinity for MHC, that maintained a population of peptide-
reactive cells although the proportion of these cells that expressed Foxp3 was not 
enhanced. Importantly these data also show that tolerance induced against MBP(Ac1-9) 
resulted in reduced disease relapses when induced with PLP(139-151), a distinct myelin 
antigen. 
 
Defective Treg function is not limited to MS, but also noted in studies of patients with 
rheumatoid arthritis (Ehrenstein et al., 2004) and type 1 diabetes (Lindley et al., 2005) 
therefore developing protocols to generate sufficient Treg numbers for adoptive transfer 
therapy would be beneficial in a number of disease settings. A major issue in both 
mouse and human studies is that Tregs represent a small population of CD4+ T cells (2-
10%), therefore isolation of enough cell numbers to transfer therapeutically is difficult. 
Isolation and expansion of Tregs in vivo represents one mechanism whereby the 
numbers of Tregs can be enhanced. Initially, it wasreported that Tregs were anergic to 
antigenic stimulation in vitro (Jonuleit et al., 2001; Walker et al., 2003). In vivo, Tregs 
require stimulation via the TCR and CD28 co-stimulation for their homeostasis 
(Salomon et al., 2000; Tang et al., 2003). They are also critically dependent on IL-2 for 
their expansion in vivo (Bayer et al., 2005; Setoguchi et al., 2005). It is therefore 
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unsurprising that these three components (TCR stimulation, CD28 co-stimulation and 
IL-2) have now been shown to efficiently expand both murine and human Tregs in vitro 
(Chai et al., 2008; Dieckmann et al., 2001; Earle et al., 2005; Fisson et al., 2006; 
Hoffmann et al., 2004; Nishimura et al., 2004).  
 
In our studies, we have shown that antigen-specific Tregs are more potent at suppressing 
disease than polyclonal Tregs (Fig. 4.2). The increased potential of disease relevant 
Tregs to suppress inflammation has also been demonstrated in other models (Masteller 
et al., 2005; Tang et al., 2004b; Tarbell et al., 2004). It is important to note that the 
frequency of antigen specific Tregs in a polyclonal population is obviously far reduced 
compared to the expansion of antigen-reactive Tregs by the expansion of TCR 
transgenic T cells or after antigen-specific selection from a polyclonal repertoire, as can 
be achieved using peptide:MHC instead of anti-CD3/anti-CD28 stimulation (Fisson et 
al., 2006). Tarbell et al. (Tarbell et al., 2004) used islet antigen specific Tregs from 
BDC2.5 TCR transgenic mice that were expanded in vitro using DCs from NOD mice 
and showed that transfer of only 5000 islet-specific Tregs could give disease 
suppression. In a different model, Taylor et al. showed that 1-2x106 polyclonal in vitro 
expanded Tregs were required to prevent graft versus host disease (GVHD) (Taylor et 
al., 2002). This suggests that the specific targetin  of antigen-reactive Tregs will be 
more effective for therapy as fewer cells are required for suppression and are more 
effective than polyclonal Tregs.  
 
The use of transgenic systems allows antigen reactive ells to be tracked and assessed ex 
vivo. However, the ability to convert studies using transgenic models to polyclonal 
populations will be difficult, as has been highlighted by the Bluestone group (Masteller 
et al., 2005).  Using IL-2 and beads coated with recombinant islet peptide-mimic:MHC 
and anti-CD28 mAb, their study investigated the capa ity of expanded islet reactive 
Tregs to suppress diabetes in NOD mice. By mixing transgenic Tregs at various ratios 
with polyclonal Tregs it was shown that the antigen coated beads preferentially 
expanded the antigen-reactive Tregs in vitro from a frequency as low as 1:100,000. They 
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also showed that islet-reactive Tregs could be expanded from polyclonal populations, 
but that these Tregs were not as effective as the transgenic expanded Tregs in 
suppressing diabetes. It was noted that expanded transgenic Treg cultures had higher 
levels of IL-10 and TGFβ compared to polyclonal expanded cultures and that w ile WT 
expanded Tregs were oligoclonal, as assessed by TCR expression, they showed varying 
avidities for p:MHC class II multimers. These data highlight that while transgenic 
systems are useful to track antigen-reactive cells in vivo, care must be taken when 
investigating the potential of Treg therapy in non-transgenic populations.  
 
Other considerations must be made with regard to the ex vivo expansion of Tregs. 
Technical issues include the source of T cells from which to expand Treg populations. 
Human T cell isolation is largely restricted to peri heral blood as it is a relatively non-
invasive procedure. However, the most potent and disease relevant Tregs will likely be 
focused at the site of inflammation, which for MS presents an obvious problem. The 
ability to expand myelin-reactive T cells from the p ripheral blood of MS patients has 
been described (Arbour et al., 2006) and could potentially be tailored towards the 
expansion of myelin reactive regulatory cells. Another major consideration is that while 
the findings of many mouse studies have been replicated in human studies, there are a 
number of differences in mouse and human Tregs. For example, while mouse Tregs lack 
expression of MHC class II, human Tregs are MHC class II bright as assessed by flow 
cytometry (June and Blazar, 2006) and these differences may affect the capacity to use 
human Tregs in a similar way to mouse Tregs. 
 
The main issue in our expansion protocol was the apparent loss of Foxp3-expression 
from Treg cultures after the 7 day in vitro expansio  step. Although most of the Treg 
populations had initially been sorted to a high purity of Foxp3+ cells, the frequency of 
Foxp3-expressing cells was reduced to varying degrees after expansion (Fig. 4.1B). It 
could be argued that the reduced frequency of Foxp3-e ressing cells was solely due to 
the selective out-growth of Foxp3 negative cells, however, this population represented a 
very small fraction of the sorted population and would seem an unlikely explanation. 
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The death of Foxp3+ cells could also have contributed to the loss of Foxp3+ cells in 
culture. However this scenario would also seem unlikely as we would have expected 
fewer cells to be recovered from the cultures at day 7 nd this was not the case. It has 
also been suggested that Tregs show an intrinsic restance to TCR-signalling induced 
apoptosis relative to conventional T cells, which also argues against the deletion of 
Foxp3+ cells (Taylor et al., 2007). The levels of cell death in culture could be assessed 
using Annexin V staining. 
 
The remaining scenario to explain the reduced proportions of Foxp3+ cell after 
expansion is the selective loss of Foxp3-expression by some of the cells in culture. The 
lineage decisions made by a developing Treg have been investigated extensively over 
the last few years, as discussed in Chapter 1. Of particular interest is wether Foxp3-
expression and Treg status is fixed or if cells within this lineage demonstrate some 
degree of plasticity. The stability of Foxp3 expression has more recently been accredited 
to the epigenetic modulations at the foxp3 locus. Comparisons of CD25- and CD25+ 
cells showed differences in the methylation status of the foxp3 locus, such that in 
CD25+ cells the CpG motifs on the foxp3 locus were almost completely demethylated in 
one region, while they were methylated in the CD25- population (Floess et al., 2007). 
They also showed that developing Treg thymocytes show a partial degree of de-
methylation at the foxp3 locus, while full de-methylation is only evident on mature 
Tregs which are about to exit the thymus. In contrast to this finding in naturally 
occurring Tregs, the foxp3 locus of Tregs induced by culture with TGFβ showed 
reduced de-methylation and this was rapidly lost upon further stimulation without 
additional TGFβ. These results suggest that only cells which are committed to the Treg 
lineage, i.e. originating in the thymus, will stably express Foxp3 due the epigenetic 
imprinting given to these cells upon development.  
 
However, the targeting of antigen to DC in the steady state via DEC-205 has shown to 
generate Foxp3+ Tregs which maintain Foxp3 expression for up to 9 weeks even in the 
absence of cognate antigen (Kretschmer et al., 2005). This has recently been shown to be 
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due to the change in DNA methylation, such that Tregs by this protocol showed similar 
de-methylation in the foxp3 locus as that of naturally occurring Tregs (Polansky et al., 
2008).  This paper showed strong evidence to suggest that there is a functional link 
between DNA de-methylation of the Treg-specific de-m thylation region (TSDR) on the 
foxp3 locus and stable Foxp3 expression. Interestingly, Foxp3-expression has been 
shown to be up-regulated at some stage in all activated human T cells, merely a product 
of T cell activation designed to dampen down the response (Pillai and Karandikar, 
2007). This would make sense to dampen T cell responses late in the response to prevent 
excessive pathology and tissue damage. Foxp3 expression in most of these cells was 
shown to be rapidly lost, with only a few cells maint ining expression. This residual 
Treg population would enhance the Treg repertoire by adding to the TCR diversity in 
these cells. 
 
Collectively these results suggest that Foxp3 expression may be up-regulated in some 
cells at inflamed sites but that this expression is ot stable. These studies have important 
implications in Treg-based therapies. It would be highly dangerous to expand Tregs to 
an auto-antigen in the hope of reducing autoimmunity if these cells would have the 
capacity to lose regulatory activity and convert to an auto-aggressive effector T cell. 
Indeed, this has been documented recently with the discovery of the IL-17 producing 
CD4+ T cell population, Th17 cells (Langrish et al., 2005). The pathway which leads to 
differentiation of Th17+ cells overlaps with that of Tregs as both populations utilise 
TGFβ. In the presence of TGFβ, cells are directed towards, a Treg/Foxp3+ fate. 
However, addition of IL-6 to the culture can drive a pathogenic Th17/RORγT+ 
population, proposed to be instrumental in many pathologies which were classically 
associated with Th1 cells (Bettelli et al., 2006b). This would then suggest that one cell 
could become either a regulatory cell or pathogenic cell depending on the cytokine 
milieu (Weaver et al., 2006; Xu et al., 2007) and that Tregs themselves can be converted 
to Th17+ cells (Xu et al., 2007). If committed Tregs which have fully demthylated 
TSDR can also be driven towards a Th17 fate is as yet unknown. 
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Ultimately, to overcome many of the problems and potential dangers of ex vivo Tregs 
expansion, direct expansion of antigen-reactive Tregs in vivo is desirable. We have used 
an APL of MBP(Ac1-9) with an amino acid substitution at position 4 from Lys to Tyr 
(4Tyr) that binds with a higher affinity to I-Au  (Fairchild et al., 1993). Previous studies 
using this APL showed that treatment with 100ug Ac1-9(4Tyr) i.p. either before or after 
the induction of EAE with MBP(Ac1-9) protected or reduced disease respectively (Liu 
and Wraith, 1995). As Ac1-9(4Tyr) binds to MHC with high affinity, it could be 
suggested that the peptide functioned by blocking the MHC, however this was ruled out 
as a single dose of 4Tyr given after disease induction was sufficient to reduce disease. 
This study also ruled out class switching from Th1 to Th2 as reductions in the levels of 
both IFNγ and IL-4 were observed. Cells from 4Tyr treated mice did not suppress cells 
from Ac1-9-primed mice, suggesting that the effect was not mediated by regulatory T 
cells; however these observations were made before definitive markers for Tregs were 
identified.  
 
Later studies determined that a single intranasal high dose (100ug) of Ac1-9(4Tyr) 
resulted in priming of T cells in Tg4 TCR transgenic mice, while multiple doses resulted 
in tolerance (Burkhart et al., 1999; Sundstedt et al., 2003). Both studies demonstrated a 
role for IL-10 in suppression. The tolerant cells generated by Sundstedt et al. (Sundstedt 
et al., 2003) were mostly CD25-CTLA-4+ and anergic to antigenic stimulation in vitro; 
however, the anergic state could be reversed by the addition of IL-2. Burkhart et al. 
however report that antigen-induced unresponsiveness could not be reversed by the 
addition of IL-2 (Burkhart et al., 1999). The experiments described in this chapter 
showed that treatment with Ac1-9(4Tyr) results in expansion of adoptively transferred 
peptide-reactive T cells and tolerance to peptide stimulation but did not increase the 
proportion of cells that express Foxp3 (Fig. 4.2). Peptide treatment reduced the 
proportion of MBP(Ac1-9) reactive T cells in the CNS, suppressed MBP(Ac1-9)-
induced EAE (Fig. 4.7) and reduced relapses in PLP(139-151)-induced EAE (Fig. 4.8). 
IL-10 production could not be detected by the TCR transgenic cells in any experiments 
using i.v. administration of Ac1-9(4Tyr) although tis could be due to restriction in the 
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sensitivity of the assays used to detect IL-10 in these studies. The differences observed 
in this study and those of Burkhart et al. and Sundstedt et al. could be reflective of the 
differences in route of administration (i.v. vs. i.n.) or antigen dose (1 x 200µg vs. 10 x 
100µg), however we similarly did not detect the expression of Foxp3 in peptide treated 
cells. Interestingly, while some studies have shown deletion of most peptide reactive T 
cells after antigen administration (Critchfield et al., 1994; Liblau et al., 1996) a more 
recent study has shown that anergy is sufficient to induce tolerance in T cells that are 
deficient in the pro-apoptotic molecule, Bim (and therefore cannot undergo deletion) 
(Barron et al., 2008). It would be of interest to assess the levels of apoptotic and anergic 
markers in Tg4 cells to gain a greater understanding of the signals imprinted after Ac1-
9(4Tyr) encounter. 
 
It has been reported that i.v. administration of antigen in the absence of inflammation 
results in the expansion of Foxp3+ Tregs while Foxp3- T cells undergo abortive 
activation after interaction with CD11c+ DC in the spleen (Chappert et al., 2008). The 
expansion of Foxp3+ T cells was not evident in the 4Tyr treated groups in our Tg4 
transfer model (Fig. 4.3). Other studies that have documented the expansion or 
generation of Foxp3+ T cells have used low dose antige  under non-inflammatory 
conditions by targeting antigen to immature DCs (Kretschmer et al., 2005) or by 
subcutaneous peptide infusion using osmotic mini-pum s (Apostolou and von Boehmer, 
2004; Verginis et al., 2008). The conversion of Foxp3- T cells to Foxp3+ was observed 
only under sub-immunogenic conditions where T cells did not undergo extensive 
proliferation. While T cells that proliferated vigorously initially upregulated Foxp3, this 
was lost over time suggesting that upregulation of Foxp3 is only transient under strong 
antigenic stimuli (Kretschmer et al., 2005). Stimulation with 200µg Ac1-9(4Tyr) has 
been shown to induce strong proliferation of Tg4 cells in vivo (Joanne Konkel, 
unpublished observations). High dose antigen administrat on and proliferation has been 
reported to favour the induction of Tr1 cells (Battaglia et al., 2006a). Thus, Ac1-9(4Tyr) 
stimulation may be unfavourable for the induction or expansion of Foxp3+ Tregs and 
this could explain why we find no increase in the fr quency of Ac1-9-reactive Foxp3+ 
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cells when this peptide is administered at high doses intravenously. The exact 
mechanism underlying 4Tyr induced tolerance remains to be clarified. 
 
B10.PLxSJL mice that had received Tg4 Tregs prior to disease induction showed fewer 
relapses after immunization with PLP(139-151) (Fig. 4.6B). As Ac1-9(4Tyr) has been 
shown to persist for longer periods in vivo than WT MBP(Ac1-9) it may be suggested 
that Ac1-9(4Tyr) functions to maintain the transferred Tg4 cells until CNS destruction 
occurs and releases epitopes of MBP that could activate Tg4 Tregs. In this scenario, 
MBP-reactive Tregs require encounter with their cognate antigen to become activated to 
suppress. Once the Tg4 Tregs gain access to the CNS they may encounter MBP(Ac1-9) 
and become activated to control the inflammation in situ. Other work in the lab has 
demonstrated that co-immunisation with PLP(139-151) and MBP(Ac1-9) further 
enhanced the suppressive capacity of Tg4 Tregs (Leigh Stephens, unpublished data), 
suggesting that encounter with cognate antigen further potentiates the ability of Tg4 
Tregs to suppress disease targeted against distinct myelin antigens.  
 
To determine if encounter with Ac1-9(4Tyr) is sufficient to imprint regulatory function 
we treated Tg4 mice directly with Ac1-9(4Tyr). After 6 days, CD4+ cells were sorted 
from the Tg4 mice and transferred to mice which hadbeen immunised with MBP or PLP 
10 days earlier (Fig. 4.11A). After 7 days Tg4 cells in the mice were assessed for Foxp3 
expression and cytokine production to determine if the proportion of Foxp3+ cells was 
higher in cells that had previously encountered Ac1-9(4Tyr). It was found that both PBS 
and Ac1-9(4Tyr) pre-treated Tg4 cells infiltrated the CNS and but that Ac1-9(4Tyr) pre-
treated cells produced greater amounts of IFNγ and IL-17 after peptide stimulation in 
vitro (Fig. 4.11 and 4.12). Single doses of 100µg Ac1-9(4Tyr) have been shown to 
induce hyper-responsiveness to MBP(Ac1-9) stimulation when given to MBP-reactive 
transgenic mice, however tolerance can be induced aft r multiple doses of Ac1-9(4Tyr) 
are administered (Burkhart et al., 1999; Liu et al., 1995). It would be important to repeat 
this experiment using a protocol that will induce tolerance in the Tg4 mice prior to cell 
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recovery and transfer, as administration of a single shot of 200µg Ac1-9(4Tyr) will have 
been unlikely to induce tolerance in this setting, although this was not investigated here. 
 
While these studies using peptide based therapies have shown protective effects in 
mouse models, there exist a number of questions regarding the feasibility of these 
systems in human disease. Firstly, the use of peptid  administration (WT and APLs) as 
therapy will be restricted in human disease where the antigens are poorly defined. 
Peptides that have been altered in the key TCR conta t residues have been shown to alter 
T cell responses from the generation of peptides with full agonistic properties to 
complete antagonism (Evavold et al., 1993). APLs that antagonise TCR binding have 
been shown to be effective in the suppression of EAE (Franco et al., 1994; Kuchroo et 
al., 1994; Nicholson et al., 1997). However, care must be taken as data show that while 
an APL may act as an antagonist for one T cell, the effect could be markedly different in 
another (Anderton et al., 1998). The dangers of this were highlighted in clinical trials 
using an MBP(83-99) APL in MS patients where disease was exacerbated by APL-
induced expansion and activation of  MBP-reactive encephalitogenic T cells (Bielekova 
et al., 2000). Secondly, it has been suggested that selective peptide based therapy will be 
of limited efficacy in chronic human diseases that show a diverse autoimmune repertoire 
(Lehmann et al., 1993; McCarron et al., 1990). However, during chronic responses, T 
cells will receive continual antigenic stimulation. Repeated antigenic stimulation has 
been shown to drive the preferential selection of certain clonotypes within polyclonal 
populations in vitro and antigen based repertoire restriction may also occur in MS as T 
cells from chronic plaques have shown restricted T cell repertoires (Wucherpfennig et 
al., 1992). Furthermore, recent studies have reportd that antigen-reactive Tregs also 
show restricted repertoires during EAE (Madakamutil e  al., 2008). These findings 
suggest that while the immune response in MS is diverse, a degree of repertoire 
restriction occurs and that these cells may be preferentially targeted in vivo.  
 
Taken together, the data presented here demonstrated hat in vitro expansion and transfer 
of Foxp3+ Tregs that are reactive to one myelin antige  can suppress disease induced 
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with the same, but also distinct, myelin antigens. This can be extended to peptide based 
tolerance, whereby tolerance induced against one antigen can also affect the immune 
response to distinct antigens. These data have important implications in antigen based 
therapies, particularly for inflammatory conditions that will involve immune responses 
targeted against a number of different antigens over th  course of disease. While these 
studies have not identified expansion of Foxp3+ Tregs using peptide in vivo, the 
questions of Foxp3 stability in expanded and induce Tregs highlight that the 
development of protocols to expand Foxp3+ cells will require long term tracking of 
Foxp3-expression in these cells. By determining the antigenic reactivity of Tregs in the 
CNS it is hoped that mechanisms to target the preferential expansion of pre-committed, 
disease relevant T cells that stably express Foxp3+ will provide potential antigen-based 
therapeutic targets to prevent and treat CNS inflamm tion. 
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Figure 4.1: Tg4 CD25+CD62L hi sorted cells maintain Foxp3 expression after 
expansion. A: Representative plot of Tg4 cell surface expression on whole CD4+ 
purified splenocytes pre-sort. Each group was sorted to high purity on FACSAria under 
sterile conditions. Cells were then expanded in RPMI-5% FCS plus anti-CD3/anti-CD28 
coated beads + 1000U/ml IL-2 for 7 days. B: Foxp3 expression by each subset before 
(left hand column) and after (right hand column) in vitro expansion. Black line = isotype
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Figure 4.2: In vitro expanded CD4+CD25+CD62L hi cells from naïve Tg4 
transgenic mice suppress MBP(Ac1-9) induced EAE bet ter than 
polyclonal Tregs. B10.PL mice received 1.5x105 CD4+CD25+CD62Lhi cells 
sorted from Tg4 mice (∆) or B10.PL mice (□) or no transfer (○) one day prior 
to EAE induction with 100µg MBP(Ac1-9)/CFA. Numbers in brackets 
represents incidence of disease. Data is representative of two individual 
experiments with 3-4 mice per group. * = p<0.05. Statistical difference 
between day 10-17 of EAE assessed by Mann Whitney of cumulative disease 
scores per group, per day.







105 polyclonal Tregs (4/4)










Chapter 4 - Figures 
143 




















































































































Figure 4.3: Treatment with high dose Ac1-9(4Tyr) ex pands MBP-reactive cells in 
vivo and tolerises the response to WT MBP in vitro. A: Tg4Ly5.1+ cells were purified 
by MACS to ~98% CD4+. Cells were assessed for Foxp3 expression prior to i.v. transfer 
to B10.PL hosts (2x106/mouse). 1 day post cell transfer mice received PBS, 10µg or 
100µg 4Tyr or 10µg 4Tyr plus 20µg LPS i.v. B:  6 days later spleens were harvested and 
the proportion of Tg4 cells assessed by FACS. C: Proportion of Foxp3+ cells in Tg4 cell 
(top panels) and host cells (bottom panels). Filled plots = isotype control. All plots show 
one mouse representative of three mice per group D: Splenocyte proliferation in 
response to MBP(Ac1-9) in vitro assessed by 3H-thymidine incorporation, error bars 
showing 3 individual mice per group. Data representative of two independent 
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Figure 4.4: High dose Ac1-9(4Tyr) treatment results  in tolerance to MBP re-
stimulation after 14 days but does not increase the  proportion of MBP-reactive 
Foxp3+ cells in vivo. B10.PL mice received 2x106 Tg4 CD4+ cells followed by i.v. 
administration of 100µg 4Tyr or PBS one day later. Spleens were harvested 14 days 
after peptide treatment. A: Tg4 populations (top panels) and Foxp3 expression in Tg4 
cells (bottom panels) of 4Tyr treated mice. B: Tg4 populations (top panels) and Foxp3 
expression in Tg4 cells (bottom panels) of PBS treated mice. Plots show three 
individual mice per group. C: MBP(Ac1-9)-induced proliferation of splenocytes from 
4Tyr treated (○) and PBS treated mice (□). Data shown represents mean +/- S.D. of 3 
mice per group, representative of two independent experiments with similar results. 
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Figure 4.5: High dose pre-treatment with 4Tyr suppr esses MBP-induced 
EAE. 2x106 Tg4 CD4+ cells or PBS alone was transferred i.v. to B10.PLxSJL 
mice. Mice were treated the following day with 200µg 4Tyr, 200µg 4Lys (WT) or 
PBS i.v. 7 days later, mice were immunised with MBP(Ac1-9)/CFA, plus 
pertussis toxin i.p x 2. A: Experimental outline. B: EAE  plots. Data shown from 
experiment performed by J. Konkel, showing mean +/- S.E.M. of 6 mice/group. 
Data representative of five experiments, some performed in collaboration with J. 
Konkel. Statistical analysis performed using Mann Whitney test comparing mean 
scores per group, per day.
B
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Figure 4.6: In vitro expanded Tg4 Tregs supress prima ry episodes of MBP-
induced EAE and reduce relapses in PLP-induced EAE. A: Experimental outline 
– Tg4 CD4+CD25+CD62Lhi Tregs (>95% purity, 80% Foxp3+) were expanded in 
vitro for 7 days using anti-CD3/anti-CD28 coated beads + 1000U/ml IL-2. 3x105
expanded Tregs were transferred i.v. to B10.PLxSJL mice one day prior to EAE 
induction using MBP(Ac1-9) (Fig. B: left hand plot) or PLP(139-151) (Fig. B: right 
hand plot). Control mice received PBS i.v. at the time of cell transfer. Data shows 
mean +/- S.D. of 4 mice per group, representative of one of three reproducible 
experiments.

























































































Figure 4.7: High dose 4Tyr treatment suppresses dis ease induced with MBP(Ac1-9) 
after transfer of CD4+ Tg4 cells. B10.PLxSJL mice were given 1.5x106 CD4+ Tg4 cells 
i.v. Mice were then treated with PBS or 200µg 4Tyr i.v. After 7 days mice were 
immunised with MBP(Ac1-9)/CFA to induce EAE. A: EAE plot of MBP-induced EAE after 
Tg4 transfer and treatment with 4Tyr (red line) or PBS (black line). Data shows mean +/-
S.D. of 5 mice/group. B: Proportions of Tg4 cells in CNS, LN and spleen 7 days after 
immunisation. Data points show individual mice. C: IFNγ (left) and IL-17(right) production 
by Tg4 cells in CNS after in vitro stimulation with the indicated peptide. D: IFNγ (left) and 
IL-17(right) production in LN. Bars show pooled results of two mice per group. Data 
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Figure 4.8: 4Tyr treatment reduces relapses in PLP- induced EAE following 
Tg4 cell transfer. 2x106 Tg4 CD4+ cells or PBS alone was transferred i.v. to 
B10.PLxSJL mice. Mice were treated the following day with 200µg 4Tyr i.v. 7 
days later, mice were immunised with PLP/CFA, plus Ptx i.p. A: Experimental 
outline. B: EAE  plots showing mean +/- S.D. of  6 mice per group. C and D: 
CNS, LN and spleen were harvested from three mice per group at day 14 of 
EAE. C: % transferred cells in the CNS and D: % Foxp3+ cells in total host 
CD4+ cells from the CNS. Data points show individual mice. * p<0.05. Data 
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Figure 4.9: 4Tyr treatment reduced the production o f effector cytokines by 
CD4+ cells in the CNS and increases IL-10 productio n. Lymphocytes from the 
CNS of mice from day 14 of previous figure were stimulated overnight with the 
indicated antigens. After 18h, BrfA was added to cultures for 4h. Total CD4+ cells 
were analysed for A: IFNγ, B: IL-17 and C: IL-10 intracellular cytokine production via 
FACS. Error bars represent 3 individual wells from pooled samples between groups. 
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Figure 4.10: Exposure of Tg4 cells to 4Tyr in vivo prior to adoptive transfer does 
not suppress EAE or enhance the proportion of Tg4 F oxp3+ cells in the CNS. A: 
Experimental outline – Tg4 mice were given 200µg 4Tyr i.v. 6 days before CD4-
purification of splenocytes. 2x106 CD4+ Tg4 cells were then transferred i.v. to 
B10.PLxSJL mice which had been immunised with MBP/CFA 10 days earlier to induce 
EAE. B: EAE plots showing mean +/- S.D of three mice per group. C and D: 7 days after 
transfer, CNS LN and spleens were harvested to assess the proportion of Tg4 cells (C) 
and Foxp3+Tg4 cells (D) in each organ. Data points show individual mice and represent 
one of two repeat experiments with similar results.
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Figure 4.11: Exposure of Tg4 cells to 4Tyr in vivo p rior to adoptive transfer
does not suppress PLP-induced EAE or enhance the pr oportion of Tg4 
Foxp3+ cells in the CNS. A: experimental outline. B: EAE plots showing mean +/-
S.D. of four mice per group. C: Proportion of Tg4 cells in each organ. D: Proportion 
of Foxp3+ cells in Tg4 populations. Data points show individual mice analysed and 
are representative of two separate experiments with similar results.
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Figure 4.12: Proliferation and cytokine production of cells from PLP-immunised 
mice that had received Tg4 cells 10 days post EAE i nduction. Splenocytes from 
mice given 4Tyr treated Tg4 cells, PBS treated Tg4 cells or no transfer 7 days after 
induction of EAE with PLP(139-151) were stimulated with A: MBP(Ac1-9) and B:PLP 
(139-151) in vitro and proliferation assessed by 3H-Thymidine incorporation for the last 
18h of a 72h culture. Data shows mean proliferation +/- S.D. of 4 mice/group. C and D: 
IL-17 and IFNγ production by CNS derived Tg4 cells in response to MBP(Ac1-9) (C) 
and PLP(139-151) (D) in vitro as determined by ICCS. Data points show cytokine 
production by individual CNS samples, 4 mice per group. Data shows one of two repeat 
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5 Investigating the effect of superantigens on the 
peripheral Foxp3+ T cell repertoire 
5.1 Introduction 
 
There is an extensive literature on the impact of superantigens (SAg) on immunological 
tolerance; either as endogenous superantigens, derive  from mouse mammary tumour 
viruses (MMTV), or as exogenous superantigens (usually staphylococcal enterotoxins 
(SE)) administered experimentally. For instance, the expression of particular Mtv-
encoded SAg by particular mouse strains leads to the absence of T cells bearing certain 
TCR Vβ chains, due to clonal deletion in the thymus (Rammensee et al., 1989). 
Similarly, injection of SEA or SEB can be used to activate T cells bearing particular 
TCR Vβs, but repeated application results in their deletion via extensive activation-
induced cell death (AICD), whilst those that remain re rendered unresponsive (Herman 
et al., 1991; O'Hehir and Lamb, 1990; Rellahan et al., 1990; White et al., 1989). 
Moreover there is evidence that those T cells that persist can have a regulatory function 
(Noel et al., 2001; Papiernik et al., 1997; Sundstet t al., 1997). During our 
investigation into the TCR Vβ-usage of Tregs in naïve C57BL/6 mice we discovered 
that mice expressing Vβ5+ TCRs had an over-representation of Foxp3+ cells (Figure 
3.17). We therefore began to investigate the mechanism behind this finding. 
 
Towards the end of the 1980’s, it was found that certain self antigens formed ligands in 
combination with particular products of the murine MHC, H-2, that deleted almost all T 
cells bearing particular TCR Vβ chains (Kappler et al., 1987; Kappler et al., 1988; 
MacDonald et al., 1988; Marrack and Kappler, 1988; Pullen et al., 1988). Vβ5+ T cells 
are deleted in mice that express mtv-3, -8, -9, -117 and -30 and also express I-E, 
although a hierarchy exists in the capacity of each superantigen to delete Vβ+ T cells 
(Scherer et al., 1995). The deletion of Vβ5+ T cells has been shown to occur in mtv-6+ 
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and -9+ mouse strains that also express I-E (Bill et al., 1990). C57BL/6 mice lack I-E 
and in this strain Vβ5+ cells are not deleted in the thymus, but are delted over time in 
the periphery (Fink et al., 1994; Fink et al., 1992). Although I-E+ mouse strains have 
been reported to present SAgs more efficiently, some studies have shown that in I-E- 
mice (such as C57BL/6 and C57B.10 strains), I-A molecu es can also present SAgs to a 
level sufficient to induce the chronic deletion of Vβ5+ T cells (Dyson and Elliott, 1999) 
and explain the findings of Fink et al. (Fink et al., 1994).  
 
Although the stimulation of T cells by I-A/SAg occurs in I-E-I-A+ mice, the strength of 
signal must be reduced as the cells are not deleted in rathymically. Peripheral induction 
of regulatory T cells has been documented by groups sing persistent antigen 
stimulation, for example using osmotic minipumps (Apostolou and von Boehmer, 2004). 
SAg stimulation of TCRs by mtv-derived or exogenous SAg in I-E-I-A+ strains may also 
chronically stimulate SAg-reactive T cells in the pri hery. Indeed, the induction of 
anergic and ‘regulatory’ cells after superantigen stimulation has been documented by a 
number of groups, including the generation of CD4+CD25+ Tregs by some (Feunou et 
al., 2003; Grundstrom et al., 2003; O'Hehir and Lamb, 1990; Papiernik et al., 1997; 
Sundstedt et al., 1997); however, enhanced proportions of SAg-reactive Foxp3+ cells in 
the periphery had not been documented. In fact some studies suggested that Foxp3- 
regulatory T cells were responsible for superantige-induced tolerance (Feunou et al., 
2003).  
 
We proposed that SAg stimulation may allow continual ‘tickling’ of specific Vβ+ TCRs 
and subsequently drive their commitment to a Foxp3+ lineage in the periphery. 
Alternatively, Foxp3+ T cells may have an enhanced r sistance to SAg-mediated 
deletion in the periphery and therefore survive peripheral activation and deletion induced 
by chronic superantigen stimulation. We addressed these questions using un-
manipulated C57BL/6 mice to assess the effect of endogenous SAg (mtv-8) on the Vβ5+ 
repertoire by testing the effects of low dose i.v. administration of SEB as a model for 
chronic SAg stimulation. The data show that SAg stimulation enhances the proportions 
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of Foxp3+ T cells in the periphery. This was not due to the proliferation of Foxp3+ T 
cells, but rather the preferential activation and deletion of Foxp3- cells, suggesting that 
Foxp3+ Tregs show an intrinsic resistance to SAg mediat d activation and deletion. 
Furthermore, SAg-induced/survived Tregs suppressed the primary response of 
transgenic T cells to both cognate antigen and SAg stimulation in vitro, suggesting that 
chronic exposure to SAg will favour the balance of the immune system towards 
regulation. This will have important consequences on the ability to mount protective 
immune responses and has implications in the susceptibility to autoimmunity. 
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5.2 Results  
5.2.1 Naïve C57BL/6 mice show elevated levels of 
Vβ5+Foxp3+ T cells 
 
We have recently described a critical role for Foxp3+ Tregs in recovery from 
experimental autoimmune encephalomyelitis (EAE) (McGeachy et al., 2005). Several 
models of autoimmune disease show an oligoclonal expansion of T cells expressing 
TCR Vβ8 genes (Acha-Orbea, 1991) (Steinman, 2001). This is particularly notable in 
EAE, suggesting that the Vβ8+ T cell repertoire might have a predilection for myelin-
derived self antigens. We therefore reasoned that the Vβ8+ repertoire might have a 
selectively higher frequency of Foxp3-expressing cells during EAE. To test this we 
made use of a panel of anti-Vβ antibodies to analyse Foxp3-expression in the periph al 
immune repertoire. In naïve C57BL/6 mice maintained in specific-pathogen free 
conditions, the frequency of CD4+ cells derived from spleen or lymph nodes that 
expressed Foxp3 was consistently around 10%. This did not increase when we looked 
specifically at those cells that stained for Vβ8 (Fig. 5.1A). There was, however, a 
striking increase in Foxp3-expression in CD4+Vβ5+ cells, reaching a frequency of up to 
1 in 3 (Fig. 5.1A and B). To determine if the over-r presentation of Foxp3+ cells in the 
Vβ5+ population was evident from the generation of Vβ5+ cell in the thymus, or if this 
effect was mediated by a peripheral event, we compared the Foxp3 expression of thymic 
Vβ5+ and peripheral (LN) Vβ5+ cells. The over-representation of Foxp3 was not 
evident in Vβ5+CD4+CD8- thymocytes (Fig. 5.1C). Thus, although the possibility that 
the selective accumulation of Foxp3+ cells in the Vβ5+ population begins in the thymus 
cannot be ruled out, these data suggest that it is driven chiefly in the periphery. 
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5.2.2 B cells play a partial role in SAg presentati on to T cells 
in vivo 
 
One of the initial findings that Vβ-specific deletion occurred in mice demonstrated that
the antigen was B cell derived (Kappler et al., 1987). The preferential infection of B 
cells by MMTVs and the presentation of MMTV-derived superantigens on the surface 
after infection was later described (Beutner et al., 1994; Held et al., 1993).  
 
To determine which cells may potentially be responsible for the presentation of 
endogenous superantigens to Vβ5+ T cells, we made use of the µMT mice (Kitamura 
and Rajewsky, 1992), which lack B cells, and therefore have an over-representation of T 
cells (Fig. 5.2A).  However, the proportion of CD4+Foxp3+ cells in µMT mice was 
significantly reduced compared to WT mice (Fig. 5.2B)  Analysis of the CD4+Vβ5+ 
populations in µMT vs. WT C57BL/6 mice showed that µMT mice had an increased 
proportion of these cells (Fig. 5.2C).  
 
The percentage of both Vβ5+ and Vβ5- Foxp3+ cells was reduced in µMT mice (Fig. 
5.2D). Because the overall proportion of CD4+Foxp3+ cells was reduced in µMT mice, 
we determined the ratios of CD4+, Vβ5+ and Foxp3+ cells in µMT/WT mice to identify 
where the differences between the strains could be found (Fig. 5.2E). These ratios 
confirmed that the proportion of CD4+Vβ5+ cells was indeed higher in µMT mice. This 
was shown to be due to the enhanced proportions of Vβ5+Foxp3- cells in µMT mice 
compared to WT mice, as the ratio of Vβ5+Foxp3+ cells was not enhanced (Fig. 5.2E).  
 
The increase in Vβ5+Foxp3+ cells compared to Vβ5-Foxp3+ cells appeared less in µMT 
mice compared to WT (Fig. 5.2D). To assess this, the ratio of the difference from 
Vβ5+Foxp3+ to Vβ5-Foxp3+ between the two strains was calculated using the equation 
shown in Fig. 5.2F. If the absence of B cells was not having an effect on Vβ5+ T cells 
then the result of this equation (ratio) would be 1. However, the ratio was found to be 
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0.82, confirming that the fold increase from Vβ5-Foxp3+ to Vβ5+Foxp3+ cells was 
reduced in µMT mice compared to WT mice.  
 
These data show that while µMT mice have a decreased frequency of total CD4+Foxp3+ 
cells, this is due to the enhanced proportions of Foxp3- cells in these mice and may 
suggest Vβ5+Foxp3- cells are not deleted as efficiently in mice which lack B cells, 
possibly representing a role for B cells in the presentation of endogenous superantigens 
in this system 
 
5.2.3 Vβ5+foxp3- T cells show higher turnover rates in vivo  
 
As the proportion of Vβ5+Foxp3+ cells was increased in the periphery we sought to 
determine if these cells were proliferating at a higher rate than other CD4+ T cells. BrdU 
was administered i.p. to naïve C57BL/6 mice on three consecutive days. 18 hours after 
the final administration spleens were harvested and the rate of turnover of the Foxp3-
enriched Vβ5+ population was measured by FACS (Fig. 5.3A). The“background” level 
of in vivo proliferation of total CD4+Foxp3+ cells was ~4-fold higher than that of 
CD4+Foxp3- cells. This is consistent with similar data that used CD25 expression as a 
marker for Tregs to assess their turnover in vivo (Fisson et al., 2006). However, the rate 
of turnover in the Vβ5+Foxp3+ population was not significantly greater than that of the 
total CD4+Foxp3+ population as a whole, or than that of the Vβ5-Foxp3+ population. In 
marked contrast, the turnover rate of the CD4+Vβ5+Foxp3- population was clearly 
higher than that of the total CD4+Foxp3- population, and was raised to a level 
equivalent to that of Foxp3+ cells. These results would suggest that the Foxp3+ cells do 
not have an increased rate of mitosis in response to SAg stimulation and that, 
potentially, the increase in Treg frequency arises from AICD of the foxp3- population, 
although further investigation is required to confirm this theory. 
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5.2.4 Vβ5+ cells display enhanced levels of regulatory cell  
markers due to their expression by V β5+Foxp3+ cells 
 
To further characterise the phenotype of Vβ5+ cells we analysed surface marker 
expression associated with Tregs and markers of T cell a tivation (Fig. 5.3B and C). 
Firstly, the cell surface markers on CD4+Vβ5+ compared to CD4+Vβ5+ cells were 
analysed (Fig. 5.3B). Vβ5+ T cells displayed a slight reduction in the leves of CD62L, 
while the levels of CD44 appeared similar to Vβ5- cells. The levels of ‘regulatory’ cell 
markers CD25, CTLA-4, GITR, OX-40 and CD103 appeared enhanced in Vβ5+ cells, 
with some markers showing distinct populations showing highest expression (CD25 and 
GITR) and others displaying a general shift in marker expression (CTLA-4, OX-40 and 
CD103). No differences were observed in the levels of CD5 or Fas (data not shown), 
arguing against the higher expression levels of all surface markers in Vβ5+ T cells. 
Next, the surface marker expression by Foxp3+ and Foxp3- populations within the Vβ5+ 
compartment was assessed (Fig. 5.3C). Vβ5+Foxp3+ cells displayed lower levels of 
CD62L but higher levels of CD44, CD25 and CD103. However, CTLA-4 expression 
was equal in both the Vβ5+Foxp3+ and foxp3- populations. Thus, the Vβ5+Foxp3- cells 
expressed marker levels associated with activation (CD62LloCD44hi) consistent with the 
theory that these cells undergo activation by SAg, possibly followed by their death. The 
population shifts in expression of CD25 and CD103 in Vβ5+ vs. Vβ5- cells must be due 
to the up-regulation of these markers by both Foxp3+ and Foxp3- Vβ5+ cells, suggesting 
that SAg encounter is affecting the surface expression of these markers in both 
populations. It would be of interest to determine of SAg stimulation could also induce 
the conversion of Foxp3- cells towards a regulatory phenotype. 
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5.2.5 Vβ5+ cells have an enhanced regulatory capacity 
compared to V β5- cells in vitro  
 
Although a higher proportion of Vβ5+ T cells expressed Foxp3, it was unclear if these 
cells could exert regulatory function. To determine th  suppressive activity of Vβ5+ T 
cells, we set up an assay to test their ability to suppress the response of T effector cells in 
vitro (Fig. 5.4). CD4+ cells were sorted from naïve C57BL/6 mice by MACS-
purification, followed by Vβ5+, Vβ5- and CD25+ sorting to generate ‘suppressor’ cell 
populations. CD25- cells were sorted as ‘effector’ cells and the foxp3-expression of each 
population assessed prior to culture (Fig. 5.4A). CD4+CD25+ populations were ~90% 
Foxp3+, while CD25- effector cells were ~4% Foxp3+. Consistent with previous data, 
Vβ5+ populations had an approximate 4-fold increase in the proportion of Foxp3+ cells 
compared to Vβ5- populations (~30% vs. ~8% respectively, Fig. 5.4A) Effector cells 
were cultured with various ratios of suppressor cells and stimulated with anti-CD3 in 
vitro for 48 before analysis of proliferation by addition of 3H-Thymidine for the final 18 
hours of culture. The suppression of responder cells was compared to their culture with 
anti-CD3 in the absence of suppressor cells. Vβ5+ cells were as suppressive as sorted 
whole CD25+ cells when cultured with CD25- cells at high ratios (Fig. 5.4B). At lower 
ratios of Treg:Teff, Vβ5+ cells lost the capacity to suppress, probably due to the dilution 
of Tregs in culture (Fig. 5.4B). Vβ5- cells used as a control did not show suppression at 
any ratio (Fig. 5.4B). This showed that encounter with endogenous SAg skewed SAg-
reactive populations towards a regulatory phenotype hat was capable of suppressing the 
proliferation of polyclonal effector T cells in vitro. 
5.2.6 Exposure to low dose SAg activates CD4+V β3+ and 
CD4+Vβ8+ T cells in vitro  
  
The data described above would imply that encounter with SAg skews the T cell 
population towards the regulatory, Foxp3-expressing component. We reasoned that if 
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this was the case, we should be able to reproduce this effect experimentally by giving 
exogenous superantigens. Exposure to the staphylococcal enterotoxins SEA and SEB is 
a well established method inducing immune tolerance in T cells expressing the 
appropriate Vβ genes (Fink et al., 1994; Lobo-Yeo and Lamb, 1993). This tolerance 
results from a high level of AICD, coupled with anergy in those T cells that survive 
(Lobo-Yeo and Lamb, 1993; Rellahan et al., 1990; White et al., 1989) . Although 
regulatory/suppressive functions have been described in these remaining cells, such as a 
dominant production of IL-10 (Noel et al., 2001; Sundstedt et al., 1997), the over-
representation of foxp3 has not been documented. In fact, there is evidence to the 
contrary (Feunou et al., 2003). SEB has been reportd to activate T cells expressing 
either Vβ3 or Vβ8 (Rellahan et al., 1990; White et al., 1989). Similar to endogenous 
superantigens, SEB was shown to have differential stimulatory effects in mouse strains 
with different MHC backgrounds and SEB presentation was shown to be more effective 
by I-E than I-A molecules (White et al., 1989).  
 
To confirm that SEB would activate T cells bearing specific TCR Vβ chains, we 
cultured naïve splenocytes from C57BL/6 mice with various doses of SEB or with con 
A, as a control for T cell activation irrespective of Vβ-usage (Fig. 5.5A). After 
stimulation with con A, the frequencies of T cells expressing either Vβ3, Vβ8, or Vβ6 
(used as a control) remained equivalent to those found directly ex vivo (Fig. 5.5A, 
compared with Fig. 5.1A). In contrast, culture with SEB led to a two- to three-fold 
increase in the Vβ8 frequency and a five-fold increase in the Vβ3 frequency. As a 
reflection of this expansion of Vβ3 and Vβ8 T cells, the frequency of Vβ6+ cells 
dropped by around 90% (Fig. 5.5A).  
5.2.7 SEB treatment enhances frequency of SEB-reactive 
Foxp3+ cells in vivo. 
 
We next tested the effects of SEB on Vβ3 and Vβ8 expressing cells in vivo. Three or 
five intravenous doses of 1 µg SEB or PBS were administered over a five-day period to 
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naïve C57BL/6 mice (Fig. 5.6A). 24 hours after the last treatment, splenocytes were 
harvested from each mouse to assess the levels of Vβ3+ and Vβ8+ cells ex vivo. Vβ6 
staining was used as a non SEB-reactive TCR Vβ control. Treatment with 3 or 5 doses 
of 1µg SEB resulted in the depletion of CD4+ cells that expressed Vβ3 or Vβ8. This was 
coupled with an increase in Vβ6+ T cells (Fig. 5.6B, left panels). FACS analysis of 
Foxp3-expression within the Vβ+ populations showed that SEB administration increased 
the frequency of Foxp3+ cells amongst Vβ8+ cells from 10 to 15%, in contrast to the 
comparatively stable expression in Vβ6+ cells (Fig. 5.6B). More marked was the 
increase in cells that expressed Foxp3 amongst Vβ3+ cells, increasing to levels 
approaching 50% (Fig. 5.6B, right panels). This increase in Foxp3 expression 
specifically amongst SEB-sensitive T cells could be accounted for by three processes; 
either specific proliferation of Foxp3-expressing cells, their resistance to AICD 
compared with their Foxp3- counterparts, or de novo activation of foxp3.  
 
To test these possibilities we gave C57BL/6 mice thr e doses of SEB over five days and 
also gave BrdU every two days to provide a measure of mitosis over this period (Fig. 
5.7A). In confirmation with previous data, Vβ3+ T cells were depleted in response to 
SEB stimulation, while Vβ6+ cells were unaffected by SEB stimulation (Fig. 5.7B). The 
loss of total Vβ3+ cells was associated with an increase in the proporti n of 
Vβ3+Foxp3+ cells (Fig. 5.7C). In PBS treated control mice, the proportion of 
CD4+Foxp3+ cells that were cycling was approximately two-fold higher than their 
Foxp3- counterparts (Fig. 5.7D). In mice that had received SEB i.v., the level of 
proliferation in the Vβ6+ population remained higher in the Foxp3+ fraction (Fig. 5.7D). 
In contrast, in the SEB-sensitive Vβ3+ population, the level of BrdU incorporation was 
raised in the Foxp3- fraction to a level equivalent to, or higher than, the Foxp3+ fraction 
(Fig. 5.7D). Furthermore, the level of BrdU incorpoation in the Vβ3+Foxp3+ fraction 
was not increased in mice that had received SEB. This lack of enhanced in vivo 
proliferation amongst superantigen-sensitive Foxp3+ cells is supported by BrdU data 
from SEB-stimulated in vitro cultures which also did not show incorporation by SEB-
sensitive Foxp3+ cells (data not shown). These data suggest that the decrease in 
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CD4+Vβ3+ T cells in response to SEB stimulation is due to the activation, proliferation 
and death in Vβ3+Foxp3- cells, while the Foxp3+ fraction remains uresponsive to SEB 
stimulation.  
 
5.2.8 SEB-stimulated transgenic T cells are anergic t o TCR 
mediated stimulation in vitro 
 
The ability of T cells which have experienced SEB to respond in vitro was tested using a 
TCR transgenic mouse model. All T cells in Tg4 transgenic mice are reactive to only 
one peptide, MBP(Ac1-9) and express only one TCR Vβ gene, encoding Vβ8. Every T 
cell in these mice therefore has the ability to respond to SEB. After exposure to SEB (3 
doses of 1ug SEB, over three consecutive days) or PBS, splenocytes were harvested and 
assessed for foxp3 expression (Fig. 5.8A). As was seen in the C57BL/6 mice given SEB, 
Tg4 mice showed elevated frequencies (approximately 3-4 fold increase) of Foxp3+ 
cells (Fig. 5.8B, top panels). This was a greater increase than seen in the Vβ8+ 
population using SEB in C57BL/6 mice (Fig. 5.6). Interestingly, the proportion of 
Foxp3+ cells expressing CD25 drops dramatically when stimulated with SEB (Fig. 5.8B, 
bottom panels) which may explain the finding that bo h CD25+ and CD25- populations 
from SEB-treated mice are suppressive (Grundstrom et al., 2003). We next tested 
splenocytes from SEB or PBS treated Tg4 mice for a response to both SEB and 
MBP(Ac1-9) in vitro (Fig. 5.8C). Splenocytes from mice exposed to SEB in vivo 
showed very little or no proliferation to either SEB or MBP(Ac1-9) in vitro compared to 
PBS-treated mice; i.e. SEB-experienced Tg4 cells were tolerant both to SAg and to their 
cognate peptide antigen.  
 
Supernatants from the stimulated cell cultures were also assessed for the levels of IL-2 
and IFNγ by ELISA (Fig. 5.9A). This revealed a profound reduction in IL-2 production 
by SEB-treated splenocytes after re-stimulation in vitro with either SEB or MBP(Ac1-9) 
(Fig. 5.9B). The overall levels of IL-2 detected in SEB-stimulated control cultures were 
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lower than those seen in MBP(Ac1-9)-stimulated control cultures. The levels of IFNγ 
produced by cells from SEB-treated mice were also reduced compared to cells from 
PBS-treated mice (Fig. 5.9B). No IL-10 could be detected in the supernatants by ELISA 
(data not shown). These data were confirmed using intracellular cytokine staining for 
IFNγ and IL-10 after overnight stimulation with SEB or (Ac1-9) (Fig. 5.9C). IFNγ 
production in response to SEB stimulation was reduc in SEB-experienced splenocytes 
compared to splenocytes from PBS-treated mice, and lso marginally reduced in 
MBP(Ac1-9)-stimulated cultures. Very little IL-10 could be detected in any cultures and 
there was no significant change in IL-10 levels in SEB- vs. PBS-treated mice (Fig. 
5.9C). 
 
5.2.9 SEB stimulated Tg4 cells suppress naïve Tg4 T c ell 
responses to SEB and MBP(Ac1-9) in vitro 
 
The proportion of Foxp3+ cells in SEB-treated CD4+ Tg4 cells was ~4-fold higher than 
in PBS-treated mice (Fig. 5.8B). We next sought to determine whether these SEB-
experienced cells were also suppressive. Using a co-culture assay, suppressive capacity 
of naïve T cells vs. T cells from SEB-treated mice could be assessed. Sorted CD4+ cells 
(MACS CD4-positive selection) from SEB- or PBS-treaed Tg4 Thy1.1- mice were 
cultured in vitro with CD4+ cells from Thy1.1+ naïve Tg4 mice in the presence of 
irradiated APC (B10.PL splenocytes) and SEB or MBP(Ac1-9) (Fig. 5.10A). By adding 
BrdU for the final 18h of culture the proliferation f cells derived from naïve and treated 
mice in co-culture could be distinguished by Thy1.1 FACS. Co-staining of BrdU and 
Foxp3 allowed us to analyse the proliferation in Foxp3- cells and Foxp3+ cells 
individually.   
 
CD4+ populations from PBS-treated and naïve mice were ~97% foxp3-, regardless of 
the stimulus used (data not shown). When cultured without the addition of SEB-
experienced cells, one third of naïve or PBS-treated Foxp3- cells incorporated BrdU in 
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response to MBP(Ac1-9) and almost 50% responded to SEB (Fig. 5.10B and C). 
Reiterating the data shown in Fig. 5.8B, CD4+ splenocytes from SEB-treated mice 
showed reduced BrdU incorporation by Foxp3- cells to both MBP(Ac1-9) and SEB 
(only 10.5% and 3.8% respectively) (Fig. 5.10B), presumably due to the increased 
frequency of Foxp3+ cells in these cultures.  When in co-culture with cells from SEB-
treated mice, the proliferation of naïve Foxp3- cells in response to SEB was greatly 
diminished compared to when cultured alone, or with PBS-treated Tg4 cells, from ~50% 
to ~10% respectively (Fig. 5.10C). The proliferation of naïve Foxp3- cells in response to 
MBP(Ac1-9) was also suppressed by co-culture with SEB-experienced cells, although 
this effect was less pronounced (Fig. 5.10C). When co-cultured with cells from PBS-
treated mice, the proliferation of naïve Foxp3- cells was enhanced in response to both 
SEB and MBP(Ac1-9) stimulation (Fig. 5.10C).  
 
As FACS staining allowed discrimination of Foxp3+ and Foxp3- cells we could also 
study the effects of in vitro stimulation on Treg proliferation. When cultured alone, cells 
from naïve or PBS-treated mice did not show enhanced BrdU incorporation in response 
to SEB or Ac1-9 (Fig. 5.10D and E). However, SEB-experienced Foxp3+ cells did 
increase BrdU incorporation when cultured with SEB (but not when cultured with Ac1-
9) (Fig. 5.10D). Moreover, in co-cultures, SEB-experienced cells promoted a three-fold 
higher incorporation of BrdU in naïve Foxp3+ cells (Fig 5.10E). Note that this was also 
at the same time as suppressing BrdU incorporation in naïve Foxp3- cells from 32% to 
13% (Fig. 5.10C). 
 
These results suggested that T cells from SEB-treated mice TCR transgenic mice 
induced the suppression of naïve transgenic T cell pro iferation in response to SEB and 
their cognate antigen, MBP(Ac1-9). Furthermore, stimulation of naïve T cells in the 
presence of SEB-experienced cells increased the proliferation of naïve Foxp3+ cells, 
although this effect was only seen upon in vitro stimulation with SEB and not when 
MBP(Ac1-9) was used, suggesting a unique effect of SEB re-stimulation on SEB-
experienced cells. This may be via the release of IL-10 or TGFβ by SEB-experienced 
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cells. The levels of cytokines in the supernatants of the co-culture experiments were 
assessed by ELISA. Co-culture of naïve T cells with SEB-experienced T cells reduced 
the levels of IL-2 (Fig. 5.11A) and IFNγ (Fig. 5.11B) but enhanced the level of IL-10 
(Fig. 5.11C) produced in response to SEB stimulation. These data suggest that the 
suppression observed in SEB stimulated co-cultures may be due to the secretion of IL-10 
by the SEB-experienced cells. This would require further testing using blocking anti-IL-
10 antibody. 
 
5.2.10 The effect of prior exposure to low dose SEB o n the 
induction EAE using Tg4 TCR transgenic mice 
 
As Tg4 mice express a disease relevant TCR we sought to determine the effect of SEB-
stimulation on EAE induced using MBP(Ac1-9) in Tg4 mice. 1µg of SEB was 
administered i.v. directly to Tg4 mice on three consecutive days prior to induction of 
EAE using MBP(Ac1-9) one day after the final treatment (Fig. 5.12A). Tg4 mice that 
received SEB prior to disease induction were protected from disease (Fig. 5.12A). Mice 
that received PBS developed clinical signs of EAE, although the incidence of disease 
was low in this experiment (50%). This suggested that SEB administration may have 
had an effect on the encephalitogenic potential of the MBP(Ac1-9) reactive cells. 
 
It had previously been shown that B10.PLxC57BL/6 mice require the adoptive transfer 
of Tg4 cells in order to develop disease (McCue et al., 2004). We therefore transferred 
2x106 Ly5.1+ Tg4 cells into Ly5.1- B10.PLxC57BL/6 host mice to track the population 
of cells that were responsible for disease induction. Mice then received either 1µg SEB 
or PBS i.v on three consecutive days (Fig. 5.12B). As Ac1-9(4Tyr) had previously been 
shown to have profound tolerogenic properties in ths model (Fig. 4.5), one group of 
mice received 200µg Ac1-9(4Tyr) one day after adoptive transfer of Tg4 cells as a 
control to compare the tolerogenic potential of SEB. On the fourth day after T cell 
transfer all mice were immunized with MBP(Ac1-9)/CFA to induce EAE (Fig. 5.12A).  
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Mice that had received 3 doses of SEB after adoptive transfer of CD4+ Tg4 cells showed 
reduced disease incidence and severity compared to mice that received PBS (Fig. 
5.12B). However, the tolerance induced by SEB was not as profound as that seen with 
Ac1-9(4Tyr) administration. All mice were sacrificed at day 17 to assess the effect of 
SEB on the Tg4 population in the CNS, draining lymph nodes and spleen, however no 
Tg4 cells could be detected in this experiment.  




Data presented in this chapter show that exposure to superantigen has a major role in 
determining the frequency of Foxp3+ T cells in the p ripheral immune repertoire. 
Superantigens have been known for some time to haveprofound immunomodulatory 
properties (Herman et al., 1991; Lobo-Yeo and Lamb, 1993). However, this study shows 
a positive association with Foxp3, a key transcription factor associated with immune 
tolerance, such that the frequency of superantigen-reactive Foxp3+ cells is enhanced 
upon superantigen exposure. This seems to be throug l ss of foxp3- cells rather than a 
positive expansion of foxp3+ cell numbers. Furthermore, supernatigen-induced or 
‘spared’ T cells were capable of suppressing the primary response of naïve T cells in 
vitro. This was the case in both mmtv-induced Vβ5+ T cells suppressing anti-CD3-
driven proliferation of CD25- cells (Fig. 5.4) and of SEB-induced Tg4 T cells 
suppressing naïve Tg4 cell responses to both MBP(Ac1-9) and SEB (Fig. 5.9). Although 
encounter with superantigen skewed the SAg-reactive population towards Foxp3+ cells, 
it cannot be ruled out from these experiments that t e Foxp3- cells remaining after SAg-
encounter contribute to the suppression observed. This would require sorting of SEB-
experienced Foxp3+ and Foxp3- cells as can now be don  using Foxp3-GFP+ mice 
(Fontenot et al., 2005b). 
 
The data showing the effects of both endogenous and exogenous superantigen indicate 
that superantigen-reactive T cells are activated in vivo, with Foxp3- cells turning over at 
a faster rate then Foxp3+ cells. In the naïve setting, Vβ5+ cells are relatively rare in the 
total CD4+ population (3-5%, Fig. 5.1B and 5.3B) and after administration of SEB, the 
total CD4+Vβ3+ and CD4+Vβ8+ populations are reduced. These results would suggest 
that Foxp3- T cells bearing the appropriate TCR Vβ are activated and eventually 
undergo AICD when they encounter SAg in vivo. In contrast, those Vβ-expressing T 
cells that are Foxp3+ are spared this fate and as a re ult reach significant frequencies in 
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the overall Vβ+ population. Indeed the avoidance of AICD by T cells expressing 
Foxp3+ had previously been suggested (Papiernik et al., 1998).  
 
A recent study has used the thymic selection and chronic deletion of Vβ5+ T cells in 
C57BL/6 mice as a model to assess the capacity of Tregs to be deleted by TCR-mediated 
apoptosis (Taylor et al., 2007). This group proposed that as SAg-reactive T cells are not 
deleted in the thymus of these mice due to the lackof I-E molecules, then these cells 
should have a high avidity towards self and be select d close to the level of stimulation 
that would normally induce negative selection. As Vβ5+ cells show a skewing toward 
Foxp3-expression, this may be explained by the preferential selection of high avidity 
self-reactive T cells to become Foxp3+ cells in the thymus. However, similar to our data, 
it was shown that positive selection of Vβ5+Foxp3+ and Foxp3- cells occurred with a 
similar efficiency, regardless of the avidity for self antigen. The skewed frequency of 
Vβ5+Foxp3+ cells was shown to be due to the selective resistance of Foxp3+ cells in 
response to both thymic and peripheral SAg stimulation (Taylor et al., 2007), in 
agreement with the data presented in this chapter.  
 
Of note, regarding superantigen-mediated deletion of transgenic T cells, OT-II mice that 
express a Vα2+Vβ5+ TCR and are on the C57BL/6 background (mtv-8+) do not 
undergo TCR revision or show deletion of CD4+ T cells (Zehn et al., 2007). This 
suggests that an aspect of this transgenic mouse strain prevents the stimulation of the 
transgenic T cells by endogenous supreantigens, although the mechanism behind this is 
unknown 
 
The ability of bacterial superantigens to induce thactivation of Vβ-specific T cells, 
followed by the deletion of the majority of these clls (and those remaining being 
anergic), has long been known (Kawabe and Ochi, 1990; Kawabe and Ochi, 1991; 
MacDonald et al., 1991). Furthermore, data from numerous groups have shown that 
repeated exposure to low dose superantigen can prevent superantigen-induced shock 
(Feunou et al., 2003; Florquin and Goldman, 1996; Grundstrom et al., 2003; Miller et 
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al., 1999; Noel et al., 2001; Sundstedt et al., 1997). Similar data had also been shown for 
the T cells that remain after MMTV-mediated deletion n vivo (Papiernik et al., 1997) 
and suggest that active regulation may be responsible for SAg-induced tolerance. Other 
studies reported that superantigen challenge was associ ted with a decrease in IL-2 and 
IFNγ production and unchanged, or enhanced production of IL-4, IL-5 and IL-10 
(Florquin and Goldman, 1996; Noel et al., 2001), suggesting that Th2 deviation was 
responsible for SAg-induced tolerance (Kuschnaroff et al., 1999).  
 
Using i.p. administration of SEB, Fenou et al. (Feuno  et al., 2003) found that while 
natural Tregs were responsible for the prevention of excessive cytokine release in 
response to superantigen challenge, the tolerance obs rved post SEB-treatment was due 
to a CD4+CD25-Foxp3-  population via the secretion of IL-10. A similar study by Braun 
and colleagues (Noel et al., 2001) found a role for CD4+IL-10+ cells in the suppression 
of naïve T cell responses to superantigen. Importantly, these studies suggest that the 
mechanisms responsible for anergy in response to SAg stimulation is distinct from the 
suppression of SAg induced stimulation. The former ay involve nTregs, as shown in 
RAG-/- mice where SAg-induced tolerance is reduced ompared to RAG-sufficient 
hosts (Grundstrom et al., 2003), while the latter scenario seems to depend on IL-10 and 
perhaps TGFβ (Feunou et al., 2003; Noel et al., 2001). Sundstedt et al. also reported a 
role for CD4+ IL-10 producing cells in SAg-induced tolerance (Sundstedt et al., 1997), 
however this study was performed prior to the identification of Foxp3 as a nTreg 
marker. 
 
A study in the late 90’s by Papiernik et al. (Papiernik et al., 1997) suggested that after 
infection with viral mmtv, the chronic stimulation of Vβ6+ T cells by virally-encoded 
superantigen spared a population of CD4+CD25+ cells that produced IL-10. Similar to 
our data, it was shown that while the total SAg-reactive Vβ6+ T cells were reduced, this 
was due to the loss of Vβ6+CD25- cells as the levels of Vβ6+CD25+ cells remained 
constant and these cells did not proliferate. This is omewhat strange since, although 
Tregs show profound anergy in vitro, there is now considerable evidence that they are 
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capable of clonal expansion in vivo in response to a range of antigenic stimuli (Klein et 
al., 2003). Thus it seems that Tregs can expand to antigen, but not to superantigen. This 
does, however, make some evolutionary sense. If the response to superantigen was for 
Foxp3- cells to die and Foxp3+ cells to selectively expand, then, over time and repeated 
superantigen exposure, the T cell repertoire would become skewed heavily towards the 
Treg phenotype. This could have profound consequences for the ability to fight infection 
effectively. Our data show that while primary exposure to superantigen does not induce 
the proliferation of SAg-reactive Tregs, re-stimulation in vitro could drive the 
proliferation of some of these cells (Fig. 5.9B). However, re-stimulation did not induce 
the proliferation of the Foxp3- cells in culture (Fig. 5.9D). This suggests that while one 
mechanism to induce tolerance to superantigen re-exposure is the selective survival of 
Foxp3+ cells, the superantigen-reactive Foxp3- cells that remain are also refractory to 
further stimulation.  
 
The co-culture of naïve Tg4 cells with SEB-experienced Tg4 cells demonstrated the 
profound suppression of naïve Foxp3- cell proliferation in response to SEB or 
MBP(Ac1-9) stimulation (Fig. 5.9B). When re-stimulated with SEB, Foxp3+ cells from 
SEB-treated mice showed enhanced proliferation compared to cells from PBS-treated 
mice and naïve mice. Moreover, Foxp3+ cells from naïve mice were induced to 
proliferate in response to SEB when in the presence of SEB-experienced cells (Fig. 
5.9E). This suggests that prior exposure to SEB induces a proportion of cells that, when 
re-stimulated with SEB, can be induced to expand aninduce expansion of naïve 
Foxp3+ T cells, perhaps reminiscent of infectious tolerance (Andersson et al., 2008; 
Cobbold and Waldmann, 1998). The enhancement of Foxp3+ cell proliferation will 
likely contribute to the suppression of Foxp3- cells. It is notable that the proliferation of 
SEB-experienced and naïve Foxp3+ cells does not occur in MBP(Ac1-9) stimulated 
cultures, however, the Foxp3- cells in these cultures were still suppressed, suggesting 
that proliferation of the Foxp3+ compartment is not ecessary for their suppressive 
function in this assay.  
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One explanation for the reduced proliferation of SEB-experienced Foxp3- cells may be 
that SEB had induced TCR rearrangements and skewed the TCR away from the 
transgenic Vα4.2+ (as these mice are not RAG-/-) making these cells un-responsive to 
MBP. TCR revision has been described as a mechanism whereby T cells that are 
chronically stimulated with antigen can escape AICD. Indeed this was shown to be the 
case in Vβ5-expressing transgenic mice upon their encounter with mmtv in the periphery 
(Blish et al., 1999; McMahan and Fink, 2000). A recent study by Zehn et al. (Zehn et al., 
2007) has investigated TCR revision in Vβ5+ T cells in response to mmtv-derived 
superantigen stimulation. This study found that Vβ5+Foxp3- cells routinely revised their 
TCR to express another Vβ-chain, while Vβ5+Foxp3+ cells did not undergo TCR 
revision and were not deleted to the same extent as their Foxp3- counterparts. This could 
explain the reduced response of Foxp3- (but not the Foxp3+) SEB-experienced Tg4 cell 
to SEB re-stimulation in vitro (Fig. 5.9B vs. D). To test if TCR revision is responsible 
for the reduced responsiveness of SEB-treated CD4+Foxp3- cells the levels of Vβ8 on 
the Tg4 cells could be assessed after SEB administration. 
 
It would seem unlikely that all cells stimulated with SEB would lose the transgenic Vβ 
chain, therefore this cannot completely explain theobserved unresponsiveness to 
MBP(Ac1-9) and SEB by SEB-experienced Foxp3- cells in vitro. Furthermore, this 
would not explain the reduced response of naïve Foxp3- cells in response to MBP(Ac1-
9) or SEB (Fig. 5.9C) and argues for the active regulation by SEB-experienced T cells in 
culture. To confirm this it would be possible sort Foxp3- cells away from Foxp3+ cells 
and assess if they remain refractory to superantigen stimulation. This would determine if 
their un-responsiveness is a cell intrinsic mechanism or due to the suppression exerted 
by the SAg-induced Tregs.  
 
It is possible that re-stimulation of SEB-experiencd cells in vitro causes release of 
suppressive and Foxp3-inducing cytokines which would affect the naïve T cell response. 
Indeed, in these co-culture experiments IL-10 could be detected in SEB-
experienced/naïve cell co-cultures by ELISA (Fig. 5.11), but not in any of the single 
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cultures (Data not shown). TGFβ is another potential regulatory cytokine known to 
induce Tregs. A recent study has suggested that Treg -d rived TGFβ is responsible for 
Treg-mediated infectious tolerance as this cytokine can induce the conversion of naïve 
cells towards a Foxp3+ cell with regulatory capacity (Andersson et al., 2008). The role 
of this cytokine in the experiments described here is yet to be identified with the use of 
blocking TGFβ-antibody.  
 
The deletion of all TCRs bearing particular TCRβ chains by superantigens will have 
profound consequences on the peripheral T cell repertoir . These may include the 
deletion of potentially protective pathogen-responsive T cells, to the beneficial removal 
of self-reactive T lymphocytes. The preferential use of the TCR Vβ gene segment 
encoding Vβ8 has been documented in EAE (Urban et al., 1988) and because SEB has 
been shown to stimulate T cells bearing this Vβ chain, it is unsurprising that the effect of 
SEB on EAE has been well studied. Our studies have shown that SEB administration 
can reduce disease induced with MBP(Ac1-9) in Tg4 transgenic and B10.PLxC57BL/6 
mice. Other studies have shown that the administration of one high dose of SEB (100µg 
i.p.) prior to disease induction with Ac1-9 was shown to reduce clinical signs of EAE 
(Soos et al., 1993). However, SEB was also demonstrated to induce relapses in MBP-
induced EAE when given after the primary episode of disease (Brocke et al., 1993). Das 
et al., also reported that disease was exacerbated wh n SEB was given prior to EAE 
induction by immunization with PLP (Das et al., 1996), suggesting the effect of SEB 
depends on the diversity of the T cell repertoire and likely the frequency of SAg-reactive 
cells in the population.  
 
The important question that arises from these studies is how superantigens impact on 
humans. The expression of endogenous superantigens n humans has been identified, 
derived from human endogenous retroviruses (HERVs) (Nelson et al., 2004). It was 
identified that infection with EBV could transactivate HERV-K18 that encodes a 
superantigen able to stimulate Vβ7+ and Vβ13+ T cells (Sutkowski et al., 2001). One 
study, using HLA class II transgenic mouse strains ha demonstrated that exposure to 
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endogenous human superantigens can induce thymic deletion of T cells bearing SAg-
reactive TCRs and reduce the capacity of these miceto r spond to SAg in the periphery 
(Rajagopalan et al., 2005). It would be interesting o determine if these mice also have 
reduced capacity to respond to other (non-super) antigens also. These studies suggest 
that, similar to mice, endogenous superantigens mayhave the capacity to profoundly 
influence the T cell repertoire in humans.  
 
Interestingly, two studies have suggested that exposure to bacterial superantigen is 
detrimental to Treg function. Cardona et al. (Cardona et al., 2006) reported the 
upregulation of GITRL on monocytes when human PBMCs were stimulated with SEB 
in vitro. As ligation of GITR has been shown to block the function of Tregs (McHugh et 
al., 2002; Shimizu et al., 2002) the capacity of Tregs to suppress after SEB stimulation 
was shown to be reduced (Cardona et al., 2006). The chronic inflammatory skin disease 
atopic dermatitis (AD) is associated with colonization of the skin by S. aureus (Hauser et 
al., 1985; Leyden et al., 1974).  A study by Ou et al. has assessed the number and 
function of Tregs in AD patients and showed that ADpatients have enhanced levels of 
CD4+CD25+ T cells. However, while the Tregs from these patients could suppress anti-
CD3 driven T cell response, the AD Tregs did not suppress SEB driven proliferation. 
The clarity of these studies is clouded by the facttha  suppression of the CD25- cells in 
culture with CD25+ cells from AD patients was measured by 3H-Thymidine 
incorporation. As the data in our studies show, and by the admission of the investigators 
in the paper, SEB re-stimulation induces the proliferation of SEB-experienced Tregs, 
suggesting that the suppressive capacity of Tregs in AD may not be reduced and requires 
further investigation. 
 
The effect of superantigens on autoimmunity was ident fi d almost twenty years ago, 
while investigating the observation that mice expressing I-E were protected from 
diabetes (Nishimoto et al., 1987). Reich et al. repo ted that diabetogenic T cell clones 
bore receptors encoded by the Vβ5 gene segment (Reich et al., 1989). As these cells are 
deleted in I-E-expressing mice, this explained the pr vious findings, although that the 
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effect was directly caused by endogenous superantigen presentation was not yet 
understood. Ultimately, all of the studies discussed highlight that the effect of 
superantigen on the immune repertoire (and the response that an individual can mount) 
is dependent on the type of superantigen expressed and/or encountered, but also on 
genetic background, particularly related to the MHC molecules expressed.  
 
In line with this, HLA polymorphisms have been shown to influence superantigen 
presentation and the outcome of bacterially induced shock (Llewelyn, 2005). Increased 
binding of superantigen is associated with and increased magnitude of T cell response 
and the levels of shock induced. As many autoimmune dis ases are associated with 
specific HLA molecules (Zanelli et al., 2000) and particular Vβ use (Acha-Orbea, 1991) 
it would seem that superantigens could have dramatic effect on the protection from, or 
susceptibility to, these diseases. 
 
While exposure to exogenous superantigen is normally associated with development of 
cytokine induced shock (Krakauer, 1999), this is likely to occur when exposed to a 
single, high dose of antigen. In a setting where chronic exposure to superantigen occurs, 
the data presented here, and those of others, would argue that rather than developing 
excessive immune responses, the outcome would be in favour of regulatory immune 
responses. Evidence points to crucial roles for Treg cells in the resolution of 
inflammation (McGeachy et al., 2005; Sakaguchi, 2005) and also of immune responses 
to pathogens (Belkaid and Rouse, 2005). If such a mechanism of superantigen-driven 
maintenance of Treg frequencies is truly at work in humans, this would represent a 
subtle further refinement of the “hygiene hypothesis” whereby autoimmune and allergic 
diseases appear to be minimised, at the cost of increased infectious load (Yazdanbakhsh 
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Figure 5.1: CD4+V β5+ cells have a high frequency of foxp3+ cells in t he 
periphery of naïve C57BL/6 mice. A: spleen and lymph node samples were 
stained for expression of CD4, Vβ and Foxp3 expression. B: Representative plot 
of foxp3 staining on CD4+Vβ5+ splenocytes. C: Thymocytes (gated on 
CD4+CD8-) were compared with peripheral CD4+CD8- T cells for specific Vβ
and foxp3 expression. Errors bars show mean +/- S.D. of three individual mice 
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Figure 5.2: CD4+V β5+ T cells from µMT mice have decreased proportions 
of Foxp3+ cells compared to WT C57BL/6mice. Proportion of A: CD4+, B: 
CD4+Foxp3+ and C: CD4+Vb5+ cells in WT C57BL/6 mice (black bars) and 
uMT mice (red bars). D: Proportion of Foxp3+ cells in CD4+Vβ5+ and 
CD4+Vβ5- compartments. E: Ratio of means in µMT vs. WT cells, calculated 
from mean percentage of the indicated population in µMT divided by mean % in 
WT mice. Dotted line represents ratio of 1 (signifying no difference). F: Equation 
to calculate the ratio of the difference in the proportion of Foxp3+ cells in Vβ5+ 
vs. Vβ5- populations in µMT vs. WT mice.  *=p<0.05. Error bars show mean +/-


















Vβ5+ (%Foxp3+ in µMT / %Foxp3+ in WT)
Vβ5- (%Foxp3+ in µMT / %Foxp3+ in WT)
= 0.82
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Figure 5.3: Analysis of CD4+V β5+ proliferation in vivo and cell surface markers. 
A: In vivo proliferation of Foxp3- and Foxp3+ populations in vivo, mice were given 
BrdU i.p. on three consecutive days before sacrifice and staining for FACS analysis. 
B and C: Cell surface marker expression on Vβ5+ vs Vβ5- (B) and Vβ5+Foxp3+ vs. 
Vβ5+Foxp3- populations (C). Error bars show mean +/- S.D. of five mice. Plots show 
one representative of five mice. Data representative of three independent 
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Figure 5.4: In vitro suppression assays to determin e suppressive capacity of 
Vβ5+ cells. A: Indicated populations were sorted from naïve C57BL/6 mice and 
assessed for Foxp3- expression using FACS (gated based on isotype control for 
individual samples). B: Suppression of CD4+CD25- cells by sorted CD4+CD25+
cells (black), CD4+Vb5+ cells (red) and CD4+Vb5- cells (blue). Dotted line  
represents proliferation of CD25- cells to anti-CD3 in the absence of suppressor 
cells. Error bars show mean +/- S.D. of triplicate wells. Data representative of two 
independent experiments with similar results.
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Figure 5.5: SEB selectively induces the expansion o f Vβ3+ and Vβ8+ T cells 
in vitro. Naïve splenocytes from C57BL/6 mice were stimulated with the 
indicated dose of SEB or conA for 72h in vitro. The proportion of CD4+ cells 
expressing the indicated Vβ was assessed by FACS. Data representative of 
triplicate wells, showing data from one of two separate experiments with similar 
results.
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Analyse by FACS
Figure 5.6: SEB induces the depletion of V β3+ and Vβ8+ T cells and 
enhances the frequency of V β3 and Vβ8+ Foxp3+ cells in vivo. A: 
Experimental outline to assess the expansion of TCR Vβ+ cells in response to in 
vivo administration of SEB. Naïve C57BL/6 mice were given PBS or 1ug SEB i.v. 
on three or five consecutive days. B: Splenocytes were removed 24h after the last 
treatment and assessed for levels of TCR Vβ expression (left panels) and Foxp3 
expression (right panels). Data representative of three independent experiments, 
error bars show mean +/- S.D. of 4 individual mice per group. * = p<0.05. Data 
shows one of three repeat experiments with similar results.
A
B
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Figure 5.7: SEB stimulation depletes CD4+V β3+ T cells and increases the 
proportion of V β3+Foxp3+ cells. A: Experimental outline - naïve C57BL/6 mice 
were given PBS or 1ug SEB i.v. and BrdU (2mg) i.p. every two days for 5 days. 24h 
after final treatment splenocytes were removed and CD4+ cells assessed for B: Vβ
expression, C: Foxp3 expression and D: BrdU incorporation by FACS. Data 
representative of three independent experiments. Error bars show mean +/- S.D. of 
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Figure 5.8: Treatment of Tg4 mice with SEB enhances  the proportions of 
Foxp3+ cells and renders the treated Tg4 cells  ane rgic to SEB and MBP 
stimulation in vitro. Tg4 mice received PBS or 1µg SEB i.v. on three consecutive 
days and were sacrificed 24h after the last treatment. A: Splenocytes were 
assessed for Foxp3 and CD25 expression by FACS. Two plots shown per group as 
a representative of 5 mice per group. B: Splenocytes and lymph nodes were 
assessed for proliferation in response to MBP(Ac1-9) and SEB in vitro by 3H-
thymidine incorporation. Error bars show mean +/- S.D. of 5 mice/group. Data 
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Figure 5.9: Splenocytes from Tg4 mice that have been  treated with SEB do 
not produce cytokines in response to SEB or MBP in vitro. A: Experimental 
outline. B: splenocytes were stimulated with indicated dose of MBP(Ac1-9) or 
SEB in vitro for 72h prior to assessment of supernatants by cytokine ELISA or C: 
splenocytes were stimulated overnight with 50µg MBP(Ac1-9) or SEB for 
cytokine analysis by ICCS and FACS. Error bars show mean +/- S.D. of 
individual mice, three mice/group. Plots show one representative of three 
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Figure 5.10: CD4+ T cells from SEB treated mice ind uce proliferation of naive 
Foxp3+ T cells and suppress proliferation of naïve Foxp3- T cells in response to 
SEB and MBP(Ac1-9) stimulation in vitro. A: Experimental outline - Tg4 mice were 
treated with 3x1µg SEB or PBS on three consecutive days prior to the sorting of CD4+ 
cells from the spleen (% CD4+Foxp3+ cells from each group as assessed by FACS is 
indicated by number) and pooling samples between groups. B-E: Cells were then cultured 
alone (open bars) or in co-culture with an equal number of CD4+ cells isolated from naïve 
Thy1.1+ Tg4 mice (closed bars). Cells were stimulated with MBP(Ac1-9) or SEB (both 
10µg/ml) for 48h. BrdU was added to culture for the final 12h to assess proliferation of 
Foxp3- cells (B and C) and Foxp3+ cells (D and E) by FACS. Figures B and D showing 
Thy1.1- gated PBS or SEB treated populations, fig. C and E show Thy1.1+ gated naïve 
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Figure 5.11: Co-culture of naïve Tg4 cells with SEB -experienced Tg4 
cells reduced IL-2 and IFN γ production but enhances IL-10 production.
Supernatants from co-culture assays shown in Fig. 5.10 were assessed by 
ELISA for the levels of A: IL-2, B: IFNγ and C: IL-10 in response to SEB 
stimulation. Data representative of three separate experiments with similar 
results.
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Figure 5.12: Pre-treatment with low dose SEB reduce s EAE induced with 
MBP(Ac1-9) in Tg4 transgenic mice and after adoptiv e transfer of Tg4 cells.
A: Tg4 mice received either PBS or 1µg SEB i.v. on 3 consecutive days prior to the 
induction of EAE by immunisation with MBP(Ac1-9). B: B10.PLxC57BL/6 mice 
received a transfer of 2x106 CD4+Tg4 one day before treatment with SEB/PBS 
and immunisation as in A. Data representative of two independent experiments, 
error bars show mean +/- S.D of 4 mice per group.
Tg4




















6 General Discussion 
 
Tregs expressing the transcription factor Foxp3 have been shown to be crucial in 
preventing autoimmunity (Kim et al., 2007; McGeachy et al., 2005). Using a mouse 
model of MS, EAE, studies from this laboratory have id ntified that Foxp3+ Tregs 
accumulate and proliferate in the CNS and are essential for the recovery phase of disease 
(McGeachy et al., 2005; O'Connor et al., 2007). The data presented in this thesis 
investigated the antigenic reactivity of Tregs that arise in response to active induction of 
EAE and the capacity for myelin-reactive Foxp3+ Tregs to be expanded or induced for 
the prevention and suppression of disease. Furthermor , the effect of superantigenic 
stimulation on the peripheral Foxp3+ compartment was assessed after identification of 
specific enhancement in the frequency of Foxp3+ cells in Vβ5+ T cells in the periphery 
of naïve mice. The data can be summarised as follows; 
 
• Antigen-reactive Tregs can be detected in the periph y and CNS of mice after 
immunisation with myelin antigens. This occurs both to self and non-self antigens. 
 
• Endogenous expression of self antigen appears to influence the peripheral self antigen-
reactive Foxp3+ and Foxp3- repertoires. Furthermore, endogenous antigen expression is 
not necessary for the expansion/induction of antige reactive Tregs. 
 
• Pre-treatment with an APL of MBP(Ac1-9) can suppress EAE induced with 
MBP(Ac1-9) and reduce relapses in EAE induced with PLP(139-151) after adoptive 
transfer of MBP(Ac1-9)-reactive CD4+ T cells. 
 
• Encounter with SAg enhances the frequency of Foxp3+ T cells in peripheral SAg-




These results have shown that antigen-reactive Tregs can be identified using in vitro 
based assays. The targeting of disease-relevant antigen-reactive T cells in vivo can 
suppress disease induced against the initiating antigen, but also induce bystander 
suppression against distinct antigens. Understanding the antigenic reactivity of Tregs in 
EAE and MS and the molecular mechanisms behind their selection and expansion in 
vivo will provide potential therapeutic strategies to prevent or suppress disease.  
 
6.1 Determining the antigenic reactivity of Tregs i n EAE and 
MS 
 
Data from mouse models of autoimmune inflammation have highlighted the enhanced 
function of antigen-reactive Tregs compared to polycl nal Tregs (Tang et al., 2004b; 
Tarbell et al., 2004). However, the antigenic-reactivity of Tregs in MS are unknown 
therefore expansion of disease relevant Tregs requires a greater understanding of the 
antigenic reactivity of the regulatory cells involved in disease suppression and/or 
prevention..  
 
Determining the antigens that drive the in vivo activation, proliferation and expansion of 
Foxp3+ Tregs has proved difficult in the absence of antigen-reactive tetramers. In these 
studies BrdU-incorporation assays were utilised in combination with Foxp3-staining as a 
mechanism to detect the proliferation of Foxp3+ cells in vitro. However, this assay was 
limited, as the proliferation of Foxp3+ cells was almost universally accompanied by 
Foxp3- cell proliferation. It is therefore difficult to rule out that Treg proliferation was 
induced by the antigen in vitro, and not in response to a Foxp3- derived factor, such as 
IL-2. Further refinement of this protocol would be n cessary to definitively conclude 
that the Tregs in culture were indeed antigen-reactive. However, the data presented here 
is in agreement with those of the Kuchroo group (Korn et al., 2007) using antigen-




Determining the antigenic-reactivity of Tregs in humans will be much more complex 
than in the models used in this study. The initiating antigens for disease are unknown 
and as many patients have undergone substantial de-myelination before clinical 
manifestations, a number of myelin antigens are likly to be involved. However, the 
identification of auto-reactive T cells in MS patients has been shown in the blood of MS 
patients (Hellings et al., 2001; Zhang et al., 1994); this could also be used to determine 
the antigenic reactivity of Foxp3+ cells from the pri heral blood of patients. One major 
caveat of human studies is the accessibility to Tregs from the site of inflammation. 
While most of the studies on human Tregs have isolated these cells from peripheral 
blood, it is likely that Tregs from the CNS have refin d specificities and may differ from 
peripheral Tregs.  
 
6.2 Therapeutic targeting of Tregs in MS 
 
Transfer of large number of naïve polyclonal Tregs has been shown to reduce the 
severity of EAE (Kohm et al., 2002; Zhang et al., 2004). Previous data from our 
laboratory has shown that depletion of Tregs using a ti-CD25 antibody resulted in 
exacerbated EAE, while depletion after the initial phase of disease prolonged the disease 
course (McGeachy et al., 2005; Stephens et al., 2005).  These studies highlighted the key 
function of Tregs in EAE, therefore their role in MS has also been investigated. 
 
CD4+CD25hi cells from human peripheral blood represent a regulatory T cell population 
with properties similar to those isolated from mice (Baecher-Allan et al., 2001; 
Dieckmann et al., 2001).  CD4+CD25+ cells from MS patients were shown to be present 
at similar numbers relative to healthy controls however, Tregs from MS patients were 
shown to have reduced functional suppressive capacities (Haas et al., 2005; Viglietta et 
al., 2004). Immunotherapy that enhances the capacity of Tregs to suppress auto-




Our data demonstrated that MBP(Ac1-9) reactive Tregs can be expanded in vitro and 
suppress MBP(Ac1-9)-induced EAE when transferred at low cell numbers. The 
expansion of human myelin reactive Tregs in vitro has also now been shown (Arbour et 
al., 2006). The in vitro expansion and transfer of myelin reactive Tregs as therapy would 
be a technically difficult and expensive method to treat MS patients. However, this has 
provided a model to test the capacity of myelin-reactive T cells in vivo. We used this 
model to determine that MBP(Ac1-9) reactive Tregs could reduce relapses of disease 
induced against the 139-151 epitope of PLP, a distinct myelin antigen. 
 
To overcome the demands of cellular therapies, targe in  Treg expansion directly in vivo 
is a possibility for MS treatment. Certain protocols f antigen administration have been 
shown to favour the induction and expansion of Foxp3+ T cells, such as low antigen 
dose that provides continual antigenic-stimulation (Apostolou and von Boehmer, 2004; 
Kretschmer et al., 2005). We utilised an APL of MBP(Ac1-9), 4Tyr, that had previously 
been shown to have profound tolerogenic properties in EAE (Burkhart et al., 1999; 
Sundstedt et al., 2003). Treatment of mice that had received Tg4 cells with this peptide 
suppressed disease induced against MBP(Ac1-9) and PLP139-151. However, no Foxp3+ 
cells were detected in these studies. Nonetheless, the fact that Tregs reactive against one 
antigen can induce suppression against a distinct antigen has important implications in 
MS. Similar to mouse models, human studies have suggested that epitope spreading can 
also occur in MS (Goebels et al., 2000). Although not every antigen can be identified in 
MS, it is likely that identification of key epitopes that the immune system is recognising 
will allow the targeting of these cells towards a regulatory phenotype, or the expansion 
of nTregs recognising these antigens. Bystander suppression mechanisms will then help 
generate a regulatory and suppressive environment in the CNS. 
 
Some studies have suggested that Tregs do not function optimally in settings of 
inflammation (Pasare and Medzhitov, 2003). One study has suggested that although 
Tregs accumulate in the CNS, they fail to suppress auto-aggressive T cell responses 
(Korn et al., 2007). Data from our group have also suggested that Tregs do not suppress 
General Discussion 
192 
Th17 responses, but can suppress Th1 responses (O'Connor et al., 2007). Combination 
protocols promoting Tregs and reducing inflammation will therefore provide optimal 
therapies for CNS inflammation, although specific targeting of the CNS environment 
will be difficult and may still involve some aspect of general immunosuppression. 
Rapamycin, which inhibits the response to IL-2, has been shown to preferentially 
promote Treg expansion while inhibiting effector T cell proliferation  (Battaglia et al., 
2006c). Combination peptide and rapamycin therapy would be a potential therapy that 
requires investigation. 
 
Peptide therapy as a treatment for human inflammatory c nditions has shown some 
promise (Larche and Wraith, 2005). However, the molecular mechanisms that result in 
tolerance require deeper understanding to ensure that only Tregs are targeted and that 
activation or enhancement of Teff cells is not induced. Furthermore, the longevity of the 
tolerance must be addressed. Potentially, patients may require continual doses of peptide 
to maintain suppression and developing protocols to induce long-term tolerance to many 
CNS-derived antigens will be required to circumvent this problem. 
 
6.3 Superantigens and their implications in autoimmu nity 
 
Studies on the TCR use of Foxp3+ Tregs lead us to investigate the finding that Vβ5+ T 
cells were under-represented in total CD4+ populations and ~30% of these cells were 
Foxp3+. Mmtv-derived superantigen-mediated deletion of T cells bearing particular 
TCRβ chains had been extensively documented in the 1990’s (Lobo-Yeo and Lamb, 
1993; Scherer et al., 1995) and accounted for the loss of Vβ5+ cells from the total CD4+ 
compartment. However, while some studies had reportd that the remaining Vβ5+ cells 
had regulatory properties, Foxp3-expression had not been documented. 
 
The data presented here demonstrates that exposure to superantigen (both endogenous 
and exogenous) results in the proliferation of T cells bearing particular Vβ chains, 
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followed by their elimination. However, Foxp3+ cells were refractory to primary 
superantigen stimulation and were presumable spared f om deletion. Overall, 
superantigen encounter skews the SAg-reactive population towards a regulatory 
phenotype by enhancing the frequency of Foxp3+ cells. Furthermore, SAg-exposed T 
cells induce suppression of primary T cell responses, potentially via the release of IL-10 
and favour the balance of the immune system towards regulation. 
 
As superantigens target T cells based on the expression of TCR β chains, they can affect 
a vast proportion of all T cells; much larger than the population of T cells that would be 
affected by antigenic encounter. In this way, superantigens can have profound 
consequences on the generation of subsequent immune responses, including 
autoimmune responses. 
 
Exposure to SEB can have differential effects in EAE, depending on the strain of mouse 
used, initiating antigen and time of administration (Brocke et al., 1993; Kuschnaroff et 
al., 1999). MBP-reactive T cell clones from the blood of MS patients have been shown 
to be reactive to superantigens (Zhang et al., 1995). Furthermore, the association of MS 
with viral infection, such as EBV, have suggested that exposure to superantigens may be 
a risk factor for MS (Tai et al., 2008). However, the data shown here suggests that 
chronic exposure to superantigen may result in enhanced immune regulation and 
suppress autoimmunity. It is likely the timing and i tensity of exposure (high dose vs. 
chronic low dose stimulation) to superantigens will affect the outcome that these 
antigens have in autoimmunity. 
 
While superantigens do not provide potential theraputic strategies for the prevention of 
autoimmunity, they can be used to examine the molecular responses of T cells in vivo. 
Clearly, the data presented here shows that Teff and Tregs respond differently to the 
same (super)antigen. Understanding the mechanisms behind the selective elimination of 
Teff compared to the lack of proliferation and hence survival of Tregs is of great 
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interest, particularly in diseases such as MS, where the selective survival of Tregs and 
elimination of effector T cells would be advantageous. 
 
This project provides insight into the antigenic reactivity and functional capacity of 
CNS-relevant Foxp3+ Tregs in models of EAE. The molecu ar requirements for Treg 
selection and expansion and their response to superantigen stimulation highlight 
important properties of Foxp3+ Tregs that must be considered to translate Treg-based 
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2 x Tg4 transgenic mice








Day 6: PEG fusion with BW5147 thymoma cell line
Post expansion
Foxp3-analysis
Day 7: addition of HAT (hypoxanthine/aminopterin/thymidine)
Day 14/15: Score hybrids – clonal growth <20%.
Transfer cells to 1ml HAT medium
Day 4:
Tg4 5x106 Spleen cells/well 
stim. with Ac1-9 
(10µg/ml) for 2 days.
CONTROL
(Naïve)
Day 20: Test for TCR-specificity vs. MBP(Ac1-9)
(IL-2 ELISA)
Appendix 1A: Outline of the protocol to generate Treg hybridomas
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Hybrids generated from the indicated cell populations 
were cultured in medium alone (white), with PL8 (B cell 
line) as APC (black), or with APC plus 4µg/ml of MBP 
Ac1-9(4K) (red). After 24h, supernatants were removed 
and tested for IL-2 by ELISA. Data shows one of three 
repeat experiments. 
Appendix 1B: IL-2 ELISA showing Tg4 hybrid responsiveness to MBP(Ac1-9)
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Top panels: control Tg4 cells (un-sorted, whole spleen Tg4) - isotype control 
(left) and foxp3 expression (right). Bottom panels: three representative plots of 
Foxp3 expression in fused CD25+CD62Lhi Tg4 hybrids, black line = isotype
control.
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Splenocytes from naïve C57BL/6 mice were labelled with CFSE and stimulated for 
24 (top panels) and 48h (bottom panels) with anti-CD3 (1µg/ml final concentration). 
For the final 12h of each culture BrdU was added to assess BrdU incorporation 
and CFSE dilution simultaneously via FACS. Plots show a representative of 3 
separate wells showing similar results.
24H
48H
Appendix 2: Double staining for BrdU and CFSE to show BrdU incorporation 








































































WT and MOGKO mice were immunised with pMOG in CFA or IFA. 10 days later, 
DLN were removed and assessed for in vitro reactivity to pMOG. Top panels: 
Proportion of Foxp3+ cells in cultures from CFA-immunised (A) and IFA immunised 
(B) mice. Bottom panels: Proportion of Foxp3+BrdU+ cells in culture from CFA 
immunised (C) and IFA immunised (D) mice. *p<0.05. Data show duplicate wells of 




Appendix 3A: Assessing the effect of CFA  vs. IFA  immunisation on 










































































Appendix 3B: Assessing the effect of CFA  vs. IFA  immunisation on 
determining antigen-reactivity ex vivo (cell numbers).
WT and MOGKO mice were immunised with pMOG in CFA or IFA. 10 days later, 
DLN were removed and assessed for in vitro reactivity to pMOG. Top panels: 
Proportion of Foxp3+ cells in cultures from CFA-immunised (A) and IFA immunised 
(B) mice. Bottom panels: Proportion of Foxp3+BrdU+ cells in culture from CFA 
immunised (C) and IFA immunised (D) mice. *p<0.05. Data show duplicate wells of 
pooled samples between groups and represents one of two repeat experiments with 
similar results. 
